1 00:00:04,925 --> 00:00:08,662 I WILL NOW CALL THE 117th 2 00:00:08,662 --> 00:00:10,964 MEETING OF THE NATIONAL 3 00:00:10,964 --> 00:00:13,567 ARTHRITIS AND MUSCULAR SKELETAL 4 00:00:13,567 --> 00:00:16,870 ADVISORY COUNCIL TO ORDER. 5 00:00:16,870 --> 00:00:17,571 AS YOU KNOW, ALL COUNCIL 6 00:00:17,571 --> 00:00:19,039 MEETINGS ARE OPEN TO THE PUBLIC 7 00:00:19,039 --> 00:00:21,341 AS REQUIRED BY LAW EXCEPT FOR 8 00:00:21,341 --> 00:00:22,509 THE REVIEW, DISCUSSION AND 9 00:00:22,509 --> 00:00:24,711 EVALUATION OF GRANT APPLICATIONS 10 00:00:24,711 --> 00:00:26,146 AND RELATED INFORMATION. 11 00:00:26,146 --> 00:00:28,949 I ALSO WANT TO REMIND YOU THAT 12 00:00:28,949 --> 00:00:30,584 THIS MEETING IS BROADCAST BY NIH 13 00:00:30,584 --> 00:00:32,786 VIDEOCAST AND IS BEING RECORDED. 14 00:00:32,786 --> 00:00:34,388 SO, I WOULD LIKE TO WELCOME THE 15 00:00:34,388 --> 00:00:35,856 STAFF AND GUESTS IN THE ROOM 16 00:00:35,856 --> 00:00:38,125 WITH US ATTENDING THE MEETING IN 17 00:00:38,125 --> 00:00:39,927 PERSON AS WELL AS THOSE 18 00:00:39,927 --> 00:00:41,295 ATTENDING VIRTUALLY AND THOSE 19 00:00:41,295 --> 00:00:42,796 WATCHING US THROUGH THE NIH 20 00:00:42,796 --> 00:00:43,197 VIDEOCAST. 21 00:00:43,197 --> 00:00:44,298 AND BEFORE WE GET STARTED I'D 22 00:00:44,298 --> 00:00:46,700 LIKE TO GO AROUND THE TABLE FOR 23 00:00:46,700 --> 00:00:47,301 INTRODUCTIONS. 24 00:00:47,301 --> 00:00:52,673 AND THEN I'LL CALL ON THE 25 00:00:52,673 --> 00:00:54,141 COUNSELORS VIRTUALLY TO 26 00:00:54,141 --> 00:00:56,009 INTRODUCE THEMSELVES AS WELL. 27 00:00:56,009 --> 00:00:57,311 LET'S START ON THE FAR RIGHT. 28 00:00:57,311 --> 00:01:01,181 I THINK WE'RE STILL HAVING AUDIO 29 00:01:01,181 --> 00:01:10,457 ISSUES BUT TO SPEAK PRESS YOUR 30 00:01:10,457 --> 00:01:16,029 AUDIO BUTTON. 31 00:01:16,029 --> 00:01:18,932 GO AHEAD AND WE'LL GO DOUBLE THE 32 00:01:18,932 --> 00:01:19,299 ROW. 33 00:01:19,299 --> 00:01:20,968 >> I'M SHARON AND RECENTLY THE 34 00:01:20,968 --> 00:01:22,169 CEO OF THE ORTHOPEDIC RESEARCH 35 00:01:22,169 --> 00:01:27,241 SOCIETY. 36 00:01:27,241 --> 00:01:28,408 >> GOOD MORNING I'M A PROFESSOR 37 00:01:28,408 --> 00:01:32,346 OF BIO MEDICAL ENGINEERING AT 38 00:01:32,346 --> 00:01:34,014 THE WALLACE COULTER DEPARTMENT 39 00:01:34,014 --> 00:01:38,819 AT GEORGIA TECH AND EMORY. 40 00:01:38,819 --> 00:01:43,090 GOOD MORNING I'M SOCIAL DEAN OF 41 00:01:43,090 --> 00:01:43,357 RESEARCH. 42 00:01:43,357 --> 00:01:45,092 >> I'M THE FORMER EXECUTIVE 43 00:01:45,092 --> 00:01:48,128 DIRECTOR OF THE AMERICAN SOCIETY 44 00:01:48,128 --> 00:01:52,466 FOR BONE RESEARCH. 45 00:01:52,466 --> 00:01:53,734 >> DOUGLAS KIEL SENIOR 46 00:01:53,734 --> 00:01:59,306 SCIENTIST, MARCUS INSTITUTE FOR 47 00:01:59,306 --> 00:02:01,675 AGING RESEARCH. 48 00:02:01,675 --> 00:02:11,752 >> 49 00:02:12,185 --> 00:02:20,694 >> I'M TAMARA ALLISTON. 50 00:02:20,694 --> 00:02:22,396 >> I'M THE NIAMS DEPUTY 51 00:02:22,396 --> 00:02:22,663 DIRECTOR. 52 00:02:22,663 --> 00:02:24,331 >> FOR THOSE LISTENING AND 53 00:02:24,331 --> 00:02:27,868 JOINING IN ON THE VIDEOCAST I'M 54 00:02:27,868 --> 00:02:31,605 LINDSEY CRISWELL THE DIRECTOR OF 55 00:02:31,605 --> 00:02:32,539 NIAMS. 56 00:02:32,539 --> 00:02:35,008 >> I'M THE DIRECTOR OF 57 00:02:35,008 --> 00:02:36,243 EXTRAMURAL ACTIVITIES AND 58 00:02:36,243 --> 00:02:39,279 EXECUTIVE SECRETARY. 59 00:02:39,279 --> 00:02:39,713 >> GOOD MORNING. 60 00:02:39,713 --> 00:02:44,051 I'M MARY GARCIA THE INTERIM 61 00:02:44,051 --> 00:02:44,918 DIRECTOR OF EXTRAMURAL RESEARCH 62 00:02:44,918 --> 00:02:45,752 AT NIAMS. 63 00:02:45,752 --> 00:02:50,390 >> I'M CHRISTEN MORGAN FROM THE 64 00:02:50,390 --> 00:02:52,359 UNIVERSITY OF CONNECTICUT. 65 00:02:52,359 --> 00:02:55,095 >> I'M MELISSA SPENCER A 66 00:02:55,095 --> 00:02:58,765 PROFESSOR OF NEUROLOGY AT UCLA. 67 00:02:58,765 --> 00:03:01,468 >> I'M WITH COLUMBIA UNIVERSITY. 68 00:03:01,468 --> 00:03:01,835 >> GOOD MORNING. 69 00:03:01,835 --> 00:03:04,237 I'M BECKY MILLER WITH THE 70 00:03:04,237 --> 00:03:05,706 SOCIETY FOR INVESTIGATIVE 71 00:03:05,706 --> 00:03:08,775 DERMATOLOGIES SO 72 00:03:08,775 --> 00:03:10,577 >> I'M AT NORTHWESTERN IN 73 00:03:10,577 --> 00:03:12,546 CHICAGO AND LEAD OUR CENTER FOR 74 00:03:12,546 --> 00:03:13,880 GENETIC MEDICINE. 75 00:03:13,880 --> 00:03:15,616 >> ABOUT MORNING I'M STEVE 76 00:03:15,616 --> 00:03:18,685 KELLER PRESIDENT AND CEO OF THE 77 00:03:18,685 --> 00:03:22,122 ARTHRITIS FOUNDATION. 78 00:03:22,122 --> 00:03:32,633 >> WE'RE EXPECTING TWO OTHERS 79 00:03:33,333 --> 00:03:37,137 AND I DO UNDERSTAND DR 80 00:03:37,137 --> 00:03:38,605 DR. SUZANNASTEIN IS JOINING US. 81 00:03:38,605 --> 00:03:40,540 DO YOU WANT TO SAY HELLO TO THE 82 00:03:40,540 --> 00:03:41,074 FOLKS? 83 00:03:41,074 --> 00:03:42,576 HER CAMERA WASN'T WORKING 84 00:03:42,576 --> 00:03:44,945 EARLIER SO SHE MAY BE HAVING 85 00:03:44,945 --> 00:03:46,146 TECHNICAL PROBLEMS BUT 86 00:03:46,146 --> 00:03:47,981 APPRECIATE HER JOINING. 87 00:03:47,981 --> 00:03:51,618 I THINK DR. BOB CARTER PREVIOUS 88 00:03:51,618 --> 00:03:56,089 DEPUTY DIRECTOR MAY BE JOINING 89 00:03:56,089 --> 00:03:56,289 LATER. 90 00:03:56,289 --> 00:03:57,491 WE HAVE MANY STAFF FROM THE 91 00:03:57,491 --> 00:03:58,659 INSTITUTE WITH US AND WON'T TAKE 92 00:03:58,659 --> 00:04:00,761 THE TIME TO INTRODUCE ALL OF 93 00:04:00,761 --> 00:04:01,962 THEM BUT AT SOME POINT DURING 94 00:04:01,962 --> 00:04:04,331 THE MEETING ONE OR MORE OF THEM 95 00:04:04,331 --> 00:04:06,366 MIGHT COME UP TO ADD COMMENTS AT 96 00:04:06,366 --> 00:04:08,502 THAT POINT THEY'LL INTRODUCE 97 00:04:08,502 --> 00:04:11,304 THEMSELVES SO YOU'LL KNOW WHO'S 98 00:04:11,304 --> 00:04:11,905 SPEAKING. 99 00:04:11,905 --> 00:04:13,840 ARRON, BACK OVER TO YOU. 100 00:04:13,840 --> 00:04:14,341 >> THANK YOU. 101 00:04:14,341 --> 00:04:15,542 VERY MUCH. 102 00:04:15,542 --> 00:04:16,943 GOOD MORNING AND WELCOME. 103 00:04:16,943 --> 00:04:18,812 I DO WANT TO POINT OUT WE HAVE 104 00:04:18,812 --> 00:04:21,348 SOME COFFEE BACK HERE IN THE 105 00:04:21,348 --> 00:04:22,783 CORNER IF YOU FEEL YOU NEED A 106 00:04:22,783 --> 00:04:24,351 LITTLE BIT OF CAFFEINE AS THE 107 00:04:24,351 --> 00:04:26,119 DAY GOES ON. 108 00:04:26,119 --> 00:04:29,122 SO COUNCIL TODAY IS IN PERSON. 109 00:04:29,122 --> 00:04:30,991 WE'RE MEETING COUNSELORS AND 110 00:04:30,991 --> 00:04:33,794 STAFF JOINING REMOTELY OR IN 111 00:04:33,794 --> 00:04:33,994 TEAMS. 112 00:04:33,994 --> 00:04:35,762 WE'RE ALSO BROADCASTING A LIVE 113 00:04:35,762 --> 00:04:37,964 NIH VIDEOCAST STREAM. 114 00:04:37,964 --> 00:04:39,800 IF ANY STAFF MEMBER WATCHING ON 115 00:04:39,800 --> 00:04:40,667 THE VIDEOCAST HAS AN URGENT 116 00:04:40,667 --> 00:04:44,438 COMMENT OR QUESTION, PLEASE 117 00:04:44,438 --> 00:04:52,412 E-MAIL SHANDA WELLINGTON AND CAN 118 00:04:52,412 --> 00:04:54,581 DIRECT IT AS APPROPRIATE. 119 00:04:54,581 --> 00:04:55,982 WE ENCOURAGE COMMENTS IN WRITING 120 00:04:55,982 --> 00:04:57,884 UP TO 15 DAYS FOLLOWING THE 121 00:04:57,884 --> 00:04:58,118 MEETING. 122 00:04:58,118 --> 00:05:00,721 WE HAVE A SPECIAL MAILBOX TO 123 00:05:00,721 --> 00:05:04,157 RECEIVE YOUR COMMENTS SENT TO 124 00:05:04,157 --> 00:05:08,095 NIAMS COUNCIL MAIL ALL ONE WORD 125 00:05:08,095 --> 00:05:13,233 AT MAIL DOT NIH DOT GOV. 126 00:05:13,233 --> 00:05:14,835 ANYONE ON TEAMS MY SPEAK. 127 00:05:14,835 --> 00:05:16,603 PLEASE MAKE SURE TO MUTE YOUR 128 00:05:16,603 --> 00:05:18,138 LINE WHEN NOT SPEAKING. 129 00:05:18,138 --> 00:05:19,506 WE DO ASK DURING PRESENTATIONS 130 00:05:19,506 --> 00:05:23,910 YOU KEEP YOUR VIDEO OFF SO THE 131 00:05:23,910 --> 00:05:25,545 PRESENTERS' VIEW IS HIGHLIGHTED. 132 00:05:25,545 --> 00:05:29,316 YOU MAY ALSO RAISE YOUR HAND OR 133 00:05:29,316 --> 00:05:36,022 WE CAN ALL ON YOU. 134 00:05:36,022 --> 00:05:37,124 SHALANDA WILL HELP WITH MUTING 135 00:05:37,124 --> 00:05:39,192 AND KEEP YOUR VIDEO ON EXCEPT 136 00:05:39,192 --> 00:05:40,193 DURING PRESENTATIONS. 137 00:05:40,193 --> 00:05:41,328 IF YOU NEED COMPUTER SUPPORT OR 138 00:05:41,328 --> 00:05:43,096 HELP WITH THE ELECTRONIC COUNCIL 139 00:05:43,096 --> 00:05:45,899 BOOK OR ECB DURING THE MEET 140 00:05:45,899 --> 00:05:48,568 CONTACT SHALANDA. 141 00:05:48,568 --> 00:05:50,570 SHE'S A KEY PERSON HERE FOR 142 00:05:50,570 --> 00:05:52,005 EVERYTHING WE DO. 143 00:05:52,005 --> 00:05:54,141 A NOTICE OF THIS COUNCIL MEETING 144 00:05:54,141 --> 00:05:56,243 WAS PUBLISHED IN THE FEDERAL 145 00:05:56,243 --> 00:05:57,344 REGISTER. 146 00:05:57,344 --> 00:06:00,213 COUNCIL MEMBERS WERE ASKED TO 147 00:06:00,213 --> 00:06:03,250 REMOVE THEMSELVES IF THEIR 148 00:06:03,250 --> 00:06:06,153 PRESENCE MAY APPEAR AS A 149 00:06:06,153 --> 00:06:07,854 CONFLICT OF INTEREST AND THE 150 00:06:07,854 --> 00:06:08,789 REPORTING DATES WILL BE 151 00:06:08,789 --> 00:06:11,391 REQUESTED IN JUNE, OCTOBER AND 152 00:06:11,391 --> 00:06:11,658 FEBRUARY. 153 00:06:11,658 --> 00:06:13,794 WHEN YOU RECEIVE THE REQUEST, 154 00:06:13,794 --> 00:06:15,796 PLEASE RESPOND WITHIN 30 DAYS TO 155 00:06:15,796 --> 00:06:17,397 RESPOND COUNCIL RELATED 156 00:06:17,397 --> 00:06:17,697 ACTIVITIES. 157 00:06:17,697 --> 00:06:19,432 FURTHER INFORMATION REGARDING 158 00:06:19,432 --> 00:06:21,668 CONFLICT OF INTEREST REGULATION 159 00:06:21,668 --> 00:06:22,836 INCLUDED ALSO IN THE ELECTRONIC 160 00:06:22,836 --> 00:06:23,403 COUNCIL BOOK. 161 00:06:23,403 --> 00:06:26,306 THE MEETINGS OF OUR APRIL 21 162 00:06:26,306 --> 00:06:28,375 MEETING ARE POSTED ALSO IN THE 163 00:06:28,375 --> 00:06:30,577 ELECTRONIC COUNCIL BOOK. 164 00:06:30,577 --> 00:06:33,380 IF YOU WISH TO LOOK AT THOSE, I 165 00:06:33,380 --> 00:06:35,315 WOULD ALSO LIKE TO NOW REMIND 166 00:06:35,315 --> 00:06:37,717 YOU ABOUT THE DAYS OF FUTURE 167 00:06:37,717 --> 00:06:38,952 COUNCIL MEETINGS IN THE ECB AND 168 00:06:38,952 --> 00:06:42,789 ON OUR WEBSITE BUT OUR NEXT IN 169 00:06:42,789 --> 00:06:45,225 PERSON MEETING OPEN SESSION WILL 170 00:06:45,225 --> 00:06:47,394 BE OCTOBER 14, 2025 A HYBRID 171 00:06:47,394 --> 00:06:47,627 MEETING. 172 00:06:47,627 --> 00:06:50,664 GOING FORWARD WE PLAN TO HOLD 173 00:06:50,664 --> 00:06:52,732 THE SPRING MEETING IN PERSON AND 174 00:06:52,732 --> 00:06:55,302 THE FALL MEETING HYBRID AND THE 175 00:06:55,302 --> 00:06:59,406 FALL MEETING VIRTUALLY, ACTUALLY 176 00:06:59,406 --> 00:07:03,910 THE SPRING MEETING HYBRID TOO. 177 00:07:03,910 --> 00:07:06,646 WE APPRECIATE YOUR PARTICIPATION 178 00:07:06,646 --> 00:07:09,583 SO MAKE SURE THE DATES ARE ON 179 00:07:09,583 --> 00:07:09,916 YOUR CALENDAR. 180 00:07:09,916 --> 00:07:11,251 WE UPDATE THESE OCCASIONALLY ON 181 00:07:11,251 --> 00:07:12,719 OUR WEBSITE AND WE'LL LET YOU 182 00:07:12,719 --> 00:07:14,955 KNOW IF THERE ARE ANY CHANGES. 183 00:07:14,955 --> 00:07:17,390 ARE THERE ANY QUESTIONS ABOUT 184 00:07:17,390 --> 00:07:27,500 THIS? 185 00:07:30,203 --> 00:07:32,105 S SEEING NO QUESTIONS I'LL PASS 186 00:07:32,105 --> 00:07:34,140 IT BACK TO DR. CRISWELL. 187 00:07:34,140 --> 00:07:41,081 >> I'LL START WITH MY REPORT AND 188 00:07:41,081 --> 00:07:42,148 THANK YOU ARRON FOR COVERING THE 189 00:07:42,148 --> 00:07:42,515 LOGISTICS. 190 00:07:42,515 --> 00:07:46,286 SO I WANT TO START BY WELCOMING 191 00:07:46,286 --> 00:07:48,955 BACK OUR AD HOC COUNCIL MEMBERS 192 00:07:48,955 --> 00:07:52,425 DR. SARAH DEBAUR AND CHRISTEN 193 00:07:52,425 --> 00:07:54,394 MORGAN AROUND AS IN PREVIOUS 194 00:07:54,394 --> 00:07:57,130 MEETINGS WE INVITED OUTSTANDING 195 00:07:57,130 --> 00:08:01,134 INVESTIGATORS FROM THE K01, K08 196 00:08:01,134 --> 00:08:06,506 AND TO PARTICIPATE AS AD HOC 197 00:08:06,506 --> 00:08:09,676 MEMBERS AND TO ALLOW US TO 198 00:08:09,676 --> 00:08:11,645 OBTAIN INPUT FROM SCIENTISTS AT 199 00:08:11,645 --> 00:08:13,647 THE AN EARLIER CAREER STAGE THAN 200 00:08:13,647 --> 00:08:15,882 OUR FULL COUNCIL MEMBERS 201 00:08:15,882 --> 00:08:17,584 TYPICALLY ARE. 202 00:08:17,584 --> 00:08:23,423 DR. GOBAUER IS FROM THE SCHOOL 203 00:08:23,423 --> 00:08:25,692 OF MEDICINE AND DR. MORGAN IS AT 204 00:08:25,692 --> 00:08:27,794 THE UNIVERSITY OF CONNECTICUT 205 00:08:27,794 --> 00:08:30,163 AND THEY JOINED US FOR OUR VERY 206 00:08:30,163 --> 00:08:31,798 BRIEF COUNCIL MEETING IN APRIL 207 00:08:31,798 --> 00:08:34,100 AND WILL BE PARTICIPATING AGAIN 208 00:08:34,100 --> 00:08:34,768 TODAY. 209 00:08:34,768 --> 00:08:36,770 SO PLEASE, BOTH OF YOU PROVIDE 210 00:08:36,770 --> 00:08:38,805 YOUR VALUABLE PERSPECTIVES ON 211 00:08:38,805 --> 00:08:44,444 ANY OR ALL TOPICS WE COVERED. 212 00:08:44,444 --> 00:08:46,579 NOW, BEFORE MOVING ON TO TODAY'S 213 00:08:46,579 --> 00:08:48,682 REPORT I'D LIKE TO TAKE A MOMENT 214 00:08:48,682 --> 00:08:49,983 TO RECOGNIZE THE NIAMS 215 00:08:49,983 --> 00:08:51,051 SCIENTIFIC REVIEW BRANCH. 216 00:08:51,051 --> 00:08:53,086 AS I MENTIONED AT THE APRIL 217 00:08:53,086 --> 00:08:55,922 MEETING, THE NIH ANNOUNCED PLANS 218 00:08:55,922 --> 00:08:57,357 TO CENTRALIZED PEER REVIEW OF 219 00:08:57,357 --> 00:08:59,626 APPLICATIONS WITHIN THE NIH 220 00:08:59,626 --> 00:09:01,094 CENTER FOR SCIENTIFIC REVIEW 221 00:09:01,094 --> 00:09:02,228 ALSO CALLED CSR. 222 00:09:02,228 --> 00:09:04,064 SO WITH MIXED EMOTIONS, I'D LIKE 223 00:09:04,064 --> 00:09:06,599 TO SHARE THIS WILL BE THE LAST 224 00:09:06,599 --> 00:09:08,535 COUNCIL MEETING THE 225 00:09:08,535 --> 00:09:11,404 SCIENTIFIC REVIEW OFFICERS OR 226 00:09:11,404 --> 00:09:17,310 SROs, SCIENTIFIC REVIEW BRANCH. 227 00:09:17,310 --> 00:09:26,119 DR. FANG AND ARGENITA AND MANY 228 00:09:26,119 --> 00:09:27,287 WHO HAVE WORKED WITH AS WELL AS 229 00:09:27,287 --> 00:09:29,422 OTHERS WHO WILL BE JOINING THE 230 00:09:29,422 --> 00:09:30,757 CSR. 231 00:09:30,757 --> 00:09:32,625 NOW, THE GOOD NEWS IS THOUGH THE 232 00:09:32,625 --> 00:09:34,861 TWO NIAMS STANDING STUDY 233 00:09:34,861 --> 00:09:38,798 SECTIONS AMS AND AMC WILL BE 234 00:09:38,798 --> 00:09:39,332 DISCONTINUED. 235 00:09:39,332 --> 00:09:40,700 MOST SROs WILL CONTINUE WORKING 236 00:09:40,700 --> 00:09:42,135 ON APPLICATIONS WITHIN THE 237 00:09:42,135 --> 00:09:43,737 MISSION AREAS IN NEW POSITIONS. 238 00:09:43,737 --> 00:09:46,139 SO WE'D LIKE TO THANK THEM FOR 239 00:09:46,139 --> 00:09:48,775 THEIR OUTSTANDING CONTRIBUTIONS, 240 00:09:48,775 --> 00:09:52,212 THEY'RE UNWAVERING COMMITMENT 241 00:09:52,212 --> 00:09:54,948 AND UTMOST PROFESSIONALISM AND 242 00:09:54,948 --> 00:10:04,591 TIRELESS DEDICATION IN SERVICE 243 00:10:04,591 --> 00:10:06,426 TO NIAMS. 244 00:10:06,426 --> 00:10:09,295 NOW, DURING THIS TRANSITION 245 00:10:09,295 --> 00:10:10,463 DR. SALIDA CHIEF OF THE NIAMS 246 00:10:10,463 --> 00:10:11,398 SCIENTIFIC REVIEW BRANCH WILL 247 00:10:11,398 --> 00:10:13,066 REMAIN AT THE INSTITUTE TO 248 00:10:13,066 --> 00:10:14,567 MANAGE OUR RECEIPT AND REFERRAL 249 00:10:14,567 --> 00:10:16,669 AND ASSIST WITH ACTIVITIES IN 250 00:10:16,669 --> 00:10:17,804 THE DIVISION OF EXTRAMURAL 251 00:10:17,804 --> 00:10:18,138 RESEARCH. 252 00:10:18,138 --> 00:10:21,708 THANK YOU SO MUCH, KATHY. 253 00:10:21,708 --> 00:10:24,444 SO MY REPORT TODAY WILL FOCUS ON 254 00:10:24,444 --> 00:10:26,146 THE NIH AND NIAMS BUDGET AND 255 00:10:26,146 --> 00:10:27,680 ACTIVITIES THAT MAY BE OF 256 00:10:27,680 --> 00:10:29,249 GENERAL INTEREST. 257 00:10:29,249 --> 00:10:32,318 NOW, TODAY'S DIRECTOR'S REPORT 258 00:10:32,318 --> 00:10:34,621 IS A BIT SHORTER THAN USUAL 259 00:10:34,621 --> 00:10:38,124 BECAUSE COUNCIL MET A BIT OVER 260 00:10:38,124 --> 00:10:41,661 THE MONTH AGO WHEN WE HAD THE 261 00:10:41,661 --> 00:10:43,763 RESCHEDULED MEETING THAT WAS 262 00:10:43,763 --> 00:10:45,098 SUPPOSED TO HAPPEN AT THE 263 00:10:45,098 --> 00:10:45,765 BEGINNING OF THE YEAR. 264 00:10:45,765 --> 00:10:48,068 THEY'RE OPERATING UNDER THE FULL 265 00:10:48,068 --> 00:10:50,236 YEAR CONTINUING APPROPRIATIONS 266 00:10:50,236 --> 00:10:53,473 AND EXTENSIONS 2025 ALSO KNOWN 267 00:10:53,473 --> 00:10:56,242 AS HR1968 WHICH THE PRESIDENT 268 00:10:56,242 --> 00:10:58,511 SIGNED MARCH 25, 2025. 269 00:10:58,511 --> 00:11:01,681 NOW, FOR NIAMS, THIS MEANS OUR 270 00:11:01,681 --> 00:11:03,683 CURRENT FISCAL YEAR 2025 ENACTED 271 00:11:03,683 --> 00:11:05,618 BUDGET EQUALS THE COMPARABLE 272 00:11:05,618 --> 00:11:09,722 BUDGET NUMBER FROM FISCAL YEAR 273 00:11:09,722 --> 00:11:10,423 2024. 274 00:11:10,423 --> 00:11:12,225 AND CONSISTENT WITH OUR PREVIOUS 275 00:11:12,225 --> 00:11:14,127 PRACTICE IN RECENT YEARS WE 276 00:11:14,127 --> 00:11:16,062 DECIDED THE BEGINNING OF THE 277 00:11:16,062 --> 00:11:17,831 FISCAL YEAR TO SET OUR PAY LINE 278 00:11:17,831 --> 00:11:21,101 AT THE EIGHT PERCENTILE MORE 279 00:11:21,101 --> 00:11:23,937 GENEROUS FOR EARLY STAGE 280 00:11:23,937 --> 00:11:26,139 INVESTIGATORS BECAUSE IT GIVES 281 00:11:26,139 --> 00:11:30,076 MORE FLEXIBILITY. 282 00:11:30,076 --> 00:11:31,711 WE'LL CONTINUE TO SCRUTINIZE THE 283 00:11:31,711 --> 00:11:33,813 MERITORIOUS APPLICATIONS IN 284 00:11:33,813 --> 00:11:34,948 THEIR PORTFOLIOS TO IDENTIFY 285 00:11:34,948 --> 00:11:35,682 HIGH PRIORITY PROJECTS FOR THE 286 00:11:35,682 --> 00:11:40,420 INSTITUTE TO FUND. 287 00:11:40,420 --> 00:11:42,122 NOW, MOVING TO THE NEXT FISCAL 288 00:11:42,122 --> 00:11:45,391 YEAR'S BUDGET, IN MAY, PRESIDENT 289 00:11:45,391 --> 00:11:47,293 TRUMP WILL RELEASE THE OVERVIEW 290 00:11:47,293 --> 00:11:49,762 OF HIS DISCRETIONARY FUNDING 291 00:11:49,762 --> 00:11:51,764 REQUEST FOR FISCAL YEAR 2026 292 00:11:51,764 --> 00:11:54,400 THAT WOULD START OCTOBER 1. 293 00:11:54,400 --> 00:11:58,138 THE BUDGET REQUEST FOR NIH IS 294 00:11:58,138 --> 00:11:59,973 APPROXIMATELY $27 BILLION 295 00:11:59,973 --> 00:12:01,674 REPRESENTING AN $18 BILLION 296 00:12:01,674 --> 00:12:04,344 REDUCTION FROM THE FISCAL YEAR 297 00:12:04,344 --> 00:12:05,912 2025 ENACTED LEVELS. 298 00:12:05,912 --> 00:12:07,480 LAST FRIDAY THE DEPARTMENT OF 299 00:12:07,480 --> 00:12:09,649 HEALTH AND HUMAN SERVICES 300 00:12:09,649 --> 00:12:13,153 PRESENTED THE HHS FISCAL YEAR 301 00:12:13,153 --> 00:12:14,154 2026 BUDGET IN BRIEF WHICH 302 00:12:14,154 --> 00:12:17,157 PROVIDES MORE DETAILS ABOUT THE 303 00:12:17,157 --> 00:12:19,359 AGENCY'S BUDGETARY PLAN FOR ITS 304 00:12:19,359 --> 00:12:21,561 COMPONENTS INCLUDING NIH. 305 00:12:21,561 --> 00:12:23,296 THE BUDGET PROPOSAL FOR NIH IS 306 00:12:23,296 --> 00:12:26,766 SHOWN ON THIS SLIDE AND IT 307 00:12:26,766 --> 00:12:29,469 PROVIDES $27.5 BILLION IN 308 00:12:29,469 --> 00:12:31,905 DISCRETIONARY BUDGET AUTHORITY 309 00:12:31,905 --> 00:12:32,705 FOR NIH. 310 00:12:32,705 --> 00:12:35,408 NOW, IT ALSO PROPOSES TO 311 00:12:35,408 --> 00:12:38,678 RESTRUCTURE NIH BY CONSOLIDATING 312 00:12:38,678 --> 00:12:41,414 PROGRAMS INTO FIVE FOCUS AREAS. 313 00:12:41,414 --> 00:12:42,615 THE NATIONAL INSTITUTE ON BODY 314 00:12:42,615 --> 00:12:44,617 SYSTEMS RESEARCH, THE NATIONAL 315 00:12:44,617 --> 00:12:47,287 INSTITUTE ON NEURAL SCIENCE AND 316 00:12:47,287 --> 00:12:50,123 BRAIN INSTITUTE, THE GENERAL 317 00:12:50,123 --> 00:12:51,391 MEDICAL SCIENCES, NATIONAL 318 00:12:51,391 --> 00:12:52,892 INSTITUTE FOR CHILD AND 319 00:12:52,892 --> 00:12:53,493 WOMEN'S'S DISORDERS AND 320 00:12:53,493 --> 00:12:55,295 COMMUNICATION AND THE NATIONAL 321 00:12:55,295 --> 00:12:56,529 INSTITUTE ON BEHAVIORAL 322 00:12:56,529 --> 00:12:56,963 RESEARCH. 323 00:12:56,963 --> 00:13:06,839 THE BUDGET WILL RETAIN THE NCI, 324 00:13:06,839 --> 00:13:10,143 NIAD AND ELIMINATING MINORITY 325 00:13:10,143 --> 00:13:15,582 HEALTH, THE FOGARTY CENTER AND 326 00:13:15,582 --> 00:13:20,420 NATIONAL INSTITUTE FOR 327 00:13:20,420 --> 00:13:21,020 INTEGRATIVE AND COMPLEMENTARY 328 00:13:21,020 --> 00:13:22,155 HEALTH AND THE ENVIRONMENTAL 329 00:13:22,155 --> 00:13:23,122 HEALTH SCIENCES INSTITUTE WOULD 330 00:13:23,122 --> 00:13:24,924 BECOME PART OF THE NEW 331 00:13:24,924 --> 00:13:27,227 ADMINISTRATION FOR A HEALTHY 332 00:13:27,227 --> 00:13:27,794 AMERICA. 333 00:13:27,794 --> 00:13:28,928 IMPORTANTLY THOUGH OVER THE NEXT 334 00:13:28,928 --> 00:13:31,965 FEW MONTHS, THE HOUSE AND SENATE 335 00:13:31,965 --> 00:13:33,333 WILL DEVELOP THEIR OWN BUDGET 336 00:13:33,333 --> 00:13:37,170 PROPOSALS FOR FISCAL YEAR 2026 337 00:13:37,170 --> 00:13:39,772 WHICH WILL THEN NEED TO BE 338 00:13:39,772 --> 00:13:41,507 RECONCILED AND A FINAL BILL 339 00:13:41,507 --> 00:13:46,145 GOING BACK TO THE PRESIDENT FOR 340 00:13:46,145 --> 00:13:47,146 SIGNATURE. 341 00:13:47,146 --> 00:13:50,416 NEXT I WANT TO HIGHLIGHT TWO 342 00:13:50,416 --> 00:13:52,885 EVENTS THE NIAMS DEPUTY DIRECTOR 343 00:13:52,885 --> 00:13:55,521 ENGAGED IN WITH CONGRESSIONAL 344 00:13:55,521 --> 00:13:56,689 MEMBERS AND THE NIAMS 345 00:13:56,689 --> 00:13:56,990 COMMUNITIES. 346 00:13:56,990 --> 00:14:00,460 YOU CAN SEE DR. PAYNE AND OTHERS 347 00:14:00,460 --> 00:14:02,028 ON EITHER SIDE OF ANNA ON THE 348 00:14:02,028 --> 00:14:06,599 LEFT AT ONE OF THESE ACTIVITIES. 349 00:14:06,599 --> 00:14:10,837 SO FIRST, THERE WAS A 350 00:14:10,837 --> 00:14:14,140 CONGRESSIONAL BRIEFING THE PHOTO 351 00:14:14,140 --> 00:14:15,608 ON THE LEFT. 352 00:14:15,608 --> 00:14:17,443 REPRESENTATIVE JOHN JOYCE A 353 00:14:17,443 --> 00:14:19,279 DERMATOLOGIST FEATURED INSPIRING 354 00:14:19,279 --> 00:14:20,680 SKIN DISEASE PATIENTS, 355 00:14:20,680 --> 00:14:21,281 RESEARCHERS AND HEALTH CARE 356 00:14:21,281 --> 00:14:22,949 PROVIDERS TO BRING AWARENESS OF 357 00:14:22,949 --> 00:14:24,651 SKIN DISEASES TO MEMBERS OF 358 00:14:24,651 --> 00:14:27,353 CONGRESS, THEIR STAFFERS AND 359 00:14:27,353 --> 00:14:29,389 FEDERAL AGENCY EMPLOYEES. 360 00:14:29,389 --> 00:14:32,659 LATER IN MAY, DR. MAZUKA JOINED 361 00:14:32,659 --> 00:14:34,794 MANY NIH LEADERS AND SEVERAL 362 00:14:34,794 --> 00:14:37,397 CONGRESS MEMBERS AT THE 2025 363 00:14:37,397 --> 00:14:46,139 ACCEPTABILITY GALA ORG -- 364 00:14:46,139 --> 00:14:50,143 ORGANIZED BY DOWNS SYNDROME. 365 00:14:50,143 --> 00:14:51,678 NIH PARTICIPATES IN THE INCLUDE 366 00:14:51,678 --> 00:14:53,980 PROJECT FOR INVESTIGATION OF 367 00:14:53,980 --> 00:14:56,449 CO-OCCURRING CONDITIONS ACROSS 368 00:14:56,449 --> 00:14:57,984 THE LIFE SPAN TO UNDERSTAND 369 00:14:57,984 --> 00:14:59,485 DOWNS SYNDROME. 370 00:14:59,485 --> 00:15:00,787 DR. MAZUKO HAS BEEN INVOLVED IN 371 00:15:00,787 --> 00:15:01,921 THE PLANNING, COORDINATION AND 372 00:15:01,921 --> 00:15:04,223 EXECUTING OF THIS INITIATIVE IN 373 00:15:04,223 --> 00:15:06,492 HER PREVIOUS ROLES WITHIN THE 374 00:15:06,492 --> 00:15:07,493 NIH OFFICE OF THE DIRECTOR. 375 00:15:07,493 --> 00:15:11,230 AND AS PART OF THE INCLUDE 376 00:15:11,230 --> 00:15:13,566 PROJECT, NIAMS RESEARCHERS ARE 377 00:15:13,566 --> 00:15:15,702 EVALUATING THE SAFETY AND 378 00:15:15,702 --> 00:15:21,441 EFFICACY OF A JAK INHIBITOR AND 379 00:15:21,441 --> 00:15:23,876 DEVELOPED WITH HELP MUCH OUR 380 00:15:23,876 --> 00:15:27,547 INTRAMURAL RESEARCH PROGRAM IN 381 00:15:27,547 --> 00:15:31,050 ADOLESCENTS WITH DOWNS SYNDROME 382 00:15:31,050 --> 00:15:32,151 OR AUTOIMMUNE SKIN CONDITION. 383 00:15:32,151 --> 00:15:35,021 THANK YOU, ANNA FOR REPRESENTING 384 00:15:35,021 --> 00:15:37,957 NIAMS AT THAT EVENT AND WE 385 00:15:37,957 --> 00:15:39,359 APPRECIATE OPPORTUNITIES LIKE 386 00:15:39,359 --> 00:15:43,396 THESE TO EDUCATE CONGRESSIONAL 387 00:15:43,396 --> 00:15:45,465 MEMBERS TO ENGAGE WITH THE 388 00:15:45,465 --> 00:15:45,798 COMMUNITIES. 389 00:15:45,798 --> 00:15:47,767 NOW, MOVING CLOSER TO HOME, ON 390 00:15:47,767 --> 00:15:52,739 THE SAME DAY WE MET IN APRIL, 391 00:15:52,739 --> 00:15:56,776 NIH DIRECTOR BHATTACHARYA 392 00:15:56,776 --> 00:15:57,777 INTRODUCED THEMSELVES AT THE 393 00:15:57,777 --> 00:15:59,212 COUNCIL OF COUNCIL MEETING AND 394 00:15:59,212 --> 00:16:00,046 INTRODUCE HIS VISION FOR THE 395 00:16:00,046 --> 00:16:00,380 NIH. 396 00:16:00,380 --> 00:16:02,949 AS YOU MAY KNOW, THE COUNCIL OF 397 00:16:02,949 --> 00:16:05,551 COUNCILS ADVISES THE NIH 398 00:16:05,551 --> 00:16:08,488 DIRECTOR AND THE DIVISION OF 399 00:16:08,488 --> 00:16:09,956 PROGRAM COORDINATION, PLANNING 400 00:16:09,956 --> 00:16:14,127 AND STRATEGIC INITIATIVES OR 401 00:16:14,127 --> 00:16:14,527 DPCPSI. 402 00:16:14,527 --> 00:16:16,329 THE COUNCIL ALSO PROVIDES 403 00:16:16,329 --> 00:16:18,131 FEEDBACK ON NEW POTENTIAL NIH 404 00:16:18,131 --> 00:16:18,931 WIDE INITIATIVES. 405 00:16:18,931 --> 00:16:20,833 SO I HOPE YOU HAD A CHANCE TO 406 00:16:20,833 --> 00:16:26,139 LISTEN TO HIS TALK BUT IF NOT'S 407 00:16:26,139 --> 00:16:27,006 AVAILABLE THROUGH THE NIH 408 00:16:27,006 --> 00:16:29,942 VIDEOCAST ARCHIVE. 409 00:16:29,942 --> 00:16:32,044 NEXT I'D LIKE TO HIGHLIGHT THE 410 00:16:32,044 --> 00:16:34,914 NEW TRANS NIH ACTIVITY THAT MAY 411 00:16:34,914 --> 00:16:36,315 BE OF INTEREST TO YOU 412 00:16:36,315 --> 00:16:38,885 SPECIFICALLY THE NIH RECENTLY 413 00:16:38,885 --> 00:16:40,420 ANNOUNCED IT IS ADOPTING AN 414 00:16:40,420 --> 00:16:42,488 INITIATIVE TO EXPAND INNOVATIVE 415 00:16:42,488 --> 00:16:45,324 HUMAN-BASED SCIENCE WHILE 416 00:16:45,324 --> 00:16:46,659 REDUCING ANIMAL USE IN RESEARCH. 417 00:16:46,659 --> 00:16:48,528 SO WHILE TRADITIONAL ANIMAL 418 00:16:48,528 --> 00:16:52,265 MODELS CONTINUE TO BE VITAL TO 419 00:16:52,265 --> 00:16:53,065 ADVANCING SCIENTIFIC KNOWLEDGE, 420 00:16:53,065 --> 00:16:54,767 USING NEW EMERGING TECHNOLOGIES 421 00:16:54,767 --> 00:16:57,236 CAN OFFER UNIQUE STRENGTHS WHEN 422 00:16:57,236 --> 00:17:00,306 UTILIZED CORRECTLY OR IN 423 00:17:00,306 --> 00:17:01,107 COMBINATION CAN EXPAND THE 424 00:17:01,107 --> 00:17:04,377 TOOLBOX FOR RESEARCHERS TO 425 00:17:04,377 --> 00:17:08,281 ANSWER PREVIOUSLY DIFFICULT OR 426 00:17:08,281 --> 00:17:09,182 UNANSWERABLE BIOMEDICAL RESEARCH 427 00:17:09,182 --> 00:17:13,152 ANSWERS INCLUDING ORGANOIDS AND 428 00:17:13,152 --> 00:17:15,021 TISSUE CHIPS AND OTHER IN VITRO 429 00:17:15,021 --> 00:17:18,825 SYSTEMS TO CAPTURE HUMAN 430 00:17:18,825 --> 00:17:20,760 VARIABILITY AND EVEN PATIENT 431 00:17:20,760 --> 00:17:22,128 SPECIFIC CHARACTERISTICS, 432 00:17:22,128 --> 00:17:23,329 COMPUTATIONAL MODELS THAT 433 00:17:23,329 --> 00:17:24,831 SIMULATE COMPLEX BIOLOGICAL 434 00:17:24,831 --> 00:17:26,833 HUMAN SYSTEMS, DISEASE PATHWAYS 435 00:17:26,833 --> 00:17:29,469 AND DRUG INTERACTIONS AND REAL 436 00:17:29,469 --> 00:17:30,770 WORLD DATA THAT ALLOWS 437 00:17:30,770 --> 00:17:32,605 SCIENTISTS TO STUDY HEALTH 438 00:17:32,605 --> 00:17:35,541 OUTCOMES IN HUMANS AT COMMUNITY 439 00:17:35,541 --> 00:17:36,676 AND POPULATION LEVELS. 440 00:17:36,676 --> 00:17:39,745 SO TO INTEGRATE INNOVATIVE 441 00:17:39,745 --> 00:17:41,547 HUMAN-BASED SCIENCE, NIH INTENDS 442 00:17:41,547 --> 00:17:43,049 TO ESTABLISH THE OFFICE OF 443 00:17:43,049 --> 00:17:46,152 RESEARCH INNOVATION VALIDATION 444 00:17:46,152 --> 00:17:48,821 AND APPLICATION OR ARIVA WITHIN 445 00:17:48,821 --> 00:17:52,525 THE NIHs OFFICE OF THE DIRECTOR. 446 00:17:52,525 --> 00:17:53,960 THIS NEW OFFICE WILL COORDINATE 447 00:17:53,960 --> 00:17:57,230 NIH EFFORTS TO VFSHLGS VALIDATE 448 00:17:57,230 --> 00:18:00,733 AND SCALE THE USE OF KNOWN 449 00:18:00,733 --> 00:18:01,667 APPROACHES ACROSS THE BIOMEDICAL 450 00:18:01,667 --> 00:18:04,370 PORTFOLIO AND SERVE AS THE HUB 451 00:18:04,370 --> 00:18:05,338 FOR INTERAGENCY COORDINATION AND 452 00:18:05,338 --> 00:18:06,138 REGULATORY TRANSLATION FOR 453 00:18:06,138 --> 00:18:09,909 PUBLIC HEALTH PROTECTION. 454 00:18:09,909 --> 00:18:11,310 IT WILL ALSO EXPAND FUNDING AND 455 00:18:11,310 --> 00:18:13,145 TRAINING IN NON-ANIMAL 456 00:18:13,145 --> 00:18:14,146 APPROACHES AND AWARENESS OF 457 00:18:14,146 --> 00:18:17,083 THEIR VALUE IN TRANSLATIONAL 458 00:18:17,083 --> 00:18:17,316 SUCCESS. 459 00:18:17,316 --> 00:18:21,187 SO WE LOOK FORWARD TO WORKING 460 00:18:21,187 --> 00:18:23,556 CLOSELY WITH ORIVA ON THE 461 00:18:23,556 --> 00:18:26,659 INITIATIVE. 462 00:18:26,659 --> 00:18:28,094 SO, WHEN COUNCIL MET IN JANUARY 463 00:18:28,094 --> 00:18:30,997 OF LAST YEAR I INTRODUCED YOU TO 464 00:18:30,997 --> 00:18:34,100 THE COMMON FUND SYSTEMS BIOLOGY 465 00:18:34,100 --> 00:18:35,568 DATA PLATFORM WHICH LEVERAGES 466 00:18:35,568 --> 00:18:38,938 THE ACCELERATED MEDICINES 467 00:18:38,938 --> 00:18:39,572 PARTNERSHIP OR AMP VENTURE 468 00:18:39,572 --> 00:18:41,374 INITIATIVE PROGRAM. 469 00:18:41,374 --> 00:18:45,678 AS YOU MAY KNOW, NIAMS IS AN 470 00:18:45,678 --> 00:18:46,946 ACTIVE PARTNER OF THE AMP 471 00:18:46,946 --> 00:18:47,413 PROGRAM. 472 00:18:47,413 --> 00:18:51,651 WE HELPED LEAD THE AMP RA LUPUS 473 00:18:51,651 --> 00:18:53,519 AND HELPING LEAD THE AUTOIMMUNE 474 00:18:53,519 --> 00:18:57,690 AND IMMUNE MEDIATED DISEASE OR 475 00:18:57,690 --> 00:19:00,393 AIMS PROGRAMS. 476 00:19:00,393 --> 00:19:03,963 THESE PROJECTS HAVE GENERATED 477 00:19:03,963 --> 00:19:09,201 IMPRESSIVE MULTI-OMIC DATA TO 478 00:19:09,201 --> 00:19:10,136 INTERROGATE SHARED MECHANISMS OF 479 00:19:10,136 --> 00:19:13,673 DISEASE. 480 00:19:13,673 --> 00:19:16,475 NOU, THE AMPS PRESENTED A RICH 481 00:19:16,475 --> 00:19:19,078 OPPORTUNITY THEY ALSO COME WITH 482 00:19:19,078 --> 00:19:21,647 CHALLENGES COMMON ACROSS THE BIO 483 00:19:21,647 --> 00:19:23,482 MEDICAL ENTERPRISE BUILT ON 484 00:19:23,482 --> 00:19:25,985 DIFFERENT PLATFORMS AND USE 485 00:19:25,985 --> 00:19:27,420 DIFFERENT DISEASE SPECIFIC DATA 486 00:19:27,420 --> 00:19:27,687 STANDARD. 487 00:19:27,687 --> 00:19:29,589 THEREFORE ALL THE INSTITUTES AND 488 00:19:29,589 --> 00:19:31,557 CENTERS PARTICIPATED IN THE AMPS 489 00:19:31,557 --> 00:19:32,224 HAVE COME TOGETHER TO ADDRESS 490 00:19:32,224 --> 00:19:34,927 THIS COMMON ISSUE. 491 00:19:34,927 --> 00:19:37,496 TO DO SO WE PARTNERED WITH THE 492 00:19:37,496 --> 00:19:41,067 NIH COMMON FUND VENTURE PROGRAM 493 00:19:41,067 --> 00:19:45,371 TO LAUNCH SYS BIO AS WHAT IS 494 00:19:45,371 --> 00:19:47,840 NEEDED TO HARMONIZE DATA AND 495 00:19:47,840 --> 00:19:49,742 PROVIDE THE SINGLE ACCESS POINTS 496 00:19:49,742 --> 00:19:52,979 FOR RESEARCHERS TO QUERY THE 497 00:19:52,979 --> 00:19:57,316 FULL DATA SETS HARMONIZED 498 00:19:57,316 --> 00:19:59,585 TOGETHER AND THE PLATFORM WILL 499 00:19:59,585 --> 00:20:03,055 PROVIDE TOOLS TO LOOK AT GENES, 500 00:20:03,055 --> 00:20:04,924 MOLECULES, CELLS AND PATHWAYS. 501 00:20:04,924 --> 00:20:08,027 WE ALSO RECOGNIZE THIS OPEN DATA 502 00:20:08,027 --> 00:20:09,428 ACCESS SUPPORTS EARLY STAGE 503 00:20:09,428 --> 00:20:14,133 INVESTIGATORS AND ENABLES A 504 00:20:14,133 --> 00:20:15,534 ROBUST SCIENTIFIC DISCOURSE. 505 00:20:15,534 --> 00:20:18,170 LAUNCHED LAST FALL AS THE FIRST 506 00:20:18,170 --> 00:20:19,839 SYS BIO AWARD OUR INVESTIGATOR 507 00:20:19,839 --> 00:20:22,708 TEAM IS BUILDING THE FAIRPLEX 508 00:20:22,708 --> 00:20:25,578 THAT IS A FAIR PLATFORM FOR 509 00:20:25,578 --> 00:20:26,846 EXPLORATION OF SYSTEMS BIOLOGY 510 00:20:26,846 --> 00:20:27,446 DATA. 511 00:20:27,446 --> 00:20:29,148 THE PLATFORM AIMS TO USE FAIR 512 00:20:29,148 --> 00:20:32,184 PRINCIPLES THAT IS FINDABLE, 513 00:20:32,184 --> 00:20:33,953 ACCESSIBLE, INTEROPERABILITY AND 514 00:20:33,953 --> 00:20:35,821 REUSABLE TO MAXIMIZE THE VALUE 515 00:20:35,821 --> 00:20:37,923 OF THE AMP DATA ECO SYSTEM AND 516 00:20:37,923 --> 00:20:38,724 THE INVESTMENTS. 517 00:20:38,724 --> 00:20:40,159 SO FAIRPLEX WILL PROVIDE A 518 00:20:40,159 --> 00:20:41,160 SINGLE POINT OF ENTRY FOR 519 00:20:41,160 --> 00:20:44,764 RESEARCHERS TO ACCESS DIVERSE, 520 00:20:44,764 --> 00:20:46,899 HARMONIZED DATA AND USER 521 00:20:46,899 --> 00:20:52,338 FRIENDLY EXPLORATORY TOOLS. 522 00:20:52,338 --> 00:20:53,305 NOW, SWITCHING TO THE NIAMS 523 00:20:53,305 --> 00:20:54,740 INTRAMURAL PROGRAM I PREVIOUSLY 524 00:20:54,740 --> 00:20:58,144 SHARED WITH YOU ABOUT THE NIAMS 525 00:20:58,144 --> 00:21:02,148 INTRAMURAL RESEARCHERS RECEIVING 526 00:21:02,148 --> 00:21:05,584 AWARDS IT FOR EXCITING WORK THAT 527 00:21:05,584 --> 00:21:06,852 FIRMS UNDER THE STRATEGIC 528 00:21:06,852 --> 00:21:09,922 PRIORITY TO STUDY MOLECULAR AND 529 00:21:09,922 --> 00:21:11,157 CELLULAR MECHANISMS OF HEALTH 530 00:21:11,157 --> 00:21:13,192 AND DISEASE IN HUMANS AND THE 531 00:21:13,192 --> 00:21:16,896 RESULTING PHENOTYPED AND 532 00:21:16,896 --> 00:21:17,163 ENDOTYPES. 533 00:21:17,163 --> 00:21:19,765 I'LL DELIGHTED TO ANNOUNCE IN 534 00:21:19,765 --> 00:21:21,033 THE OFFICE OF AUTOIMMUNE 535 00:21:21,033 --> 00:21:26,138 RESEARCH INTRAMURAL AWARDS THREE 536 00:21:26,138 --> 00:21:31,177 OTHER RESEARCHERS WERE AWARDED 537 00:21:31,177 --> 00:21:31,410 FUNDING. 538 00:21:31,410 --> 00:21:34,213 DR. KAPLAN WILL STUDY THE IMPACT 539 00:21:34,213 --> 00:21:41,654 OF GUT INFLAMMATION AND 540 00:21:41,654 --> 00:21:52,198 LOW-GRADE MYOCARDITIS AND LUPUS 541 00:21:52,665 --> 00:21:53,632 AND PRESENTS WITH PRESENTING 542 00:21:53,632 --> 00:21:56,235 WITH OVERLAPPING OR CO-OCCURRING 543 00:21:56,235 --> 00:21:58,637 SYSTEMIC AUTOIMMUNE DISEASES. 544 00:21:58,637 --> 00:22:05,711 DR. GRAYSON WILL PARTNER WITH 545 00:22:05,711 --> 00:22:16,222 WILL LOOK AT AUTOIMMUNITY AND 546 00:22:20,426 --> 00:22:26,732 DR. LEWANDOWSKI AND WE ALSO 547 00:22:26,732 --> 00:22:28,634 RECEIVED SUPPORT FOR 548 00:22:28,634 --> 00:22:32,071 COLLABORATION WITH OUR NIEHS 549 00:22:32,071 --> 00:22:33,539 COLLEAGUES TO LAUNCH THE 550 00:22:33,539 --> 00:22:35,574 LONGITUDINAL EXPOSURE DATA FROM 551 00:22:35,574 --> 00:22:38,410 THE STUDY TO STUDY SISTERS OF 552 00:22:38,410 --> 00:22:40,479 WOMEN WITH BREAST CANCER WHO 553 00:22:40,479 --> 00:22:41,580 SUBSEQUENTLY DEVELOP LUPUS. 554 00:22:41,580 --> 00:22:44,750 ONCE AGAIN MY CONGRATULATIONS TO 555 00:22:44,750 --> 00:22:49,488 DR. KAPLAN, GRAYSON AND 556 00:22:49,488 --> 00:22:51,023 LEWANDOWSKI AND LOOK FORWARD TO 557 00:22:51,023 --> 00:22:52,358 SHARING RESULTS FROM THESE 558 00:22:52,358 --> 00:22:53,058 EXCITING STUDIES. 559 00:22:53,058 --> 00:22:58,731 IN OUR LAST MEETING UP APRIL I 560 00:22:58,731 --> 00:23:00,966 MENTIONED THE POLICY TO 561 00:23:00,966 --> 00:23:02,134 ACCELERATE BROAD ACCESS TO 562 00:23:02,134 --> 00:23:03,636 RESEARCH RESULTS. 563 00:23:03,636 --> 00:23:06,138 THE MOST SIGNIFICANT CHANGE IS 564 00:23:06,138 --> 00:23:11,644 THE REMOVAL OF THE EMBARGO 565 00:23:11,644 --> 00:23:13,379 PERIOD AND THE MANUSCRIPT MUST 566 00:23:13,379 --> 00:23:15,080 BE MADE PUBLICALLY AVAILABLE. 567 00:23:15,080 --> 00:23:18,217 IN ADDITION TO THE UPDATED 568 00:23:18,217 --> 00:23:20,019 POLICY, NIH ISSUED SUPPLEMENTAL 569 00:23:20,019 --> 00:23:22,421 GUIDANCE ON PUBLICATION COSTS 570 00:23:22,421 --> 00:23:24,690 AND ON GOVERNMENT USE LICENSE 571 00:23:24,690 --> 00:23:25,491 AND RIGHTS. 572 00:23:25,491 --> 00:23:27,092 IMPORTANTLY, NIH ANNOUNCED LAST 573 00:23:27,092 --> 00:23:29,228 MONTH THE REVISED POLICY WILL GO 574 00:23:29,228 --> 00:23:33,666 INTO EFFECT FOR PEER-REVIEWED 575 00:23:33,666 --> 00:23:34,733 MANUSCRIPTS ACCEPTED ON OR AFTER 576 00:23:34,733 --> 00:23:37,236 JULY 1 OF THIS YEAR RATHER THAN 577 00:23:37,236 --> 00:23:39,371 DECEMBER 31 AS ORIGINALLY 578 00:23:39,371 --> 00:23:39,872 PLANNED. 579 00:23:39,872 --> 00:23:43,976 UNTIL THAT TIME, NIHs CURRENT 580 00:23:43,976 --> 00:23:45,344 PUBLIC ACCESS POLICY FROM 2008 581 00:23:45,344 --> 00:23:46,879 WILL REMAIN IN EFFECT. 582 00:23:46,879 --> 00:23:49,181 BROADLY THE NEW NIH POLICY AIMS 583 00:23:49,181 --> 00:23:51,183 TO MAXIMIZE AND ACCELERATE 584 00:23:51,183 --> 00:23:52,585 ACCESS TO SCIENTIFIC DATA AND 585 00:23:52,585 --> 00:23:54,687 SCHOLARLY ARTICLES RESULTING 586 00:23:54,687 --> 00:23:57,690 FROM FEDERAL FUNDING AND TO MAKE 587 00:23:57,690 --> 00:24:00,993 RESEARCH RESULTS EASIER TO FIND 588 00:24:00,993 --> 00:24:03,696 AND MORE TRANSPARENT BY USING 589 00:24:03,696 --> 00:24:10,135 METADATA AND PERSISTENT 590 00:24:10,135 --> 00:24:10,803 IDENTIFIERS. 591 00:24:10,803 --> 00:24:14,940 NEXT, NIH RECENTLY ANNOUNCED AN 592 00:24:14,940 --> 00:24:17,409 UPDATED POLICY ON FOREIGN SUB 593 00:24:17,409 --> 00:24:18,510 AWARDS. 594 00:24:18,510 --> 00:24:21,247 EFFECTIVE MAY 1, NIH WILL NOT 595 00:24:21,247 --> 00:24:23,649 ISSUE AWARDS TO DOMESTIC OR 596 00:24:23,649 --> 00:24:28,888 FOREIGN ENTITIES WHETHER NEW, 597 00:24:28,888 --> 00:24:31,257 RENEWAL OR NON-CONTINUATION AND 598 00:24:31,257 --> 00:24:34,026 NIH WILL NO LONGER ACCEPT PRIOR 599 00:24:34,026 --> 00:24:36,228 APPROVAL REQUESTS TO ADD A NEW 600 00:24:36,228 --> 00:24:37,997 COMPONENT OR SUBAWARD TO AN 601 00:24:37,997 --> 00:24:39,198 ONGOING PROJECT. 602 00:24:39,198 --> 00:24:42,268 IN ALL CASES, NIH WILL ALLOW 603 00:24:42,268 --> 00:24:44,970 INSTITUTES TO RENEGOTIATE THE 604 00:24:44,970 --> 00:24:47,239 AWARDS WHETHER NEW, RENEWAL OR 605 00:24:47,239 --> 00:24:48,908 NON-COMPETING TO REMOVE THE SUB 606 00:24:48,908 --> 00:24:50,843 AWARDS TO FOREIGN ENTITIES AND 607 00:24:50,843 --> 00:24:52,845 WHERE WORK CAN BE PERFORMED 608 00:24:52,845 --> 00:24:54,113 DOMESTICALLY REBUDGETED TO USE 609 00:24:54,113 --> 00:24:57,883 FOR THE PRIME RECIPIENT WHETHER 610 00:24:57,883 --> 00:24:59,184 DOMESTIC OR FOREIGN OR A 611 00:24:59,184 --> 00:25:00,185 DOMESTIC SUB RECIPIENT. 612 00:25:00,185 --> 00:25:03,289 IF A PROJECT IS NO LONGER VIABLE 613 00:25:03,289 --> 00:25:05,090 WITHOUT THE FOREIGN SUBAWARD, 614 00:25:05,090 --> 00:25:07,159 NIH WILL WORK WITH THE RECIPIENT 615 00:25:07,159 --> 00:25:09,695 TO NEGOTIATE A BILATERAL 616 00:25:09,695 --> 00:25:11,597 TERMINATION OF THE PROJECT 617 00:25:11,597 --> 00:25:13,299 TAKING INTO CONSIDERATION ANY 618 00:25:13,299 --> 00:25:15,267 NEED TO SUPPORT PATIENT SAFETY 619 00:25:15,267 --> 00:25:18,070 OR ANIMAL WELFARE. 620 00:25:18,070 --> 00:25:20,973 NIH'S POLICY CHANGE APPLIES 621 00:25:20,973 --> 00:25:22,274 PROSPECTIVELY TO ALL NIH GRANTS 622 00:25:22,274 --> 00:25:23,842 AND COOPERATIVE AGREEMENTS TO 623 00:25:23,842 --> 00:25:27,413 DOMESTIC AND FOREIGN ENTITIES 624 00:25:27,413 --> 00:25:28,981 AND NOT RETROACTIVELY REVISE 625 00:25:28,981 --> 00:25:30,649 ONGOING AWARDS TO REMOVE THE 626 00:25:30,649 --> 00:25:32,084 FOREIGN SUB AWARDS AT THIS TIME. 627 00:25:32,084 --> 00:25:33,953 AND THE POINT I WANTED TO 628 00:25:33,953 --> 00:25:35,654 HIGHLIGHT IS THE NEXT ONE WHICH 629 00:25:35,654 --> 00:25:38,691 IS THAT NIH CONTINUES TO SUPPORT 630 00:25:38,691 --> 00:25:39,892 DIRECT FOREIGN AWARDS. 631 00:25:39,892 --> 00:25:42,394 SO THE ISSUE IS SUBAWARDS, NOT 632 00:25:42,394 --> 00:25:43,729 DIRECT FOREIGN AWARDS. 633 00:25:43,729 --> 00:25:46,131 THIS POLICY APPLIES TO ALL 634 00:25:46,131 --> 00:25:47,666 MONETARY FOREIGN COLLABORATIONS. 635 00:25:47,666 --> 00:25:50,169 IT DOES NOT APPLY TO FUNDS 636 00:25:50,169 --> 00:25:53,739 PROVIDED TO SUPPORT FOREIGN 637 00:25:53,739 --> 00:25:56,842 CONSULTANCES OR PURCHASING 638 00:25:56,842 --> 00:25:58,177 UNIQUE EQUIPMENT OR SUPPLIES 639 00:25:58,177 --> 00:26:00,679 FROM FOREIGN VENDORS. 640 00:26:00,679 --> 00:26:02,648 ANOTHER POLICY UPDATE I HOPE YOU 641 00:26:02,648 --> 00:26:04,917 WILL SHARE WIDELY AMONG YOUR 642 00:26:04,917 --> 00:26:08,087 COLLEAGUES IS A SHORT-TERM 643 00:26:08,087 --> 00:26:12,858 EXTENSION TO THE ESI ELIGIBILITY 644 00:26:12,858 --> 00:26:13,092 PERIOD. 645 00:26:13,092 --> 00:26:14,493 IN ADDRESSING DELAYS IN 646 00:26:14,493 --> 00:26:16,729 SUBMISSIONS OR PEER REVIEW OR 647 00:26:16,729 --> 00:26:19,598 AWARD PROCESSING TIME LINES 648 00:26:19,598 --> 00:26:21,834 BETWEEN JANUARY 1 AND MAY 31 OF 649 00:26:21,834 --> 00:26:23,802 THIS YEAR AND SEEKING TO 650 00:26:23,802 --> 00:26:27,006 MITIGATE THEIR AFFECT ON THE 651 00:26:27,006 --> 00:26:28,507 COMMUNITY THERE'S AN AUTOMATIC 652 00:26:28,507 --> 00:26:33,645 EXTENSION OF ESI ELIGIBILITY FOR 653 00:26:33,645 --> 00:26:34,780 INVESTIGATORS WHOSE LAST 654 00:26:34,780 --> 00:26:37,850 SUBMISSION DATE FOR A NEW OR 655 00:26:37,850 --> 00:26:42,121 REVISED APPLICATION BASED ON ESI 656 00:26:42,121 --> 00:26:44,056 ELIGIBILITY IS OCTOBER NOVEMBER 657 00:26:44,056 --> 00:26:46,925 24 OR FEBRUARY, MARCH, 2025 OR 658 00:26:46,925 --> 00:26:50,763 JUNE, JULY, 2025. 659 00:26:50,763 --> 00:26:53,532 THE NEW LAST SUBMISSION AS AN 660 00:26:53,532 --> 00:26:54,800 ESI FOR THESE INVESTIGATORS WILL 661 00:26:54,800 --> 00:27:02,107 BE OCTOBER 2025. 662 00:27:02,107 --> 00:27:03,208 FINALLY, NIH IS REQUESTING 663 00:27:03,208 --> 00:27:05,344 STRATEGIES FOR MITIGATING 664 00:27:05,344 --> 00:27:07,880 CONTROLLED ACCESS HUMAN GENOMIC 665 00:27:07,880 --> 00:27:10,849 DATA LEAKAGE WHEN DEVELOPING AND 666 00:27:10,849 --> 00:27:12,751 SHARING GENERATIVE TOOLS AND 667 00:27:12,751 --> 00:27:14,086 APPLICATIONS. 668 00:27:14,086 --> 00:27:14,820 IMPORTANTLY, THESE STRATEGIES 669 00:27:14,820 --> 00:27:17,790 SHOULD STILL PROMOTE AND ENABLE 670 00:27:17,790 --> 00:27:19,391 WIDESPREAD INNOVATION AND 671 00:27:19,391 --> 00:27:22,127 ADOPTION OF RESPONSIBLE A.I. FOR 672 00:27:22,127 --> 00:27:24,229 BIOMEDICAL RESEARCH BUT THE NIH 673 00:27:24,229 --> 00:27:29,768 IS COMMITTED TO IMPROVE THE 674 00:27:29,768 --> 00:27:31,236 HEALTH OF THE PUBLIC AND AS YOU 675 00:27:31,236 --> 00:27:35,774 KNOW, TO UPHOLD THE PRINCIPLES 676 00:27:35,774 --> 00:27:38,243 ESPOUSES IN THE NIH GENOMIC 677 00:27:38,243 --> 00:27:40,412 SHARING POLICY, NIH HAS 678 00:27:40,412 --> 00:27:41,780 TEMPORARILY PAUSED THE SHARING 679 00:27:41,780 --> 00:27:44,083 OF GENERATIVE A.I. MODELS AND 680 00:27:44,083 --> 00:27:46,785 THEIR PARAMETERS BASED ON NIH 681 00:27:46,785 --> 00:27:49,721 HUMAN CONTROLLED ACCESS DATA AS 682 00:27:49,721 --> 00:27:51,390 WELL AS THE RETENTION OF THESE 683 00:27:51,390 --> 00:27:53,792 TOOLS BEYOND THE PROJECT'S CLOSE 684 00:27:53,792 --> 00:27:54,126 OUT. 685 00:27:54,126 --> 00:27:56,962 PUBLIC RESPONSE TO THIS RFI WILL 686 00:27:56,962 --> 00:27:59,231 HELP INFORM FUTURE GUIDANCE 687 00:27:59,231 --> 00:28:01,500 ABOUT THIS VERY IMPORTANT ISSUE. 688 00:28:01,500 --> 00:28:03,569 THE DEADLINE FOR SUBMITTING AN 689 00:28:03,569 --> 00:28:04,636 ONLINE RESPONSE IS JULY 16 OF 690 00:28:04,636 --> 00:28:06,738 THIS YEAR. 691 00:28:06,738 --> 00:28:09,041 I ENCOURAGE ALL OF YOU TO SHARE 692 00:28:09,041 --> 00:28:10,109 THIS WIDELY. 693 00:28:10,109 --> 00:28:12,911 SO I'D LIKE TO END MY REPORT 694 00:28:12,911 --> 00:28:14,379 THIS MORNING WITH A REMINDER 695 00:28:14,379 --> 00:28:16,949 ABOUT THE NIH GRANTS AND FUNDING 696 00:28:16,949 --> 00:28:18,750 WEBSITE AND ENCOURAGE ALL OF YOU 697 00:28:18,750 --> 00:28:20,853 TO CHECK THE PAGE OFF FOR THE 698 00:28:20,853 --> 00:28:22,321 LATEST POLICY UPDATES AND 699 00:28:22,321 --> 00:28:25,924 FUNDING ANNOUNCEMENTS. 700 00:28:25,924 --> 00:28:28,427 SO, ON THAT NOTE, THANK YOU VERY 701 00:28:28,427 --> 00:28:29,795 MUCH FOR YOUR ATTENTION AND I 702 00:28:29,795 --> 00:28:32,097 WANT TO OPEN THE FLOOR NOW TO 703 00:28:32,097 --> 00:28:33,932 HEAR FROM YOU ABOUT ANY 704 00:28:33,932 --> 00:28:35,767 QUESTIONS YOU'D LIKE TO RAISE OR 705 00:28:35,767 --> 00:28:43,142 QUESTIONS I CAN TRY TO ADDRESS. 706 00:28:43,142 --> 00:28:45,944 BEFORE WE MOVE I THINK 707 00:28:45,944 --> 00:28:52,518 DR. CARTER HAVE JOINED. 708 00:28:52,518 --> 00:28:54,086 LET'S LET THEM SAY HELLO AND 709 00:28:54,086 --> 00:28:58,957 INTRODUCE THEMSELVES BRIEFLY. 710 00:28:58,957 --> 00:29:01,660 >> I CAN START. 711 00:29:01,660 --> 00:29:04,096 I AM A PROFESSOR AND DIVISION 712 00:29:04,096 --> 00:29:05,797 CHIEF AT THE UNIVERSITY OF 713 00:29:05,797 --> 00:29:06,999 CALIFORNIA SAN FRANCISCO AND SAN 714 00:29:06,999 --> 00:29:08,734 FRANCISCO DENTAL HOSPITAL AND I 715 00:29:08,734 --> 00:29:11,203 STUDY THE EPIDEMIOLOGY AND 716 00:29:11,203 --> 00:29:12,905 OUTCOMES OF RHEUMATIC DISEASE. 717 00:29:12,905 --> 00:29:16,375 NICE TO BE WITH YOU ALL. 718 00:29:16,375 --> 00:29:24,883 >> THANK YOU. 719 00:29:24,883 --> 00:29:26,485 >> GOOD MORNING. 720 00:29:26,485 --> 00:29:28,554 >> HI, JOB. 721 00:29:28,554 --> 00:29:31,023 >> BOB CARTER FORMERLY DEPUTY 722 00:29:31,023 --> 00:29:33,725 DIRECTOR SUPPORTING LINDSEY AND 723 00:29:33,725 --> 00:29:35,794 NOW CONSULTANT SUPPORTING ANNA 724 00:29:35,794 --> 00:29:41,133 AND LINDSEY AND WORKING ON THE 725 00:29:41,133 --> 00:29:46,138 ROLE AS CO-COORDINATOR IN THE 726 00:29:46,138 --> 00:29:48,106 SYSCO PROJECT AND I APPRECIATE 727 00:29:48,106 --> 00:29:49,374 YOU JOINING BECAUSE IN THESE 728 00:29:49,374 --> 00:29:51,410 TOUGH TIMES YOUR SUPPORT IS 729 00:29:51,410 --> 00:29:52,144 REALLY VALUABLE AND THOUGHTS 730 00:29:52,144 --> 00:29:53,979 VERY WELCOME. 731 00:29:53,979 --> 00:29:58,050 THANK YOU. 732 00:29:58,050 --> 00:29:58,750 >> THANKS, BOB. 733 00:29:58,750 --> 00:30:02,120 I COULDN'T AGREE MORE ON THAT 734 00:30:02,120 --> 00:30:05,591 AND THANK YOU AND SUZANNA BOTH 735 00:30:05,591 --> 00:30:07,526 AND YOUR EXPERIENCE AND WISDOM 736 00:30:07,526 --> 00:30:08,860 ARE SO INCREDIBLY VALUABLE NOW 737 00:30:08,860 --> 00:30:10,362 SO APPRECIATE YOUR ONGOING 738 00:30:10,362 --> 00:30:15,367 SUPPORT. 739 00:30:15,367 --> 00:30:17,803 I'LL DO A TIME CHECK. 740 00:30:17,803 --> 00:30:20,973 WE PLANNED THIS SESSION WOULD GO 741 00:30:20,973 --> 00:30:23,175 TO 10:20 SO WE HAVE PLENTY OF 742 00:30:23,175 --> 00:30:24,276 TIME NOW TO RAISE QUESTIONS, 743 00:30:24,276 --> 00:30:27,679 ISSUES AND WE'LL HAVE MORE TIME 744 00:30:27,679 --> 00:30:28,947 AS WELL AS LATER IN THE MEETING. 745 00:30:28,947 --> 00:30:31,783 SO IF WE DON'T GET TO YOUR 746 00:30:31,783 --> 00:30:34,119 QUESTION DURING THE SUBMISSION 747 00:30:34,119 --> 00:30:38,156 SEGMENT, NO FEAR WE'LL GET TO 748 00:30:38,156 --> 00:30:46,565 THAT LATER. 749 00:30:46,565 --> 00:30:50,435 >> THANK YOU FOR THE UPDATE. 750 00:30:50,435 --> 00:30:52,871 REAL QUICK QUESTION. 751 00:30:52,871 --> 00:30:54,206 I'M NOT FAMILIAR WITH THE PLAN 752 00:30:54,206 --> 00:30:57,009 IN DETAIL DOES IT ALSO INCLUDE 753 00:30:57,009 --> 00:31:01,847 CHANGES TO THE CSR FOR REVIEW? 754 00:31:01,847 --> 00:31:05,183 >> SO LET ME EMPHASIZED THE 755 00:31:05,183 --> 00:31:06,885 PROPOSED REORGANIZATION IS NOT A 756 00:31:06,885 --> 00:31:07,486 DONE DEAL YET. 757 00:31:07,486 --> 00:31:09,254 IT'S JUST A PROPOSAL AND WE 758 00:31:09,254 --> 00:31:10,122 STILL HAVE A LOT OF THINGS THAT 759 00:31:10,122 --> 00:31:13,058 HAVE TO HAPPEN AND DISCUSSIONS 760 00:31:13,058 --> 00:31:15,761 BEFORE WE UNDERSTAND TO WHAT 761 00:31:15,761 --> 00:31:17,863 EXTENT, IF ANY, THERE'LL BE 762 00:31:17,863 --> 00:31:18,797 REORGANIZATION ALONG THOSE 763 00:31:18,797 --> 00:31:18,997 LINES. 764 00:31:18,997 --> 00:31:21,099 IN TERMS OF THE RESTRUCTURING OF 765 00:31:21,099 --> 00:31:23,602 CSR, A FEW MONTHS BACK, A 766 00:31:23,602 --> 00:31:28,507 DECISION WAS MADE TO CENTRALIZE 767 00:31:28,507 --> 00:31:29,274 REVIEW ACTIVITIES. 768 00:31:29,274 --> 00:31:32,210 AND SO THAT HAS BEEN A REALLY 769 00:31:32,210 --> 00:31:33,645 CHALLENGING PROCESS LED BY THE 770 00:31:33,645 --> 00:31:35,881 DIRECTOR OF CSR WITH THE 771 00:31:35,881 --> 00:31:36,982 COOPERATION AND COLLABORATION OF 772 00:31:36,982 --> 00:31:40,485 ALL THE INSTITUTES AND CENTERS 773 00:31:40,485 --> 00:31:49,561 AND SO NOW REVIEW STAFF I THINK 774 00:31:49,561 --> 00:31:52,698 BY END OF JUNE WILL BE 775 00:31:52,698 --> 00:31:54,132 CONSOLIDATED WITHIN CSR AND THE 776 00:31:54,132 --> 00:31:57,235 STUDY SECTIONS THAT HAD BEEN RUN 777 00:31:57,235 --> 00:31:59,304 AND STAFF OUT OF THE INSTITUTES 778 00:31:59,304 --> 00:32:02,107 NO LONGER EXIST. 779 00:32:02,107 --> 00:32:07,579 SO A VERY BIG CHANGE. 780 00:32:07,579 --> 00:32:08,780 WE'LL BEING FOLLOWING CLOSELY TO 781 00:32:08,780 --> 00:32:10,115 MAKE SURE THAT ALL OF THE 782 00:32:10,115 --> 00:32:12,384 BREADTH AND DEPTH OF THE 783 00:32:12,384 --> 00:32:13,285 SCIENTIFIC AREAS CONTINUE TO 784 00:32:13,285 --> 00:32:16,755 HAVE OUTSTANDING PEER REVIEW. 785 00:32:16,755 --> 00:32:20,025 ALSO, I WANT TO REMIND YOU ALL 786 00:32:20,025 --> 00:32:23,295 THAT WHILE THE PEER REVIEW 787 00:32:23,295 --> 00:32:24,429 PROCESS IS INCREDIBLY IMPORTANT 788 00:32:24,429 --> 00:32:28,033 AND THE SCORES REFLECT VERY 789 00:32:28,033 --> 00:32:31,336 IMPORTANT ASSESSMENTS OF 790 00:32:31,336 --> 00:32:31,870 ASPECTS, ULTIMATELY THE 791 00:32:31,870 --> 00:32:33,305 INSTITUTES DECIDE WHICH 792 00:32:33,305 --> 00:32:34,940 APPLICATIONS THEY'RE GOING TO 793 00:32:34,940 --> 00:32:35,140 FUND. 794 00:32:35,140 --> 00:32:37,409 SO WE HAVE NOT LOST ANY OF THAT 795 00:32:37,409 --> 00:32:38,110 DISCRETIONARY POWER AND 796 00:32:38,110 --> 00:32:46,184 AUTHORITY. 797 00:32:46,184 --> 00:32:47,786 DURING THIS TRANSITION PERIOD 798 00:32:47,786 --> 00:32:49,087 THAT'S AS IMPORTANT AS EVER. 799 00:32:49,087 --> 00:32:49,855 I WANT TO MAKE SURE YOU 800 00:32:49,855 --> 00:32:57,396 UNDERSTAND THAT IMPORTANT PIECE. 801 00:32:57,396 --> 00:32:59,931 DR. KIEL, PLEASE, YES. 802 00:32:59,931 --> 00:33:01,767 >> I WANTED TO RAISE A QUESTION 803 00:33:01,767 --> 00:33:02,768 ABOUT THE NEW PROCESS FOR 804 00:33:02,768 --> 00:33:10,475 SUBMITTING CONCEPT PROPOSALS, 805 00:33:10,475 --> 00:33:11,643 NOFO'S AND THE LIKE I UNDERSTAND 806 00:33:11,643 --> 00:33:14,146 IT GOES THROUGH MULTIPLE LAYERS 807 00:33:14,146 --> 00:33:15,680 OF REVIEW WHICH CONDITION RESULT 808 00:33:15,680 --> 00:33:17,682 IN DELAYS IN POSTING. 809 00:33:17,682 --> 00:33:20,585 THOSE WHO RECEIVE THE WEEKLY 810 00:33:20,585 --> 00:33:22,053 BULLETIN OF NOTICES HAVE NOTICED 811 00:33:22,053 --> 00:33:24,489 THERE ARE NO NOTICES HARDLY AND 812 00:33:24,489 --> 00:33:25,624 I WAS TOLD THAT'S BECAUSE 813 00:33:25,624 --> 00:33:26,858 THEY'RE MAKING THEIR WAY THROUGH 814 00:33:26,858 --> 00:33:27,926 THE NEW REVIEW PROCESS. 815 00:33:27,926 --> 00:33:31,363 CAN YOU COMMENT ON ANY EXISTING 816 00:33:31,363 --> 00:33:33,598 OR PLANNED PROPOSAL ANNOUNCEMENT 817 00:33:33,598 --> 00:33:35,934 THAT ARE DELAYED OR MAYBE IN THE 818 00:33:35,934 --> 00:33:39,004 NEW REVIEW PROCESS? 819 00:33:39,004 --> 00:33:41,039 >> THAT'S A BIG COMPLICATED 820 00:33:41,039 --> 00:33:42,107 TARGET AND SO MANY THINGS ARE 821 00:33:42,107 --> 00:33:42,941 THESE DAYS. 822 00:33:42,941 --> 00:33:45,777 LET ME MAKE A FEW COMMENTS AND 823 00:33:45,777 --> 00:33:47,479 I'LL CALL ON OTHERS FOR 824 00:33:47,479 --> 00:33:47,913 ADDITIONAL POINTS. 825 00:33:47,913 --> 00:33:49,981 ONE IS THAT GOING BACK I THINK 826 00:33:49,981 --> 00:33:51,583 AT LEAST SEVERAL YEARS, THE 827 00:33:51,583 --> 00:33:53,685 DEPARTMENT OF HEALTH AND HUMAN 828 00:33:53,685 --> 00:33:58,123 SERVICES HAVE HAD A STRONG 829 00:33:58,123 --> 00:34:02,127 DESIRE TO SIMPLIFY NOFOs. 830 00:34:02,127 --> 00:34:03,862 FOR THOSE WHO READ THEM I'M SURE 831 00:34:03,862 --> 00:34:04,996 IT WILL RESONATE WITH YOU. 832 00:34:04,996 --> 00:34:09,100 ONE WAS ON THE BOOKS UNTIL VERY 833 00:34:09,100 --> 00:34:10,735 RECENTLY 31 OR 41 PAGES LONG AND 834 00:34:10,735 --> 00:34:14,172 WHEN I TAKE A LOOK AT THESE I 835 00:34:14,172 --> 00:34:14,539 CRINGE. 836 00:34:14,539 --> 00:34:16,608 SO THERE'S BEEN A LONG STANDING 837 00:34:16,608 --> 00:34:20,712 EFFORT BY HHS TO TRY TO SIMPLIFY 838 00:34:20,712 --> 00:34:21,413 NOFOs. 839 00:34:21,413 --> 00:34:23,949 WITH THIS CURRENT ADMINISTRATION 840 00:34:23,949 --> 00:34:29,187 AT THE NIH VARIOUS 841 00:34:29,187 --> 00:34:32,491 CONSIDERATIONS, EFFICIENCY AND 842 00:34:32,491 --> 00:34:33,425 COORDINATION, ETCETERA HAVE 843 00:34:33,425 --> 00:34:36,561 PROMPTED THE NIH TO TAKE THIS 844 00:34:36,561 --> 00:34:39,498 ANOTHER STEP FURTHER AND TO 845 00:34:39,498 --> 00:34:42,167 FULLY EMBRACE THE SIMPLIFIED 846 00:34:42,167 --> 00:34:44,736 NOFO CONCEPT AND TO DRASTICALLY 847 00:34:44,736 --> 00:34:48,173 DECREASE THE NUMBER OF NOFO. 848 00:34:48,173 --> 00:34:50,375 AND THOSE INVOLVED IN APPLYING 849 00:34:50,375 --> 00:34:53,345 FOR GRANTS YOU KNOW THIS BETTER 850 00:34:53,345 --> 00:34:57,582 THAN I RECALL, BUT FOR EXAMPLE 851 00:34:57,582 --> 00:35:00,986 EVEN FOR A SINGLE CONCEPT THERE 852 00:35:00,986 --> 00:35:04,656 MAY BE DIFFERENT NOFOs FOR THE 853 00:35:04,656 --> 00:35:05,524 FUNDING MECHANISM. 854 00:35:05,524 --> 00:35:06,892 A LOT OF WORK HAS BEEN UNDERWAY 855 00:35:06,892 --> 00:35:08,026 WITHIN THE OFFICE OF EXTRAMURAL 856 00:35:08,026 --> 00:35:11,963 RESEARCH AND RELATED OFFICES, 857 00:35:11,963 --> 00:35:14,933 DR. BORSCH HAS STEPPED UP AND IS 858 00:35:14,933 --> 00:35:16,868 HELPING US WITH THIS PROCESS TO 859 00:35:16,868 --> 00:35:20,772 TRY TO FIGURE OUT HOW BEST TO 860 00:35:20,772 --> 00:35:23,975 CONSOLIDATE -- SIMPLIFY, 861 00:35:23,975 --> 00:35:25,176 CONSOLIDATE AND EVEN CENTRALIZE 862 00:35:25,176 --> 00:35:27,779 SOME OF THE NOTICES OF SPECIALTY 863 00:35:27,779 --> 00:35:28,246 INTEREST. 864 00:35:28,246 --> 00:35:29,214 SO INVESTIGATORS DON'T HAVE TO 865 00:35:29,214 --> 00:35:31,216 LOOK AT EVERY SINGLE INSTITUTE 866 00:35:31,216 --> 00:35:32,450 AND CENTER TO SEE WHAT ARE THEIR 867 00:35:32,450 --> 00:35:34,753 AREAS OF HAVE BUT CAN GO TO ONE 868 00:35:34,753 --> 00:35:39,190 SPOT AND SEE A LIST OF ALL THE 869 00:35:39,190 --> 00:35:41,159 NOTICES MUCH SPECIAL INTEREST. 870 00:35:41,159 --> 00:35:42,193 IT'S BEEN VERY CHALLENGING 871 00:35:42,193 --> 00:35:45,730 TRYING TO FIGURE OUT HOW TO 872 00:35:45,730 --> 00:35:47,832 STREAMLINE, ETCETERA. 873 00:35:47,832 --> 00:35:48,867 NOW, ON A SEPARATE ISSUE RAISED 874 00:35:48,867 --> 00:35:51,403 HAS TO DO WITH REVIEW OF THESE. 875 00:35:51,403 --> 00:35:53,772 SO MY UNDERSTANDING OF THE PLAN 876 00:35:53,772 --> 00:35:56,374 AND THIS IS UNDERWAY. 877 00:35:56,374 --> 00:35:58,910 IT'S POSSIBLE THAT SOME CHANGES 878 00:35:58,910 --> 00:36:01,580 MAY BE MADE BASED ON HOW THIS IS 879 00:36:01,580 --> 00:36:05,550 GOING BUT A VERY VERY HIGH LEVEL 880 00:36:05,550 --> 00:36:09,254 SUMMARY OF A CONCEPT IS SENT TO 881 00:36:09,254 --> 00:36:10,488 HHS AS A FORECAST FOR THEIR 882 00:36:10,488 --> 00:36:13,158 REVIEW AND APPROVAL. 883 00:36:13,158 --> 00:36:15,360 THEN IT COMES BACK TO THE NIH 884 00:36:15,360 --> 00:36:16,928 AND IS EVALUATED CENTRALLY AND 885 00:36:16,928 --> 00:36:21,533 THEN GETS PRESENTED TO COUNCILS 886 00:36:21,533 --> 00:36:23,602 FOR APPROVAL AND THEN THERE MAY 887 00:36:23,602 --> 00:36:26,137 OR MAY NOT BE ACTION TAKEN ON 888 00:36:26,137 --> 00:36:28,406 THE CONCEPTS. 889 00:36:28,406 --> 00:36:30,208 BUT SO IN OTHER WORDS AFTER A 890 00:36:30,208 --> 00:36:32,077 CONCEPT PRESENTED THERE MAY BE 891 00:36:32,077 --> 00:36:35,480 SPECIFIC RFAs THAT FOLLOW BUT 892 00:36:35,480 --> 00:36:36,348 GIVES US THE OPPORTUNITY TO 893 00:36:36,348 --> 00:36:40,852 CONSIDER AND THAT AND HAVE A 894 00:36:40,852 --> 00:36:42,387 COUPLE CONCEPTS TODAY. 895 00:36:42,387 --> 00:36:46,424 AND AT THE OUTSET THERE'LL BE 896 00:36:46,424 --> 00:36:47,726 DELAYS BECAUSE WE'RE TRYING TO 897 00:36:47,726 --> 00:36:48,360 ACCOMPLISH A LOT OF DIFFERENT 898 00:36:48,360 --> 00:36:48,593 THINGS. 899 00:36:48,593 --> 00:36:51,763 IT'S NOT CLEAR TO ME DOWN THE 900 00:36:51,763 --> 00:36:54,032 ROAD WE'RE GOING TO BE LOOKING 901 00:36:54,032 --> 00:36:56,368 AT SIGNIFICANTLY LONGER DELAYS. 902 00:36:56,368 --> 00:36:57,836 I THINK IT'S TOO SOON TO TELL 903 00:36:57,836 --> 00:37:00,038 AND LET ME PAUSE THERE AND SEE 904 00:37:00,038 --> 00:37:01,640 WHETHER DARREN OR OTHERS WANT TO 905 00:37:01,640 --> 00:37:04,809 ADD TO MY COMMENTS OR I MAY NOT 906 00:37:04,809 --> 00:37:06,978 HAVE EXPRESSED SOMETHING EXACTLY 907 00:37:06,978 --> 00:37:07,245 CORRECTLY. 908 00:37:07,245 --> 00:37:09,180 >> I THINK YOU EXPLAINED IT VERY 909 00:37:09,180 --> 00:37:10,115 WELL. 910 00:37:10,115 --> 00:37:11,316 THERE WERE SOME DELAYS BUT YOU 911 00:37:11,316 --> 00:37:14,119 CAN SEE WE'RE HAVING THREE 912 00:37:14,119 --> 00:37:18,056 CONCEPT CLEARANCES TODAY WE GOT 913 00:37:18,056 --> 00:37:19,357 APPROVAL FOR. 914 00:37:19,357 --> 00:37:23,094 JUSTINE BUSHMAN AND SHALANDA 915 00:37:23,094 --> 00:37:25,030 HAVE BEEN WORKING HARD TO GET 916 00:37:25,030 --> 00:37:26,531 THE SYSTEM TO WORK AND SO FAR 917 00:37:26,531 --> 00:37:29,734 EVERYTHING HAS BEEN APPROVED. 918 00:37:29,734 --> 00:37:31,636 WE HAVEN'T HAD ANY NOs FOR 919 00:37:31,636 --> 00:37:32,837 ANYTHING. 920 00:37:32,837 --> 00:37:34,272 GOING FORWARD NOW I DON'T THINK 921 00:37:34,272 --> 00:37:37,208 THERE'LL BE SIGNIFICANT DELAYS. 922 00:37:37,208 --> 00:37:39,811 WE JUST HAVE TO MAKE OUR PLANS A 923 00:37:39,811 --> 00:37:42,881 BIT FURTHER AHEAD OF TIME. 924 00:37:42,881 --> 00:37:46,117 GIVEN IN MIND YOU NEED EXTRA 925 00:37:46,117 --> 00:37:46,418 APPROVAL. 926 00:37:46,418 --> 00:37:49,421 I DON'T THINK IT WILL BE A BIG 927 00:37:49,421 --> 00:37:50,855 DEAL AND SO FAR IT'S BEEN 928 00:37:50,855 --> 00:37:52,457 WORKING FOR US. 929 00:37:52,457 --> 00:37:53,391 >> ANOTHER COMPLICATING FACTOR 930 00:37:53,391 --> 00:37:55,994 AND WE PRESENTED AND YOU MAY 931 00:37:55,994 --> 00:37:57,462 RECALL THERE ARE NEW REVIEW 932 00:37:57,462 --> 00:37:59,898 CRITERIA NOW SIMPLIFIED REVIEW 933 00:37:59,898 --> 00:38:00,999 CRITERIA. 934 00:38:00,999 --> 00:38:03,334 SO THAT WAS ANOTHER LITTLE 935 00:38:03,334 --> 00:38:10,475 HICCUP THAT CAUSED SOME NOFOs TO 936 00:38:10,475 --> 00:38:12,677 BECOME INACTIVE AND HAVE BEEN 937 00:38:12,677 --> 00:38:15,013 TRYING TO GET NOFOs WITH 938 00:38:15,013 --> 00:38:17,182 SIMPLIFIED REVIEW CRITERIA AND 939 00:38:17,182 --> 00:38:19,584 THE LAST POINT DARREN MENTIONED, 940 00:38:19,584 --> 00:38:24,456 NIAMS AT ANY GIVEN TIME HAS HAD 941 00:38:24,456 --> 00:38:26,925 RELATIVELY FEW NOFOs. 942 00:38:26,925 --> 00:38:27,959 I DON'T THINK WE'LL BE EXPECTED 943 00:38:27,959 --> 00:38:34,132 TO REDUCE THE NUMBER AT ALL. 944 00:38:34,132 --> 00:38:35,700 OTHER INSTITUTES HAD MANY MANY 945 00:38:35,700 --> 00:38:35,900 NOFOs. 946 00:38:35,900 --> 00:38:38,103 THAT'S A BIG CHALLENGE FOR THEM. 947 00:38:38,103 --> 00:38:41,439 THE OTHER AREAS WHERE THERE'S 948 00:38:41,439 --> 00:38:43,775 CHALLENGES WITH PROGRAMS LIKE 949 00:38:43,775 --> 00:38:47,645 HEAL AND NOFOs SO WE'RE SPARED A 950 00:38:47,645 --> 00:38:48,980 LOT OF THE ANGST FOR THOSE 951 00:38:48,980 --> 00:38:49,214 REASONS. 952 00:38:49,214 --> 00:38:59,724 THANKS FOR ASKING ABOUT THAT. 953 00:39:08,133 --> 00:39:11,402 >> ARE THERE QUESTIONS FOR 954 00:39:11,402 --> 00:39:12,470 AWARDS -- 955 00:39:12,470 --> 00:39:16,074 >> I EXPECT GUIDANCE WILL BE 956 00:39:16,074 --> 00:39:16,741 FORTHCOMING BUT THE MOST 957 00:39:16,741 --> 00:39:17,809 IMPORTANT THING TO KEEP IN MIND 958 00:39:17,809 --> 00:39:20,245 IS NO ONE IS SAYING YOU CAN'T 959 00:39:20,245 --> 00:39:23,114 USE ANIMAL MODELS BUT THE USE 960 00:39:23,114 --> 00:39:24,415 HAS TO BE VERY WELL JUSTIFIED. 961 00:39:24,415 --> 00:39:25,917 WHAT ALL THE OPTIONS ARE, WHAT 962 00:39:25,917 --> 00:39:27,585 YOU'RE TRYING TO ACCOMPLISH, HOW 963 00:39:27,585 --> 00:39:30,155 THIS ANIMAL MODEL OR THESE 964 00:39:30,155 --> 00:39:31,623 ANIMAL MODELS WOULD UNIQUELY 965 00:39:31,623 --> 00:39:32,457 ADVANCE THE RESEARCH. 966 00:39:32,457 --> 00:39:34,659 YOU HAVE TO JUSTIFY THE USE OF 967 00:39:34,659 --> 00:39:37,495 ANIMALS AND SHOW HOW IT'S TAKING 968 00:39:37,495 --> 00:39:42,066 YOU -- HELPING YOU MOVE TOWARDS 969 00:39:42,066 --> 00:39:45,737 HUMAN DISEASE. 970 00:39:45,737 --> 00:39:47,539 DO ANY OF MY COLLEAGUES KNOW IF 971 00:39:47,539 --> 00:39:50,141 THERE'S PLANS FOR SPECIFIC 972 00:39:50,141 --> 00:39:52,944 GUIDANCE THROUGH THE ORIVA 973 00:39:52,944 --> 00:39:53,211 EFFORT? 974 00:39:53,211 --> 00:39:55,814 >> THEY'RE WORKING ON THAT 975 00:39:55,814 --> 00:39:56,648 PRESUMABLY THEY'LL BE PUTTING 976 00:39:56,648 --> 00:39:57,649 OUT GUIDANCE ON THOSE. 977 00:39:57,649 --> 00:40:01,319 >> WE CAN TAKE A NOTE TO 978 00:40:01,319 --> 00:40:11,796 FOLLOW-UP WITH NICOLE KLE 979 00:40:17,535 --> 00:40:18,036 KLEINSTREURER. 980 00:40:18,036 --> 00:40:19,871 I'M TRYING TO LOOK AROUND FOR 981 00:40:19,871 --> 00:40:20,071 HANDS. 982 00:40:20,071 --> 00:40:21,573 ANY OTHER QUESTIONS YOU WANT TO 983 00:40:21,573 --> 00:40:24,342 RAISE AT THIS POINT ABOUT 984 00:40:24,342 --> 00:40:25,844 ANYTHING I SHARED, SOMETHING YOU 985 00:40:25,844 --> 00:40:32,550 WANT TO RAISE AT THIS POINT? 986 00:40:32,550 --> 00:40:35,854 IF NOT, WE'LL HAVE OTHER 987 00:40:35,854 --> 00:40:39,324 OPPORTUNITIES. 988 00:40:39,324 --> 00:40:41,025 IT SEEMS THERE'S BEEN PUBLIC 989 00:40:41,025 --> 00:40:43,328 STATEMENTS MADE BY THE NIH 990 00:40:43,328 --> 00:40:46,898 DIRECTOR AND OTHERS AND OST 991 00:40:46,898 --> 00:40:49,167 ABOUT GOLD STANDARD RESEARCH AND 992 00:40:49,167 --> 00:40:50,068 WHETHER WE CAN ANTICIPATE 993 00:40:50,068 --> 00:40:51,603 CHANGES COMING. 994 00:40:51,603 --> 00:40:54,105 I KNOW THERE'S BEEN A FOCUS ON 995 00:40:54,105 --> 00:40:56,441 RIGOR AND REPRODUCIBILITY FOR 996 00:40:56,441 --> 00:40:58,109 MORE THAN THE LAST DECADE AND 997 00:40:58,109 --> 00:40:59,844 DON'T KNOW IF WE CAN EXPECT 998 00:40:59,844 --> 00:41:03,214 REVISIONS OR EXPECTATIONS AROUND 999 00:41:03,214 --> 00:41:03,548 THAT. 1000 00:41:03,548 --> 00:41:04,549 >> THERE'S BEEN A LOT OF 1001 00:41:04,549 --> 00:41:07,352 CONFUSION AROUND THAT TOO. 1002 00:41:07,352 --> 00:41:09,654 SO I GUESS YOU SAID WHAT I WOULD 1003 00:41:09,654 --> 00:41:13,725 SAY WHICH IS THE MAIN THING, THE 1004 00:41:13,725 --> 00:41:17,295 WAY I INTERPRET THAT IS THAT NOW 1005 00:41:17,295 --> 00:41:18,630 MORE THAN EVER THERE'S GOING TO 1006 00:41:18,630 --> 00:41:22,267 BE A FOCUS ON REPRODUCIBILITY, 1007 00:41:22,267 --> 00:41:25,937 REPLICATION STUDIES, ROBUST 1008 00:41:25,937 --> 00:41:26,170 METHODS. 1009 00:41:26,170 --> 00:41:27,772 IT'S NOT CLEAR TO ME THAT 1010 00:41:27,772 --> 00:41:30,875 ANYTHING ELSE IS GOING TO BE 1011 00:41:30,875 --> 00:41:33,645 DRAMATICALLY DIFFERENT. 1012 00:41:33,645 --> 00:41:37,315 BUT I DON'T KNOW WHETHER ANYBODY 1013 00:41:37,315 --> 00:41:42,120 ELSE HAS HEARD DISCUSSION ON 1014 00:41:42,120 --> 00:41:44,322 WHAT THAT MIGHT MEAN FOR US 1015 00:41:44,322 --> 00:41:46,124 BEYOND REPRODUCIBILITY AND 1016 00:41:46,124 --> 00:41:52,063 REPLICATION STUDIES. 1017 00:41:52,063 --> 00:41:54,165 >> I THINK A LOT OF US WERE 1018 00:41:54,165 --> 00:41:56,634 TAKEN ABACK GIVEN THE PUSH FOR 1019 00:41:56,634 --> 00:41:59,337 SOME OF US DOING SCIENCE FOR A 1020 00:41:59,337 --> 00:42:00,104 LONG TIME. 1021 00:42:00,104 --> 00:42:03,374 I THINK RIGOR AND 1022 00:42:03,374 --> 00:42:04,542 REPRODUCIBILITY HAVE GOTTEN 1023 00:42:04,542 --> 00:42:06,077 SUBSTANTIALLY BETTER SO I WAS 1024 00:42:06,077 --> 00:42:07,679 SURPRISED TO HEAR THAT. 1025 00:42:07,679 --> 00:42:09,847 >> THE OTHER THING I'LL ADD IS A 1026 00:42:09,847 --> 00:42:13,084 BIG FOCUS FOR THE ADMINISTRATION 1027 00:42:13,084 --> 00:42:16,521 HAS BEEN ON CONCERN ABOUT 1028 00:42:16,521 --> 00:42:17,622 DISTRUST IN SCIENCE AND THE 1029 00:42:17,622 --> 00:42:19,190 SCIENTIFIC PROCESS AND 1030 00:42:19,190 --> 00:42:19,590 ACADEMICS. 1031 00:42:19,590 --> 00:42:21,993 SO I THINK THIS ALSO MAY BE AN 1032 00:42:21,993 --> 00:42:25,229 ATTEMPT AT A HIGH LEVEL TO TRY 1033 00:42:25,229 --> 00:42:32,270 TO INCREASE TRUST IN SCIENCE. 1034 00:42:32,270 --> 00:42:33,004 SO MAYBE MORE. 1035 00:42:33,004 --> 00:42:37,208 >> I WELCOME THE OPPORTUNITY TO 1036 00:42:37,208 --> 00:42:38,943 STATE IF ONE LOOKS AT THE DATA 1037 00:42:38,943 --> 00:42:41,512 FROM THE STUDY WHICH DOCUMENTS 1038 00:42:41,512 --> 00:42:43,381 REDUCTION IN TRUST, VERY SMALL, 1039 00:42:43,381 --> 00:42:44,682 I MIGHT ADD AMONG MEDICAL 1040 00:42:44,682 --> 00:42:47,418 SCIENTISTS AND SCIENTISTS, THE 1041 00:42:47,418 --> 00:42:51,622 LEVEL OF REDUCTION IN TRUST IS 1042 00:42:51,622 --> 00:42:54,125 IN FACT ALMOST EVERY OTHER 1043 00:42:54,125 --> 00:42:54,592 PROFESSION. 1044 00:42:54,592 --> 00:42:56,327 THERE'S ONLY ONE PROFESSION THAT 1045 00:42:56,327 --> 00:42:58,062 DIDN'T SHOW A DECLINE IN TRUST 1046 00:42:58,062 --> 00:42:59,864 AND THAT'S RELIGIOUS LEADERS. 1047 00:42:59,864 --> 00:43:01,866 EVERYONE ELSE SHOWED DRAMATIC 1048 00:43:01,866 --> 00:43:04,736 DECLINES FROM 2016 OR 2019 TO 1049 00:43:04,736 --> 00:43:07,005 WHEN THE DATA CAME OUT. 1050 00:43:07,005 --> 00:43:09,574 THIS DISTRUST IN SCIENCE JUST 1051 00:43:09,574 --> 00:43:11,042 SIMPLY PARALLELS AND IS ACTUALLY 1052 00:43:11,042 --> 00:43:13,544 BETTER FOR SCIENTISTS THAN IT 1053 00:43:13,544 --> 00:43:14,912 HAS BEEN FOR ANY OTHER 1054 00:43:14,912 --> 00:43:15,780 PROFESSION AND POINT OUT THE 1055 00:43:15,780 --> 00:43:18,316 GROUP WITH THE LOWEST LEVEL OF 1056 00:43:18,316 --> 00:43:20,718 TRUST AND SAW A SIGNIFICANT 1057 00:43:20,718 --> 00:43:22,854 DECLINE WAS ELECTED OFFICIALS. 1058 00:43:22,854 --> 00:43:25,323 IT'S VERY EASILY ACCESSIBLE. 1059 00:43:25,323 --> 00:43:35,066 LOOK UP THE DATA ON THE PUGH 1060 00:43:35,066 --> 00:43:36,300 FOUNDATION AND WE SHOULD BE 1061 00:43:36,300 --> 00:43:37,335 CAUTIOUS IN THE REDUCTION OF 1062 00:43:37,335 --> 00:43:40,671 TRUST IN SCIENCE AND BIO MEDICAL 1063 00:43:40,671 --> 00:43:41,906 SCIENTISTS. 1064 00:43:41,906 --> 00:43:43,608 IT REALLY ISN'T TRUE IN THAT 1065 00:43:43,608 --> 00:43:45,543 THERE'S DISTRUST IN MANY OTHER 1066 00:43:45,543 --> 00:43:48,279 THINGS AND THERE'S MANY REASONS 1067 00:43:48,279 --> 00:43:50,515 BUT ALTERNATIVE INFORMATION IN 1068 00:43:50,515 --> 00:43:50,782 RESEARCH. 1069 00:43:50,782 --> 00:43:51,682 >> THANK YOU. 1070 00:43:51,682 --> 00:43:52,583 THE BROADER CONTEXT IS 1071 00:43:52,583 --> 00:43:53,851 INCREDIBLY IMPORTANT AND THANK 1072 00:43:53,851 --> 00:43:57,021 YOU FOR THE REMINDER AND FOR 1073 00:43:57,021 --> 00:43:58,356 DIRECTING US TO THAT SURVEY. 1074 00:43:58,356 --> 00:44:07,031 THANK YOU. 1075 00:44:07,031 --> 00:44:08,566 >> THIS IS A BIT OUT OF STROKE 1076 00:44:08,566 --> 00:44:09,867 BUT IT'S MY UNDERSTANDING THE 1077 00:44:09,867 --> 00:44:12,170 PROCESS OF SCIENTIFIC REVIEW IS 1078 00:44:12,170 --> 00:44:14,005 ALSO CHANGING SUBSTANTIALLY IN 1079 00:44:14,005 --> 00:44:18,109 HOW THE STUDY SECTIONS ARE 1080 00:44:18,109 --> 00:44:19,777 PERFORMING REVIEWS AND HOW THE 1081 00:44:19,777 --> 00:44:21,079 SUMMARY STATEMENTS WILL BE. 1082 00:44:21,079 --> 00:44:24,115 >> I THINK YOU'RE REFERRING TO 1083 00:44:24,115 --> 00:44:25,950 WHAT HAVE BEEN CALLED THE 1084 00:44:25,950 --> 00:44:28,986 SIMPLIFIED REVIEW CRITERIA THAT 1085 00:44:28,986 --> 00:44:33,291 WERE LARGELY THE MAIN GOAL WAS 1086 00:44:33,291 --> 00:44:37,795 TO DECREASE REPUTATIONAL BIAS 1087 00:44:37,795 --> 00:44:39,797 AND FOCUS ON THE NEEDS OF THE 1088 00:44:39,797 --> 00:44:41,532 PROJECT INSTEAD OF SAY THE 1089 00:44:41,532 --> 00:44:45,069 REPUTATION OF THE INSTITUTION, 1090 00:44:45,069 --> 00:44:45,336 ETCETERA. 1091 00:44:45,336 --> 00:44:48,005 SO, THE SIMPLIFIED REVIEW 1092 00:44:48,005 --> 00:44:49,907 CRITERIA WENT INTO EFFECT I 1093 00:44:49,907 --> 00:44:52,977 THINK IN JANUARY. 1094 00:44:52,977 --> 00:44:56,647 IMPORTANTLY, THEY HAVE NO IMPACT 1095 00:44:56,647 --> 00:44:58,850 ON THE APPLICATIONS OR HOW 1096 00:44:58,850 --> 00:45:00,118 INVESTIGATORS SHOULD PREPARE 1097 00:45:00,118 --> 00:45:01,552 THEIR APPLICATIONS. 1098 00:45:01,552 --> 00:45:03,254 IT IS COMPLETELY ON THE SIDE OF 1099 00:45:03,254 --> 00:45:04,856 HOW REVIEWERS WILL REVIEW THEM. 1100 00:45:04,856 --> 00:45:08,159 I DON'T HAVE A SLIDE ON THAT 1101 00:45:08,159 --> 00:45:09,427 HERE BUT YEAH, I THINK THAT'S 1102 00:45:09,427 --> 00:45:12,130 WHAT YOU MUST BE THINKING ABOUT. 1103 00:45:12,130 --> 00:45:13,264 >> INDEED. 1104 00:45:13,264 --> 00:45:16,000 I WAS A LITTLE CURIOUS WITH THE 1105 00:45:16,000 --> 00:45:17,702 PAY LINE SET WHERE THEY ARE TO 1106 00:45:17,702 --> 00:45:19,137 HAVE SOME LEVEL OF FLEXIBILITY 1107 00:45:19,137 --> 00:45:21,906 OF FUNDING WITHIN THE PRIORITIES 1108 00:45:21,906 --> 00:45:24,142 OF NIAMS, THE EXTENT TO WHICH 1109 00:45:24,142 --> 00:45:27,011 THE CHANGE IN THE FORMAT MAY 1110 00:45:27,011 --> 00:45:29,981 COMPLICATE YOUR ABILITY TO 1111 00:45:29,981 --> 00:45:30,781 ASSESS THOSE THINGS. 1112 00:45:30,781 --> 00:45:33,451 THE FEEDBACK YOU MIGHT GET FROM 1113 00:45:33,451 --> 00:45:34,719 THE SCIENTIFIC REVIEW COMMITTEES 1114 00:45:34,719 --> 00:45:35,386 COULD BE. 1115 00:45:35,386 --> 00:45:38,789 >> I DON'T THINK SO BUT I GUESS 1116 00:45:38,789 --> 00:45:41,792 I'LL ALSO SHARE THAT WE HAVE 1117 00:45:41,792 --> 00:45:44,162 STFSHG REVIEW OFFICERS THAT ARE 1118 00:45:44,162 --> 00:45:48,132 INVOLVED IN OBSERVING THE STUDY 1119 00:45:48,132 --> 00:45:51,235 SECTIONS SO WE HAVE 1120 00:45:51,235 --> 00:45:53,771 OPPORTUNITIES TO TRACK THIS. 1121 00:45:53,771 --> 00:45:55,139 I'M NOT ANTICIPATING THAT THAT 1122 00:45:55,139 --> 00:45:56,541 IS GOING TO BE A COMPLICATING 1123 00:45:56,541 --> 00:45:57,542 FACTOR FOR US. 1124 00:45:57,542 --> 00:46:00,111 I THINK MUCH MORE SIGNIFICANT IS 1125 00:46:00,111 --> 00:46:03,314 CONSOLIDATING THE REVIEWS 1126 00:46:03,314 --> 00:46:07,885 CENTRALLY BUT ONCE AGAIN WE -- 1127 00:46:07,885 --> 00:46:08,853 OUR PROGRAM OFFICERS ARE 1128 00:46:08,853 --> 00:46:10,121 FAMILIAR WITH THE APPLICATION 1129 00:46:10,121 --> 00:46:11,155 AND SCIENTIFIC REVIEW OFFICERS 1130 00:46:11,155 --> 00:46:13,991 ARE INVOLVED IN THE MEET AND WE 1131 00:46:13,991 --> 00:46:15,793 HAVE A STRATEGIC PLAN AND WE DO 1132 00:46:15,793 --> 00:46:16,694 PORTFOLIO ANALYSIS SO WE HAVE 1133 00:46:16,694 --> 00:46:18,829 LOTS OF TOOLS THAT ALLOW US TO 1134 00:46:18,829 --> 00:46:20,598 TRY TO CONSIDER OTHER FACTORS 1135 00:46:20,598 --> 00:46:22,700 BEYOND THE SCORE. 1136 00:46:22,700 --> 00:46:26,003 I LIKE TO REMIND FOLKS WHENEVER 1137 00:46:26,003 --> 00:46:29,907 THE SUBJECT COMES UP THAT 1138 00:46:29,907 --> 00:46:31,642 DR. BYRNES THE DIRECTOR OF CSR 1139 00:46:31,642 --> 00:46:36,147 THAT FUNDING DECISIONS ARE NOT 1140 00:46:36,147 --> 00:46:37,748 MADE EXCLUSIVELY ON THE BASIS OF 1141 00:46:37,748 --> 00:46:39,116 THE SCORES. 1142 00:46:39,116 --> 00:46:42,119 WHERE THERE'S GAPS AND AND AVOID 1143 00:46:42,119 --> 00:46:45,790 REDUNDANCIES IN THE THINGS WE'RE 1144 00:46:45,790 --> 00:46:46,023 FUNDING. 1145 00:46:46,023 --> 00:46:48,159 THE SCORE ONE PIECE BUT NOT 1146 00:46:48,159 --> 00:46:49,126 EVERYTHING. 1147 00:46:49,126 --> 00:46:53,197 I SEE A COUPLE OTHER -- THANKS 1148 00:46:53,197 --> 00:46:57,034 FOR RAISING THAT. 1149 00:46:57,034 --> 00:47:02,106 >> FIRST, I JUST WANT TO THANK 1150 00:47:02,106 --> 00:47:09,880 YOU AND ALL THE NIAMS STAFF FOR 1151 00:47:09,880 --> 00:47:11,916 YOUR LEADERSHIP DURING THIS TIME 1152 00:47:11,916 --> 00:47:13,684 AND WE'RE VERY GRATEFUL. 1153 00:47:13,684 --> 00:47:15,186 MY QUESTION IS DO YOU EXPECT THE 1154 00:47:15,186 --> 00:47:16,320 NIAMS FUNDING PRIORITIES WILL 1155 00:47:16,320 --> 00:47:18,389 CHANGE AT ALL OVER THE LAST 1156 00:47:18,389 --> 00:47:19,190 YEAR? 1157 00:47:19,190 --> 00:47:20,291 I CONTINUE TO GET A LOT OF 1158 00:47:20,291 --> 00:47:22,126 QUESTIONS ESPECIALLY FROM 1159 00:47:22,126 --> 00:47:23,961 TRAINEES ABOUT THINGS LIKE 1160 00:47:23,961 --> 00:47:28,199 HEALTH DISPARITIES RESEARCH SO 1161 00:47:28,199 --> 00:47:30,635 ANY UPDATED GUIDANCE ON THAT 1162 00:47:30,635 --> 00:47:32,203 WOULD BE VERY APPRECIATED? 1163 00:47:32,203 --> 00:47:34,538 >> THANK YOU, FIRST OF ALL, 1164 00:47:34,538 --> 00:47:35,539 THANK YOU FOR YOUR SUPPORT. 1165 00:47:35,539 --> 00:47:37,908 I HAD THE OPPORTUNITY TO ATTEND 1166 00:47:37,908 --> 00:47:41,846 TWO MEETINGS RECENTLY THE FID 1167 00:47:41,846 --> 00:47:45,483 MEETING AND SO RATIFYING TO 1168 00:47:45,483 --> 00:47:48,185 FIELD THE REPORT FROM THE 1169 00:47:48,185 --> 00:47:52,323 COMMUNITY AND SO SOBERING TO 1170 00:47:52,323 --> 00:47:56,227 HEAR MORE DIRECTLY THE 1171 00:47:56,227 --> 00:47:56,994 CHALLENGES YOU'RE ALL FACING. 1172 00:47:56,994 --> 00:47:58,663 I APPRECIATE THE OPPORTUNITY TO 1173 00:47:58,663 --> 00:48:01,065 ENGAGE WITH INVESTIGATORS AND 1174 00:48:01,065 --> 00:48:01,832 COUNCIL MEMBERS. 1175 00:48:01,832 --> 00:48:03,834 I THINK YOU'RE ALL PROBABLY VERY 1176 00:48:03,834 --> 00:48:07,705 WELL AWARE OF A COUPLE VERY 1177 00:48:07,705 --> 00:48:09,907 SPECIFIC ISSUES, DEI, CLIMATE 1178 00:48:09,907 --> 00:48:11,742 CHANGE, ETCETERA THAT HAVE BEEN 1179 00:48:11,742 --> 00:48:15,846 IDENTIFIED AS NON-PRIORITIES FOR 1180 00:48:15,846 --> 00:48:19,083 THIS ADMINISTRATION WITH ALL THE 1181 00:48:19,083 --> 00:48:20,117 CONSEQUENCES OF THAT. 1182 00:48:20,117 --> 00:48:21,986 ON THE NOTE OF HEALTH 1183 00:48:21,986 --> 00:48:22,820 DISPARITIES THOUGH A LOT OF 1184 00:48:22,820 --> 00:48:24,155 EFFORT HAS BEEN DEVOTED TO 1185 00:48:24,155 --> 00:48:26,123 TRYING TO CLARIFY THAT HEALTH 1186 00:48:26,123 --> 00:48:27,558 DISPARITIES IS DIFFERENT FROM 1187 00:48:27,558 --> 00:48:32,463 DEI AND HEALTH DISPARITIES IS A 1188 00:48:32,463 --> 00:48:34,332 PERFECTLY LEGITIMATE IMPORTANT 1189 00:48:34,332 --> 00:48:37,435 TOPIC THAT WE NEED TO CONTINUE 1190 00:48:37,435 --> 00:48:39,370 TO WORK ON. 1191 00:48:39,370 --> 00:48:41,806 SO I KNOW IT'S A COMMON SOURCE 1192 00:48:41,806 --> 00:48:43,474 OF CONCERN AND CONFUSION. 1193 00:48:43,474 --> 00:48:46,544 IN TERMS OF THINKING MORE 1194 00:48:46,544 --> 00:48:49,280 BROADLY INCLUDING ABOUT THIS 1195 00:48:49,280 --> 00:48:50,114 ADMINISTRATION PRIORITIES WE 1196 00:48:50,114 --> 00:48:53,417 FEEL NIAMS IS VERY WELL 1197 00:48:53,417 --> 00:48:53,684 POSITIONS. 1198 00:48:53,684 --> 00:48:58,489 THERE'S AN AWFUL LOT OF CHRONIC 1199 00:48:58,489 --> 00:49:00,358 DISEASE, COMMON AND RARE, 1200 00:49:00,358 --> 00:49:03,160 AUTOIMMUNE DISEASE AND DISEASES 1201 00:49:03,160 --> 00:49:05,930 THAT AFFECT WOMEN 1202 00:49:05,930 --> 00:49:06,364 DISPROPORTIONATELY. 1203 00:49:06,364 --> 00:49:08,632 SO WE FEEL WELL POSITIONED IN 1204 00:49:08,632 --> 00:49:13,037 TERMS OF OUR PRIORITIES AND AS 1205 00:49:13,037 --> 00:49:14,071 ARTICULATED IN THE PLAN WITHIN 1206 00:49:14,071 --> 00:49:15,005 THE EXCEPTION OF A FEW SPECIFIC 1207 00:49:15,005 --> 00:49:16,574 AREAS AND OUR INVESTMENTS IN 1208 00:49:16,574 --> 00:49:18,008 THOSE AREAS ARE NOT NEARLY AS 1209 00:49:18,008 --> 00:49:20,311 SIGNIFICANT AS MANY OTHER 1210 00:49:20,311 --> 00:49:20,611 INSTITUTES. 1211 00:49:20,611 --> 00:49:22,113 SO WE HAVE HAD FEWER CHALLENGES 1212 00:49:22,113 --> 00:49:32,823 TO DEAL WITH IN TERMS OF SAD LY 1213 00:49:33,891 --> 00:49:34,592 GRANT DETERMINATIONS. 1214 00:49:34,592 --> 00:49:36,594 AND ANOTHER THING I'LL POINT OUT 1215 00:49:36,594 --> 00:49:38,562 IS THAT SOME OF OUR VERY 1216 00:49:38,562 --> 00:49:40,965 IMPORTANT EFFORTS SUCH AS THE 1217 00:49:40,965 --> 00:49:43,601 AMP PROGRAM AND SYSTEMS BIOLOGY 1218 00:49:43,601 --> 00:49:48,406 AND SYS BIO AND INTEROPERABILITY 1219 00:49:48,406 --> 00:49:50,674 ARE WELL ALIGNED ON WHAT WE'RE 1220 00:49:50,674 --> 00:49:52,476 HEARING ON A WEEKLY BASIS FROM 1221 00:49:52,476 --> 00:49:52,943 NIH LEADERSHIP. 1222 00:49:52,943 --> 00:49:55,646 I THINK WE'RE IN A GOOD POSITION 1223 00:49:55,646 --> 00:49:56,847 RELATIVELY SPEAKING FOR SURE. 1224 00:49:56,847 --> 00:49:57,415 YES. 1225 00:49:57,415 --> 00:50:00,151 >> ALONG THOSE LINES I WAS 1226 00:50:00,151 --> 00:50:04,488 NOTICING HEALTH AND DISEASE IN 1227 00:50:04,488 --> 00:50:07,525 DIVERSE POPULATION IS IN THE 1228 00:50:07,525 --> 00:50:08,726 TRIFOLD ARE YOU EXPECTING THINGS 1229 00:50:08,726 --> 00:50:13,497 OF RFAs IN THAT AREA OF 1230 00:50:13,497 --> 00:50:14,131 RESEARCH? 1231 00:50:14,131 --> 00:50:16,567 >> 1232 00:50:16,567 --> 00:50:18,402 >> YOU MEAN SETTING ASIDE FUNDS 1233 00:50:18,402 --> 00:50:21,005 FOR SPECIFIC AREAS HAS BEEN 1234 00:50:21,005 --> 00:50:22,840 CHALLENGING FOR US TO DO WITH 1235 00:50:22,840 --> 00:50:24,742 SUCH A TIGHT PAY LINE BUT WE 1236 00:50:24,742 --> 00:50:27,244 PLAN TO CONTINUE TO REFER TO OUR 1237 00:50:27,244 --> 00:50:29,847 STRATEGIC PLAN IN TERMS OF AREAS 1238 00:50:29,847 --> 00:50:32,550 WHERE INVESTMENT IS NEEDED AND 1239 00:50:32,550 --> 00:50:33,217 MONITOR AND TRACK THE PROGRESS 1240 00:50:33,217 --> 00:50:34,919 WE'RE MAKING IN THOSE AREAS AND 1241 00:50:34,919 --> 00:50:39,957 WE ALSO PLAN TO CONTINUE TO 1242 00:50:39,957 --> 00:50:42,927 ISSUE NOSIs OR NOTICES OF 1243 00:50:42,927 --> 00:50:43,527 SPECIAL INTEREST WHATEVER 1244 00:50:43,527 --> 00:50:45,930 THEY'RE CALLED IN THE FUTURE. 1245 00:50:45,930 --> 00:50:49,900 SO RFAs MAY BE TRICKY FOR US 1246 00:50:49,900 --> 00:50:55,105 BECAUSE IT REQUIRES A SET ASIDE 1247 00:50:55,105 --> 00:50:57,475 CURRENTLY WE RECEIVED 1248 00:50:57,475 --> 00:50:59,477 PROPORTIONATELY MANY MORE 1249 00:50:59,477 --> 00:51:00,244 APPLICATIONS RELATIVE TO THE 1250 00:51:00,244 --> 00:51:02,513 BUDGET WE RECEIVED FROM CONGRESS 1251 00:51:02,513 --> 00:51:05,149 COMPARED TO MOST OTHER 1252 00:51:05,149 --> 00:51:05,449 INSTITUTES. 1253 00:51:05,449 --> 00:51:07,485 SO A CHALLENGE TO SET ASIDE 1254 00:51:07,485 --> 00:51:07,718 FUNDS. 1255 00:51:07,718 --> 00:51:10,988 THAT'S WHY WE'VE WORKED SO HARD 1256 00:51:10,988 --> 00:51:13,591 TO TRY TO LEVERAGE COMMON FUND, 1257 00:51:13,591 --> 00:51:14,925 VENTURE SPACE, WHAT ARE SOME 1258 00:51:14,925 --> 00:51:15,292 OTHER THINGS? 1259 00:51:15,292 --> 00:51:20,164 WE'VE BEEN VERY SUCCESSFUL IN 1260 00:51:20,164 --> 00:51:21,165 LEVERAGING OTHER FUNDING SOURCE 1261 00:51:21,165 --> 00:51:31,509 TO MAKE UP FOR THAT. 1262 00:51:40,017 --> 00:51:42,853 YOU ALL MET BRIEFLY THIS MORNING 1263 00:51:42,853 --> 00:51:46,824 DR. ALLISTON WHO WILL PROVIDE 1264 00:51:46,824 --> 00:51:51,395 INFORMATION ON THE NIH INTERIM 1265 00:51:51,395 --> 00:51:51,629 PROGRAM. 1266 00:51:51,629 --> 00:51:53,597 SHE IS NOW THE SCIENTIFIC 1267 00:51:53,597 --> 00:51:54,798 DIRECTOR OF THE INTERIM RESEARCH 1268 00:51:54,798 --> 00:51:58,135 PROGRAM AND IN ADDITION TO 1269 00:51:58,135 --> 00:51:59,737 PLANNING, COORDINATING AND 1270 00:51:59,737 --> 00:52:02,606 DIRECTING THE IRP BASIC AND 1271 00:52:02,606 --> 00:52:03,541 SCIENTIFIC RESEARCH PROGRAMS, 1272 00:52:03,541 --> 00:52:05,976 HER KEY RESPONSIBILITIES INCLUDE 1273 00:52:05,976 --> 00:52:07,311 RECRUITING AND RETAINING WORLD 1274 00:52:07,311 --> 00:52:10,347 CLASS INVESTIGATORS AND CHARTING 1275 00:52:10,347 --> 00:52:12,249 THE FUTURE DIRECTION OF IRB 1276 00:52:12,249 --> 00:52:14,585 RESEARCH. 1277 00:52:14,585 --> 00:52:17,855 I'VE BEEN THRILLED TO HEAR FROM 1278 00:52:17,855 --> 00:52:19,557 TAMARA HER VISION EVEN IN THE 1279 00:52:19,557 --> 00:52:21,905 SHORT TIME HERE 1280 00:52:21,905 --> 00:52:26,887 DR. ALLISTON WILL 1281 00:52:26,887 --> 00:52:27,487 UPDATE YOU. 1282 00:52:27,487 --> 00:52:29,589 >> IT'S GREAT TO SHARE THIS 1283 00:52:29,589 --> 00:52:32,726 UPDATE ON BEHALF OF THE 1284 00:52:32,726 --> 00:52:34,895 INTRAMURAL RESEARCH PROGRAM. 1285 00:52:34,895 --> 00:52:39,733 BY OVERVIEW I'LL FIRST PROVIDE 1286 00:52:39,733 --> 00:52:41,868 AN INSTRUCTION. 1287 00:52:41,868 --> 00:52:44,905 I BELIEVE I NEED ASSISTANCE WITH 1288 00:52:44,905 --> 00:52:45,772 THE SLIDES. 1289 00:52:45,772 --> 00:52:47,574 I THINK THERE'S A DISCONNECT 1290 00:52:47,574 --> 00:52:50,911 WITH WHAT'S ON THE SCREEN AND 1291 00:52:50,911 --> 00:53:01,187 WHAT'S ON TEAMS. 1292 00:53:10,063 --> 00:53:11,231 FIRST BACKGROUND ABOUT MYSELF 1293 00:53:11,231 --> 00:53:15,835 BEFORE GIVING AN OVERVIEW OF THE 1294 00:53:15,835 --> 00:53:17,971 I RP THE INTRAMURAL RESEARCH 1295 00:53:17,971 --> 00:53:21,875 PROGRAM AND UPDATES ON AWARDS 1296 00:53:21,875 --> 00:53:23,143 AND PROMOTIONS AS WELL AS A 1297 00:53:23,143 --> 00:53:24,611 GLIMPSE INTO WHERE WE'RE HEADED 1298 00:53:24,611 --> 00:53:27,380 NEXT. 1299 00:53:27,380 --> 00:53:30,817 SO, ABOUT ME, I EARNED A Ph.D. 1300 00:53:30,817 --> 00:53:33,386 IN CELL BIOLOGY AND TRAINED AS A 1301 00:53:33,386 --> 00:53:34,921 BIOLOGIST THROUGH TEXAS AND THEN 1302 00:53:34,921 --> 00:53:37,223 BY WAY OF SAN FRANCISCO WHERE I 1303 00:53:37,223 --> 00:53:39,359 COMPLETED A POSTDOC STUDYING 1304 00:53:39,359 --> 00:53:42,262 BETA SIGNALLING AND WHERE MY 1305 00:53:42,262 --> 00:53:45,765 LOVE OF BONE BIOLOGY CAME INTO 1306 00:53:45,765 --> 00:53:47,100 THE FOREFRONT. 1307 00:53:47,100 --> 00:53:49,636 I WAS UNFORTUNATE TO BE ABLE TO 1308 00:53:49,636 --> 00:53:57,444 DEVELOP MY OWN LAB AT UCSF AND 1309 00:53:57,444 --> 00:54:00,847 HAVE BEEN AS A FACULTY MEMBER 1310 00:54:00,847 --> 00:54:01,915 UNTIL JANUARY. 1311 00:54:01,915 --> 00:54:05,118 I HAVE A FOCUS ON TGF BETA 1312 00:54:05,118 --> 00:54:06,519 SIGNALLING AND HOW IT'S 1313 00:54:06,519 --> 00:54:08,288 IMPORTANT IN HOMEOSTASIS AND 1314 00:54:08,288 --> 00:54:08,555 DISEASE. 1315 00:54:08,555 --> 00:54:11,257 OUR WORK LED US TO FOCUS ON 1316 00:54:11,257 --> 00:54:14,027 OSTEOCYTES AND THEIR ROLE IN 1317 00:54:14,027 --> 00:54:14,928 CONTROLLING BONE QUALITY AS WELL 1318 00:54:14,928 --> 00:54:16,830 AS OSTEOARTHRITIS AND OTHER 1319 00:54:16,830 --> 00:54:17,731 SYSTEMIC DISEASES. 1320 00:54:17,731 --> 00:54:20,266 ASIDE FROM MY CREDENTIALS AS A 1321 00:54:20,266 --> 00:54:22,435 SCIENTIST, I THINK THE THINGS 1322 00:54:22,435 --> 00:54:27,140 THAT TRACT ATTRACTED ME TO WORK 1323 00:54:27,140 --> 00:54:30,076 AT NIAMS WERE THE PROGRAMATIC 1324 00:54:30,076 --> 00:54:30,910 ACTIVITIES. 1325 00:54:30,910 --> 00:54:32,479 THE OPPORTUNITY TO MENTOR 1326 00:54:32,479 --> 00:54:34,447 TALENTED STUDENTS AND POSTDOCS, 1327 00:54:34,447 --> 00:54:37,851 PEOPLE FROM A BASIC SCIENCE, 1328 00:54:37,851 --> 00:54:38,451 ENGINEERING OR CLINICAL 1329 00:54:38,451 --> 00:54:39,586 PERSPECTIVE AS WELL AS 1330 00:54:39,586 --> 00:54:41,154 LEADERSHIP ROLES IN DIFFERENT 1331 00:54:41,154 --> 00:54:43,156 GRADUATE PROGRAMS AT UCSF 1332 00:54:43,156 --> 00:54:45,392 INCLUDING BEING A P.I. OF 1333 00:54:45,392 --> 00:54:47,193 MULTIPLE T32s AT DIFFERENT 1334 00:54:47,193 --> 00:54:48,028 POINTS. 1335 00:54:48,028 --> 00:54:49,896 IN ADDITION, I HAD SEVERAL 1336 00:54:49,896 --> 00:54:53,233 DIFFERENT ROLES IN PROGRAMATIC 1337 00:54:53,233 --> 00:54:58,238 LEADERSHIP BOTH WITHIN THE 1338 00:54:58,238 --> 00:55:00,707 MUSCULOSKELETAL SPACE AND 1339 00:55:00,707 --> 00:55:03,376 DEVELOPING A NEW MUSCULOSKELETAL 1340 00:55:03,376 --> 00:55:05,945 SYSTEM AND SERVE AS THE P.I. AS 1341 00:55:05,945 --> 00:55:10,083 THE NIAMS P30 AS A GREAT 1342 00:55:10,083 --> 00:55:11,317 OPPORTUNITY TO PROVIDE CORE 1343 00:55:11,317 --> 00:55:17,190 STRUCTURE AND SERVICE TO THAT 1344 00:55:17,190 --> 00:55:22,462 BROAD COMMUNITY FROM BIOLOGISTS 1345 00:55:22,462 --> 00:55:22,929 TO EPIDEMIOLOGISTS. 1346 00:55:22,929 --> 00:55:26,099 I HAD AN OPPORTUNITY TO SERVE IN 1347 00:55:26,099 --> 00:55:27,700 OTHER ROLES AND HAVE BEEN 1348 00:55:27,700 --> 00:55:29,235 PIVOTAL IN MY PROFESSIONAL 1349 00:55:29,235 --> 00:55:30,904 DEVELOPMENT AND JUST JOINED IN 1350 00:55:30,904 --> 00:55:32,539 2025. 1351 00:55:32,539 --> 00:55:34,007 AT A SCIENTIFIC LEVEL, THESE ARE 1352 00:55:34,007 --> 00:55:36,276 SOME BEAUTIFUL IMAGES THAT MY 1353 00:55:36,276 --> 00:55:38,011 LAB HAS DEVELOPED OVER THE YEARS 1354 00:55:38,011 --> 00:55:40,547 AND I LIKE TO SHARE THEM JUST AS 1355 00:55:40,547 --> 00:55:44,951 A POINT OF ADMIRING AND 1356 00:55:44,951 --> 00:55:46,920 APPRECIATING THE VISUAL ARTISTRY 1357 00:55:46,920 --> 00:55:48,688 AND VISUAL SCIENCE THAT WE DO 1358 00:55:48,688 --> 00:55:51,991 AND ON THE TOP LEFT IS A PICTURE 1359 00:55:51,991 --> 00:55:53,893 OF A HUMAN FEMORAL HEAD 1360 00:55:53,893 --> 00:55:56,329 COLLECTED FROM ONE OF THE 1361 00:55:56,329 --> 00:55:58,665 ORTHOPEDIC SURGEONS I HAD THE 1362 00:55:58,665 --> 00:55:59,933 FORTUNATE TO COLLABORATE WITH 1363 00:55:59,933 --> 00:56:04,704 LOOKING AT THE STRAIN THROUGH A 1364 00:56:04,704 --> 00:56:05,839 MICRO-CT SCAN THEN ON THE TOP 1365 00:56:05,839 --> 00:56:09,375 RIGHT IS AN IMAGE FROM THE 1366 00:56:09,375 --> 00:56:12,345 ADVANCED LIGHT SOURCE OF 1367 00:56:12,345 --> 00:56:14,114 LAURENCE BERKELEY NATIONAL LABS 1368 00:56:14,114 --> 00:56:16,583 LOOKING AT MINERAL DENSITY IN 1369 00:56:16,583 --> 00:56:19,119 BONES AT A HIGH RESOLUTION AND 1370 00:56:19,119 --> 00:56:22,055 THE BONE IS NETWORKS AND 1371 00:56:22,055 --> 00:56:25,925 DENDRITES AND THE LOWER RIGHT IS 1372 00:56:25,925 --> 00:56:31,831 LOOKING AT SOME TGF BETA 1373 00:56:31,831 --> 00:56:33,900 RECEPTORS TRAPPED AROUND FOCAL 1374 00:56:33,900 --> 00:56:34,167 ADHESION. 1375 00:56:34,167 --> 00:56:35,368 WE HAVE DIFFERENT LINK SCALES 1376 00:56:35,368 --> 00:56:37,670 FROM HUMAN AND CELL AND 1377 00:56:37,670 --> 00:56:39,606 MOLECULAR BIOLOGY TO NOW MORE 1378 00:56:39,606 --> 00:56:41,107 SYSTEMS APPROACHES AND THROUGH 1379 00:56:41,107 --> 00:56:44,544 THE LENS OF UNDERSTANDING THE 1380 00:56:44,544 --> 00:56:47,747 INTERACTION OF PHYSICAL SIGNALS 1381 00:56:47,747 --> 00:56:51,985 IN THESE UNIQUELY MECHANICAL 1382 00:56:51,985 --> 00:56:54,053 TISSUES THAT PLAY A ROLE IN 1383 00:56:54,053 --> 00:56:55,488 SIGNALLING ROLES FROM THE 1384 00:56:55,488 --> 00:56:57,590 PERSPECTIVE OF MECHANO BIOLOGY 1385 00:56:57,590 --> 00:57:00,560 AND HOW DO PHYSICAL FEATURES 1386 00:57:00,560 --> 00:57:03,229 DIRECT THE BIOLOGICAL FUNCTIONS 1387 00:57:03,229 --> 00:57:05,198 AROUND FROM A BIO MECHANICS 1388 00:57:05,198 --> 00:57:07,901 PERSPECTIVE AND HOW IS IT 1389 00:57:07,901 --> 00:57:09,869 BIOLOGICAL FACTORS DEFINE THE 1390 00:57:09,869 --> 00:57:10,670 UNIQUE PROPERTIES OF THE TISSUES 1391 00:57:10,670 --> 00:57:12,672 AND HOW DO THEY DECLINE WITH 1392 00:57:12,672 --> 00:57:14,908 AGING OR DISEASE. 1393 00:57:14,908 --> 00:57:17,510 TGF BETA HAS BEEN A POWERFUL 1394 00:57:17,510 --> 00:57:18,478 LENS THROUGH WHICH WE'VE TAKEN 1395 00:57:18,478 --> 00:57:20,480 ON THE CHALLENGES AND I THINK 1396 00:57:20,480 --> 00:57:23,249 THIS APPROACH GOING FROM CELL 1397 00:57:23,249 --> 00:57:26,686 AND ANIMAL MODELS TO HUMAN 1398 00:57:26,686 --> 00:57:28,988 CONDITIONS AND GENETICS THINKING 1399 00:57:28,988 --> 00:57:32,859 ACROSS THE ENGINEERING AND LIFE 1400 00:57:32,859 --> 00:57:35,228 SCIENCE BASE IS SOMETHING THAT 1401 00:57:35,228 --> 00:57:37,997 EQUIPS ME TO SERVE IN THIS ROLE 1402 00:57:37,997 --> 00:57:38,898 AT THE INTRAMURAL RESEARCH 1403 00:57:38,898 --> 00:57:39,933 PROGRAM AND EXCITE ABOUT 1404 00:57:39,933 --> 00:57:41,067 BUILDING MY OWN LABORATORY HERE 1405 00:57:41,067 --> 00:57:43,536 AS PART OF THAT PROGRAM. 1406 00:57:43,536 --> 00:57:46,906 SO, IT IS TRULY A PRIVILEGE TO 1407 00:57:46,906 --> 00:57:48,908 STEP INTO LEADERSHIP AT THIS 1408 00:57:48,908 --> 00:57:51,077 TIME AND PLACE. 1409 00:57:51,077 --> 00:57:55,081 I THINK ANYONE KNOWS YOU FEEL 1410 00:57:55,081 --> 00:57:59,185 FORTUNATE AS A LEADER TO FOLLOW 1411 00:57:59,185 --> 00:58:04,390 ON SOMEONE'S LEADERSHIP AND I'VE 1412 00:58:04,390 --> 00:58:06,292 FOLLOWED DR. O'SHAY'S DIRECTION 1413 00:58:06,292 --> 00:58:09,329 AS DIRECTOR OF THE PROGRAM. 1414 00:58:09,329 --> 00:58:11,231 HE SERVED IN THAT ROLE FOR 20 1415 00:58:11,231 --> 00:58:14,200 YEARS AND REMAINS AN INTEGRAL 1416 00:58:14,200 --> 00:58:15,969 PART OF OUR SCIENTIFIC PROGRAM 1417 00:58:15,969 --> 00:58:18,938 AND IS READY TO HAND OVER THE 1418 00:58:18,938 --> 00:58:22,942 REINS OF THIS LEADERSHIP 1419 00:58:22,942 --> 00:58:23,209 COMPONENT. 1420 00:58:23,209 --> 00:58:25,445 HE HAS BUILT A WONDERFUL STRONG 1421 00:58:25,445 --> 00:58:27,313 IRP AND IS IT EXCITING TO STEP 1422 00:58:27,313 --> 00:58:27,847 INTO THIS ROLE. 1423 00:58:27,847 --> 00:58:31,484 SO FOR THOSE WHO ARE LESS 1424 00:58:31,484 --> 00:58:33,886 FAMILIAR WITH THE INTRAMURAL 1425 00:58:33,886 --> 00:58:37,190 RESEARCH PROGRAM AS I WOULD 1426 00:58:37,190 --> 00:58:41,094 ADMIT I WAS AND HAVE BEEN 1427 00:58:41,094 --> 00:58:42,161 LEARNING A LOT THE IRP 1428 00:58:42,161 --> 00:58:47,600 REPRESENTS 11.5% OF THE BUDGET 1429 00:58:47,600 --> 00:58:50,703 AND THE BUDGET IS AROUND $79 1430 00:58:50,703 --> 00:58:50,937 MILLION. 1431 00:58:50,937 --> 00:58:52,939 THIS IS CONSISTENT ACROSS ALL OF 1432 00:58:52,939 --> 00:58:56,643 THE INSTITUTES AT NIH, THE 1433 00:58:56,643 --> 00:58:58,044 INTRAMURAL RESEARCH PROGRAM FOR 1434 00:58:58,044 --> 00:58:59,512 NIAMS IS ON TARGET WITH WHAT IT 1435 00:58:59,512 --> 00:59:01,114 IS FOR ALL THE OTHERS. 1436 00:59:01,114 --> 00:59:03,716 OF THAT BUDGET, ABOUT HALF OF IT 1437 00:59:03,716 --> 00:59:08,521 IS DEDICATED TOWARDS -- I WON'T 1438 00:59:08,521 --> 00:59:10,957 SAY INTERDIRECT COSTS BUT 1439 00:59:10,957 --> 00:59:13,192 THINGS -- INDIRECT COST BUT 1440 00:59:13,192 --> 00:59:15,862 THINGS SET AND FIXED IN TERMS OF 1441 00:59:15,862 --> 00:59:18,898 RESOURCES NEEDED TO OPERATE THE 1442 00:59:18,898 --> 00:59:20,867 REMARKABLE NIH CLINICAL CENTER 1443 00:59:20,867 --> 00:59:22,235 AND IT'S THE REMAINING PIECE WE 1444 00:59:22,235 --> 00:59:24,604 USE TO DEFINE AND RUN THE 1445 00:59:24,604 --> 00:59:26,372 SCIENTIFIC PROGRAM THAT I LEAD, 1446 00:59:26,372 --> 00:59:27,840 THE CLINICAL PROGRAM WHICH IS 1447 00:59:27,840 --> 00:59:34,914 LED BY MY COLLEAGUE, DR. RO 1448 00:59:34,914 --> 00:59:35,782 DR. ROBERTFULBERT AND THE 1449 00:59:35,782 --> 00:59:36,816 TRAINING AND ADMINISTRATION. 1450 00:59:36,816 --> 00:59:40,720 TO GIVE PERSPECTIVE, THE 1451 00:59:40,720 --> 00:59:42,889 SCIENTIFIC PROGRAM IS DIVERSE 1452 00:59:42,889 --> 00:59:45,825 AND EXPANDS FROM BASIC 1453 00:59:45,825 --> 00:59:47,260 TRANSLATIONAL AND POPULATION 1454 00:59:47,260 --> 00:59:48,761 RESEARCH AND THERE'S ABOUT 25 1455 00:59:48,761 --> 00:59:50,563 MORE SENIOR LEVEL INVESTIGATORS 1456 00:59:50,563 --> 00:59:53,366 WHO ARE DRIVING THOSE RESEARCH 1457 00:59:53,366 --> 00:59:54,901 AGENDAS AND IT'S ALSO SUPPORTED 1458 00:59:54,901 --> 00:59:56,903 BY SOME OUTSTANDING RESEARCH 1459 00:59:56,903 --> 00:59:58,905 WHICH I'LL TELL YOU A LITTLE BIT 1460 00:59:58,905 --> 01:00:01,841 MORE ABOUT. 1461 01:00:01,841 --> 01:00:05,111 THE OTHER IS THE CLINICAL 1462 01:00:05,111 --> 01:00:06,479 PROGRAM WHICH OPERATES THROUGH 1463 01:00:06,479 --> 01:00:10,350 THE NIH CLINICAL CENTER. 1464 01:00:10,350 --> 01:00:12,552 THERE'S TWO BUSY CONSULT 1465 01:00:12,552 --> 01:00:14,520 SERVICES ON RHEUMATOLOGY AND 1466 01:00:14,520 --> 01:00:15,388 DERMATOLOGY AND WE'RE TAKING 1467 01:00:15,388 --> 01:00:18,491 CARE OF AND LEARNING ABOUT 1468 01:00:18,491 --> 01:00:21,627 PEOPLE WITH RHEUMATOLOGIC AND 1469 01:00:21,627 --> 01:00:24,664 DERM TOLL OGIC DISEASE AND AND 1470 01:00:24,664 --> 01:00:25,832 PROVIDING SUPPORT IN NCI OR 1471 01:00:25,832 --> 01:00:29,335 NIDDK AND ALL THE OTHER 1472 01:00:29,335 --> 01:00:31,704 INSTITUTES WHEN THOSE PATIENTS 1473 01:00:31,704 --> 01:00:32,505 HAVE THOSE CONCERNS. 1474 01:00:32,505 --> 01:00:35,274 SO THIS IS A REALLY IMPORTANT 1475 01:00:35,274 --> 01:00:37,243 PART OF WHAT THE NIAMS 1476 01:00:37,243 --> 01:00:39,612 INTRAMURAL PROGRAM DOES THAT 1477 01:00:39,612 --> 01:00:42,548 DERMATOLOGY GROUP IS THE BUSIEST 1478 01:00:42,548 --> 01:00:45,017 OF ALL THE CLINICAL CONSULT 1479 01:00:45,017 --> 01:00:48,654 SERVICES IN ADDITION WE ALSO RUN 1480 01:00:48,654 --> 01:00:50,256 A FELLOWSHIP PROGRAM IN 1481 01:00:50,256 --> 01:00:50,890 DERMATOLOGY. 1482 01:00:50,890 --> 01:00:53,092 IN ADDITION TO THE SCIENTIFIC 1483 01:00:53,092 --> 01:00:54,360 AND CLINICAL PROGRAM LIKE 1484 01:00:54,360 --> 01:00:58,898 EXTRAMURAL INSTITUTIONS WE HAVE 1485 01:00:58,898 --> 01:01:02,368 A VIBRANT AND CRITICAL TRAINING 1486 01:01:02,368 --> 01:01:05,037 PROGRAM WITH ABOUT 90 TRAINEES 1487 01:01:05,037 --> 01:01:06,906 AND SUPPORTED BY AN 1488 01:01:06,906 --> 01:01:09,509 ADMINISTRATIVE BRANCH AND THIS 1489 01:01:09,509 --> 01:01:11,177 COMPRISES ABOUT 263 STAFF. 1490 01:01:11,177 --> 01:01:14,147 MANY OF WHOM ARE SENIOR 1491 01:01:14,147 --> 01:01:15,348 SCIENTISTS WORKING IN THE LABS 1492 01:01:15,348 --> 01:01:17,750 OF THESE DIFFERENT INVESTIGATORS 1493 01:01:17,750 --> 01:01:20,420 AND THE CLINICAL PROGRAMS. 1494 01:01:20,420 --> 01:01:21,921 SO, IT'S NICE AT THIS 1495 01:01:21,921 --> 01:01:23,289 APPOINTMENT OF COUNCIL TO TAKE A 1496 01:01:23,289 --> 01:01:26,893 SMALL STEP BACK FROM THE FIRST 1497 01:01:26,893 --> 01:01:29,929 FOUR MONTHS OF LEARNING SO MUCH 1498 01:01:29,929 --> 01:01:34,901 AND SOME UNIQUE CIRCUMSTANCES. 1499 01:01:34,901 --> 01:01:37,904 TO REFLECT ON ABOUT WHAT STANDS 1500 01:01:37,904 --> 01:01:39,739 OUT AND MAKES THE PROGRAM UNIQUE 1501 01:01:39,739 --> 01:01:41,874 AND SPECIAL AND STRONG. 1502 01:01:41,874 --> 01:01:44,844 AS AN EXTRAMURAL PERSON WE ALL 1503 01:01:44,844 --> 01:01:47,313 UNDERSTAND THE UNIQUE FUNDING 1504 01:01:47,313 --> 01:01:49,749 MECHANISM THAT WE HAVE HERE AND 1505 01:01:49,749 --> 01:01:52,351 HOW THE ACCESS TO INTRAMURAL 1506 01:01:52,351 --> 01:01:53,653 FUNDING PROVIDES THE OPPORTUNITY 1507 01:01:53,653 --> 01:01:56,823 FOR HIGH RISK, HIGH IMPACT 1508 01:01:56,823 --> 01:01:58,458 SCIENCE AND SO I THINK THESE ARE 1509 01:01:58,458 --> 01:02:00,526 POINTS THAT ARE ABOVE AND BEYOND 1510 01:02:00,526 --> 01:02:02,395 WHAT WE ALREADY KNOW THAT HAVE 1511 01:02:02,395 --> 01:02:04,931 REALLY STRUCK ME. 1512 01:02:04,931 --> 01:02:06,899 SO I THINK THE INTRAMURAL 1513 01:02:06,899 --> 01:02:07,600 PROGRAM PROVIDES AN INCREDIBLE 1514 01:02:07,600 --> 01:02:10,903 OPPORTUNITY AND I'VE SEEN IT ON 1515 01:02:10,903 --> 01:02:13,906 A DAILY BASIS FOR TRANSLATIONAL 1516 01:02:13,906 --> 01:02:14,173 DISCOVERY. 1517 01:02:14,173 --> 01:02:16,509 WHAT I MEAN BY THAT? 1518 01:02:16,509 --> 01:02:18,811 IT'S SIGN THAT IS HUMAN CENTERED 1519 01:02:18,811 --> 01:02:20,146 AND STARTS WITH OBSERVATIONS IN 1520 01:02:20,146 --> 01:02:21,848 THE CLINIC AND MOTIVATE AND 1521 01:02:21,848 --> 01:02:23,683 DRIVE THE KINDS OF DISCOVERY 1522 01:02:23,683 --> 01:02:26,385 SCIENCE IN THE LAB THAT ENABLES 1523 01:02:26,385 --> 01:02:28,254 THOSE QUESTIONS TO BE ADDRESSED. 1524 01:02:28,254 --> 01:02:30,890 SO THE SCIENCE IS DEEPLY BASIC, 1525 01:02:30,890 --> 01:02:33,025 VERY FUNDAMENTAL BUT VERY CLOSE 1526 01:02:33,025 --> 01:02:33,960 TO THE PATIENT. 1527 01:02:33,960 --> 01:02:35,294 SOME OF THE THINGS THAT ENABLE 1528 01:02:35,294 --> 01:02:37,964 THAT TO HAPPEN ARE THE STRENGTHS 1529 01:02:37,964 --> 01:02:41,200 OF THE NIH CLINICAL CENTER AND 1530 01:02:41,200 --> 01:02:42,702 STUDYING AND UNDERSTANDING RARE 1531 01:02:42,702 --> 01:02:45,004 DISEASES BOTH IT THOSE WITHIN 1532 01:02:45,004 --> 01:02:48,774 THE NIAMS MISSION AREA AND 1533 01:02:48,774 --> 01:02:51,310 BEYOND WHERE THERE ARE 1534 01:02:51,310 --> 01:02:53,513 MUSCULOSKELETAL SKIN OR 1535 01:02:53,513 --> 01:02:56,115 RHEUMATOLOGICAL COMPONENTS AN 1536 01:02:56,115 --> 01:02:57,450 ROBUST LONGITUDINAL COHORTS 1537 01:02:57,450 --> 01:02:59,285 STUDIES IN SOME CASES FOR 1538 01:02:59,285 --> 01:03:01,787 DECADES THAT ENABLE DEEP 1539 01:03:01,787 --> 01:03:02,889 DISCOVERY. 1540 01:03:02,889 --> 01:03:06,592 WE HAVE POWERFUL INTEGRATED 1541 01:03:06,592 --> 01:03:07,827 SCIENTIFIC CORPS LED BY 1542 01:03:07,827 --> 01:03:09,695 SCIENTISTS AND DEEPLY INVOLVED 1543 01:03:09,695 --> 01:03:12,031 IN THE RESEARCH OF EVERY PROGRAM 1544 01:03:12,031 --> 01:03:13,032 WITHIN THE INTRAMURAL RESEARCH 1545 01:03:13,032 --> 01:03:16,669 PROGRAM AND I THINK THAT PROPELS 1546 01:03:16,669 --> 01:03:17,770 CERTAIN PRECISION MEDICINE 1547 01:03:17,770 --> 01:03:18,938 APPROACH THAT HAS THINGS COMING 1548 01:03:18,938 --> 01:03:20,506 FROM THE LAB DIRECTLY TO 1549 01:03:20,506 --> 01:03:22,475 PATIENTS AND SUPPORTED BY 1550 01:03:22,475 --> 01:03:25,244 TECHNOLOGY TRANSFER OFFICE THAT 1551 01:03:25,244 --> 01:03:27,914 FACILITATES THIS AND I WAS PROUD 1552 01:03:27,914 --> 01:03:28,915 TO DISCOVER NIAMS INVESTIGATORS 1553 01:03:28,915 --> 01:03:31,417 ARE AMONG THE BEST AT NIH IN 1554 01:03:31,417 --> 01:03:37,156 MOVING OUR DISCOVERIES INTO THE 1555 01:03:37,156 --> 01:03:38,457 CLINIC AND COMMERCIAL SPACE. 1556 01:03:38,457 --> 01:03:42,962 ANOTHER MAJOR UNIQUE THING IS 1557 01:03:42,962 --> 01:03:44,096 THE SCIENTIFIC WORKFORCE. 1558 01:03:44,096 --> 01:03:45,298 INTERESTINGLY TODAY I HAD TO GO 1559 01:03:45,298 --> 01:03:48,301 BACK AND DOUBLE CHECK I HAD THE 1560 01:03:48,301 --> 01:03:50,136 DEGREES CORRECT ON EACH OF OUR 1561 01:03:50,136 --> 01:03:50,770 INVESTIGATORS BECAUSE IT'S 1562 01:03:50,770 --> 01:03:53,005 SOMETIMES DIFFICULT TO KNOW IF 1563 01:03:53,005 --> 01:03:54,273 SOMEBODY WAS Ph.D. TRAINED OR 1564 01:03:54,273 --> 01:03:58,911 M.D. TRAINED BECAUSE THEY'RE 1565 01:03:58,911 --> 01:04:02,848 BLURRING OR GRAZING THE LINES 1566 01:04:02,848 --> 01:04:05,451 EVERY TIME AND I CAN SAY FOR 1567 01:04:05,451 --> 01:04:08,354 ALMOST EVERY INVESTIGATOR IN THE 1568 01:04:08,354 --> 01:04:08,521 IRP. 1569 01:04:08,521 --> 01:04:13,793 ANOTHER FEATURE IS LONG-TERM 1570 01:04:13,793 --> 01:04:14,527 STAFF SCIENTISTS WITH STABILITY 1571 01:04:14,527 --> 01:04:17,296 AND DIFFICULT TO SUSTAIN IN AN 1572 01:04:17,296 --> 01:04:18,297 EXTRAMURAL ENVIRONMENT BY NATURE 1573 01:04:18,297 --> 01:04:20,566 OF THE FUNDING MECHANISM AND 1574 01:04:20,566 --> 01:04:22,201 TRAINING MISSION OF THE 1575 01:04:22,201 --> 01:04:22,568 UNIVERSITY. 1576 01:04:22,568 --> 01:04:24,804 BECAUSE WE HAVE THIS STAFF 1577 01:04:24,804 --> 01:04:26,372 SCIENTIST EXPERTISE IT ENABLED 1578 01:04:26,372 --> 01:04:29,842 US TO PROVIDE AN OUTSTANDING 1579 01:04:29,842 --> 01:04:30,943 TRAINING ENVIRONMENT FOR 1580 01:04:30,943 --> 01:04:33,179 POST-BACS RIGHT OUT OF UNDERGRAD 1581 01:04:33,179 --> 01:04:34,547 AS WELL AS FOR POSTDOCS. 1582 01:04:34,547 --> 01:04:37,350 IN THIS FORUM I WOULD LIKE TO 1583 01:04:37,350 --> 01:04:40,019 ENCOURAGE PEOPLE TO ARE IN AN 1584 01:04:40,019 --> 01:04:41,153 UNDERGRADUATE ENVIRONMENT TO 1585 01:04:41,153 --> 01:04:45,024 PLEASE ENCOURAGE YOUR STUDENTS 1586 01:04:45,024 --> 01:04:46,325 TO CONSIDER THE NIAMS POST-BAC 1587 01:04:46,325 --> 01:04:46,892 TRAINING PROGRAM. 1588 01:04:46,892 --> 01:04:48,427 THERE'S A WEBSITE WHERE PEOPLE 1589 01:04:48,427 --> 01:04:48,894 CAN APPLY. 1590 01:04:48,894 --> 01:04:50,896 WE WOULD LOVE TO GET THOSE 1591 01:04:50,896 --> 01:04:53,466 APPLICATIONS ESPECIALLY IN THE 1592 01:04:53,466 --> 01:04:54,300 NIAMS MISSION AREAS AND WE'RE 1593 01:04:54,300 --> 01:04:56,035 ALWAYS LOOKING FOR TALENTED 1594 01:04:56,035 --> 01:04:57,570 PEOPLE AND KNOW WE PROVIDE A 1595 01:04:57,570 --> 01:04:59,271 VITAL PIPELINE FOR INDIVIDUALS 1596 01:04:59,271 --> 01:05:01,173 GOING ON TO FURTHER MEDICAL 1597 01:05:01,173 --> 01:05:02,908 SCHOOL OR GRADUATE SCHOOL AND 1598 01:05:02,908 --> 01:05:04,744 OTHER PROFESSIONAL TRAINING. 1599 01:05:04,744 --> 01:05:06,312 LIKEWISE, WE WOULD ENCOURAGE 1600 01:05:06,312 --> 01:05:09,749 ESPECIALLY THOSE OF YOU WHO HAVE 1601 01:05:09,749 --> 01:05:12,485 T32s TO INTEREST ENCOURAGING 1602 01:05:12,485 --> 01:05:16,389 YOUR TRAINEES TO LOOK TO THE NIH 1603 01:05:16,389 --> 01:05:18,124 PROGRAM AS A GOOD PLACE TO 1604 01:05:18,124 --> 01:05:19,892 CONTINUE THEIR TRAINING IN THE 1605 01:05:19,892 --> 01:05:21,460 NIAMS SPACE AS POSTDOCS. 1606 01:05:21,460 --> 01:05:25,564 I WOULD BE PERSONALLY VERY HAPPY 1607 01:05:25,564 --> 01:05:26,632 TO HELP HAVE CONVERSATIONS WITH 1608 01:05:26,632 --> 01:05:27,633 ANYONE AND TO HELP DIRECT YOU TO 1609 01:05:27,633 --> 01:05:30,703 THE RIGHT PLACE. 1610 01:05:30,703 --> 01:05:33,406 AND THE LAST POINT I THINK IS A 1611 01:05:33,406 --> 01:05:36,509 UNIQUE STRENGTH OF THE NIAMS I 1612 01:05:36,509 --> 01:05:39,512 SEE YOU AS THE CONNECTED TISSUE 1613 01:05:39,512 --> 01:05:41,347 OF NIH AND A BIT OF A PUN BUT 1614 01:05:41,347 --> 01:05:41,547 TRUE. 1615 01:05:41,547 --> 01:05:43,849 THE FUNDING FOR OUR 1616 01:05:43,849 --> 01:05:44,950 INVESTIGATORS IN AUTOIMMUNE 1617 01:05:44,950 --> 01:05:46,385 DISEASE RESEARCH IN PARTICULAR 1618 01:05:46,385 --> 01:05:48,521 IS A GREAT EXAMPLE OF THE WAY 1619 01:05:48,521 --> 01:05:53,125 THAT WE MAKE BRIDGES ACROSS THE 1620 01:05:53,125 --> 01:05:54,694 INSTITUTES AND HOPEFULLY AS WELL 1621 01:05:54,694 --> 01:05:58,664 AS NOT JUST BEING A CONNECTED 1622 01:05:58,664 --> 01:06:00,433 TISSUE WITHIN NIH AND BETWEEN 1623 01:06:00,433 --> 01:06:01,000 INTRAMURAL AND EXTRAMURAL 1624 01:06:01,000 --> 01:06:02,301 SCIENCE GOING FORWARD. 1625 01:06:02,301 --> 01:06:04,303 TO GIVE YOU MORE SPECIFICITY, 1626 01:06:04,303 --> 01:06:07,440 THESE ARE THE TENURED 1627 01:06:07,440 --> 01:06:08,474 INVESTIGATORS WITHIN THE NIAMS 1628 01:06:08,474 --> 01:06:08,641 IRP. 1629 01:06:08,641 --> 01:06:11,143 YOU CAN SEE WITH THE ICONS ON 1630 01:06:11,143 --> 01:06:15,414 THE SIDE THEY SPAN THE MISSION 1631 01:06:15,414 --> 01:06:15,614 AREAS. 1632 01:06:15,614 --> 01:06:17,983 MARCUS TAFNER AND PAUL LINKFIELD 1633 01:06:17,983 --> 01:06:21,654 ARE THE MOST BASIC SCIENTISTS 1634 01:06:21,654 --> 01:06:23,689 LOOKING AT BASIC BIOLOGY AND 1635 01:06:23,689 --> 01:06:26,759 STRUCTURAL BIOLOGY AND PROTEIN 1636 01:06:26,759 --> 01:06:30,096 STRUCTURES AND THEN 1637 01:06:30,096 --> 01:06:35,401 INVESTIGATORS THAT ARE FOCUSSED 1638 01:06:35,401 --> 01:06:42,908 ON BONE AND RHEUMATOLOGIC AND 1639 01:06:42,908 --> 01:06:44,677 IMMUNOLOGIC AND LOOKING AT THE 1640 01:06:44,677 --> 01:06:48,647 IN CAN AND UNCOVER THE 1641 01:06:48,647 --> 01:06:50,082 UNDERLYING MECHANISM. 1642 01:06:50,082 --> 01:06:52,051 WE HAVE KEN TURE PRAC 1643 01:06:52,051 --> 01:06:53,385 INVESTIGATORS AND OTHERS WHO ARE 1644 01:06:53,385 --> 01:06:55,955 AT DIFFERENT STAGES AND TYPES OF 1645 01:06:55,955 --> 01:06:58,624 POSITIONS WHO REALLY COMPLEMENT 1646 01:06:58,624 --> 01:07:01,894 AND ROUND OUT THE EXPERTISE 1647 01:07:01,894 --> 01:07:02,895 ACROSS THE RANGE OF MISSION 1648 01:07:02,895 --> 01:07:04,497 AREAS. 1649 01:07:04,497 --> 01:07:05,364 NOW, SPEAKING ABOUT THE PROGRAMS 1650 01:07:05,364 --> 01:07:10,903 I ALREADY ALLUDED TO AND THE 1651 01:07:10,903 --> 01:07:12,938 PROGRAM WHICH IS RICH WITH STAFF 1652 01:07:12,938 --> 01:07:14,540 CONDITIONS AND CLINICAL 1653 01:07:14,540 --> 01:07:17,343 INVESTIGATORS AND NURSE 1654 01:07:17,343 --> 01:07:18,410 PRACTITIONERS THAT FACILITATE 1655 01:07:18,410 --> 01:07:19,712 THE CLINICAL RESEARCH THAT 1656 01:07:19,712 --> 01:07:23,015 HAPPENS HERE AND I'D MENTIONED 1657 01:07:23,015 --> 01:07:26,619 THE RHEUMATOLOGY CONSULT 1658 01:07:26,619 --> 01:07:26,886 SERVICE. 1659 01:07:26,886 --> 01:07:28,487 TO SUPPORT THE TRAINING MISSION 1660 01:07:28,487 --> 01:07:29,388 OF THE INTRAMURAL RESEARCH 1661 01:07:29,388 --> 01:07:33,359 PROGRAM WE HAVE THE OFFICE OF 1662 01:07:33,359 --> 01:07:43,903 SCIENTIFIC OPERATIONS THE MAIN S 1663 01:07:45,905 --> 01:07:47,673 THAT FLOURISH ARE THE POST-BACS 1664 01:07:47,673 --> 01:07:50,142 AND POSTDOCS. 1665 01:07:50,142 --> 01:07:50,943 IT'S AN EXTRAORDINARY TRAINING 1666 01:07:50,943 --> 01:07:53,379 FOR THE GROUPS AND CLINICAL 1667 01:07:53,379 --> 01:07:55,281 FELLOWS AN IN MOST YEAR SUMMER 1668 01:07:55,281 --> 01:07:58,484 STUDENTS THOUGH THAT IS ON HOLD 1669 01:07:58,484 --> 01:08:00,686 FOR THIS YEAR. 1670 01:08:00,686 --> 01:08:11,230 THE OFFICE SUPPORT THE RETREAT 1671 01:08:11,831 --> 01:08:14,099 OF OTHERS AND THE OTHER IS THE 1672 01:08:14,099 --> 01:08:18,904 OFFICE OF SCIENCE AND 1673 01:08:18,904 --> 01:08:19,205 TECHNOLOGY. 1674 01:08:19,205 --> 01:08:22,208 THIS GROUP OF SCIENTISTS YOU SEE 1675 01:08:22,208 --> 01:08:26,912 LISTED ON THE LEFT OVERSEE A 1676 01:08:26,912 --> 01:08:30,683 RANGE OF CORPS THAT PROVIDE 1677 01:08:30,683 --> 01:08:31,217 INTRAMURAL INVESTIGATORS 1678 01:08:31,217 --> 01:08:34,887 EXPERTISE IN GENOMICS. 1679 01:08:34,887 --> 01:08:38,924 IT'S ARGUABLE WE HAVE THE BEST 1680 01:08:38,924 --> 01:08:41,393 GENOMICS CORPS OF THE NIH AND 1681 01:08:41,393 --> 01:08:44,063 IT'S EXCITING THE WAY THEY SEE 1682 01:08:44,063 --> 01:08:45,631 SERVICE AND PROPEL THE FIELD 1683 01:08:45,631 --> 01:08:49,335 THROUGH THE TECHNOLOGIES THEY'RE 1684 01:08:49,335 --> 01:08:49,902 DEVELOPING. 1685 01:08:49,902 --> 01:08:53,372 WE HAVE IMMUNOLOGY AND FLOW 1686 01:08:53,372 --> 01:08:56,508 CYTOMETRY AND GREAT LIGHT 1687 01:08:56,508 --> 01:09:00,112 IMAGING BIO DATA MINING 1688 01:09:00,112 --> 01:09:01,847 DISCOVERY AND ANIMAL PROGRAM IN 1689 01:09:01,847 --> 01:09:03,782 THE LAST SEVERAL MONTHS I'VE HAD 1690 01:09:03,782 --> 01:09:05,551 THE OPPORTUNITY TO WITNESS THE 1691 01:09:05,551 --> 01:09:08,354 DEDICATION AND EXPERTISE OF OUR 1692 01:09:08,354 --> 01:09:10,823 ADMINISTRATIVE BRANCH LED BY 1693 01:09:10,823 --> 01:09:12,324 VALERIE GREEN WHO HAVE BEEN 1694 01:09:12,324 --> 01:09:14,894 TIRELESS AND CREATIVE IN TRYING 1695 01:09:14,894 --> 01:09:20,532 TO HELP US ALL KEEP GOING AS THE 1696 01:09:20,532 --> 01:09:21,800 DIFFERENT CHALLENGES HAVE 1697 01:09:21,800 --> 01:09:26,138 EMERGED AND RETAINING A STRONG 1698 01:09:26,138 --> 01:09:28,440 ROBUST EXTRAMURAL PROGRAM GOING 1699 01:09:28,440 --> 01:09:29,375 FORWARD. 1700 01:09:29,375 --> 01:09:32,878 SO SO BECAUSE OF THE WAY THESE 1701 01:09:32,878 --> 01:09:36,682 CORE TECHNOLOGIES ARE INTEGRATED 1702 01:09:36,682 --> 01:09:40,185 IN THE SCIENCE OF ESSENTIALLY 1703 01:09:40,185 --> 01:09:42,888 EVERY PROJECT THE IMPACT AND 1704 01:09:42,888 --> 01:09:44,023 QUANTITY IS EXTRAORDINARY. 1705 01:09:44,023 --> 01:09:46,926 THIS SHOWCASES VISUALLY SOME OF 1706 01:09:46,926 --> 01:09:49,695 THOSE SUCCESSES ACROSS THE 132 1707 01:09:49,695 --> 01:09:52,731 THAT HAVE BEEN PUBLISHED IN THE 1708 01:09:52,731 --> 01:09:56,435 LAST YEAR EVEN IN THE TIME HERE 1709 01:09:56,435 --> 01:10:00,472 WE'VE HAD TWO PAPERS ACCEPTED 1710 01:10:00,472 --> 01:10:01,740 FROM OUR EXTRAMURAL 1711 01:10:01,740 --> 01:10:02,908 INVESTIGATORS. 1712 01:10:02,908 --> 01:10:05,444 ONE UNDERSTANDING THE ROLE OF 1713 01:10:05,444 --> 01:10:07,279 MICROBIOME AND PATHOGEN 1714 01:10:07,279 --> 01:10:11,183 RESISTANCE ON THE SKIN BY HEIDI 1715 01:10:11,183 --> 01:10:14,219 CONG AND ONE LOOKING AT THE ROLE 1716 01:10:14,219 --> 01:10:17,056 OF SINGLE LIP IT SIGNALLING IN 1717 01:10:17,056 --> 01:10:18,891 NK CELLS AND INFECTION AND 1718 01:10:18,891 --> 01:10:19,558 IMMUNITY. 1719 01:10:19,558 --> 01:10:21,994 WE'RE PROUD OF THE WAY THIS 1720 01:10:21,994 --> 01:10:25,564 SUPPORT SYSTEM ENABLES FANTASTIC 1721 01:10:25,564 --> 01:10:28,767 SCIENCE. 1722 01:10:28,767 --> 01:10:31,904 HERE'S ANOTHER EXAMPLE FROM ONE 1723 01:10:31,904 --> 01:10:34,540 OF OUR LEAD INVESTIGATORS 1724 01:10:34,540 --> 01:10:35,841 FOCUSSING ON MUSCLE BIOLOGY AND 1725 01:10:35,841 --> 01:10:39,445 I LIKED THE WAY HE TITLED HIS 1726 01:10:39,445 --> 01:10:42,481 SLIDE AS AN OVERNIGHT SUCCESS 1727 01:10:42,481 --> 01:10:50,222 AND SO YOU CAN SEE THE BENCH AND 1728 01:10:50,222 --> 01:10:52,491 SOME IMAGES THAT HIGHLIGHT THE 1729 01:10:52,491 --> 01:10:53,225 FUNDAMENTAL RESEARCH HE HAS DONE 1730 01:10:53,225 --> 01:10:57,262 WITH THIS GROUP LOOKING AT THE 1731 01:10:57,262 --> 01:11:07,773 ROLE OF HISTONE DECETLASE AND 1732 01:11:09,775 --> 01:11:11,910 MUSCLE GENE EXPRESSION AND 1733 01:11:11,910 --> 01:11:12,711 MUSCLE CELL FUSION AND THEN 1734 01:11:12,711 --> 01:11:15,647 CONTINUING ON TO THINK ABOUT THE 1735 01:11:15,647 --> 01:11:19,485 WAY INHIBITION OF HVACs USING A 1736 01:11:19,485 --> 01:11:22,021 PHARMACOLOGIC AGENT WAS ABLE TO 1737 01:11:22,021 --> 01:11:23,756 IMPROVE OUTCOMES IN A MOUSE 1738 01:11:23,756 --> 01:11:27,326 MODEL OF MUSCULAR DYSTROPHY AND 1739 01:11:27,326 --> 01:11:30,896 MOVING ON INTO PHASE I, II AND 1740 01:11:30,896 --> 01:11:32,031 III CLINICAL TRIALS AT THIS 1741 01:11:32,031 --> 01:11:37,803 POINT IN 2024, THE FIRST NON 1742 01:11:37,803 --> 01:11:39,972 STEROIDAL TREATMENT FOR DUCHENNE 1743 01:11:39,972 --> 01:11:48,080 MUSCULAR DYSTROPHY WAS INITIATED 1744 01:11:48,080 --> 01:11:49,982 BASED ON THE WORK FROM THIS LAB. 1745 01:11:49,982 --> 01:11:53,485 I THINK THIS IS A HALLMARK 1746 01:11:53,485 --> 01:11:57,990 EXAMPLE WHERE THE INVESTMENT AND 1747 01:11:57,990 --> 01:12:02,194 THE INFRASTRUCTURE OF THE UNIQUE 1748 01:12:02,194 --> 01:12:03,796 INTRAMURAL PROGRAM IS POWERFUL 1749 01:12:03,796 --> 01:12:04,696 AND IMPORTANT. 1750 01:12:04,696 --> 01:12:06,665 THERE'S GREAT ACCOMPLISHMENTS IN 1751 01:12:06,665 --> 01:12:09,168 THE PAST YEAR. 1752 01:12:09,168 --> 01:12:14,840 A FEW IN PARTICULAR DR. GRAYSON 1753 01:12:14,840 --> 01:12:18,911 RECENTLY RESOURCE D RECEIVED 1754 01:12:18,911 --> 01:12:23,649 TENURE AND DR. KAPLAN HAS BEEN 1755 01:12:23,649 --> 01:12:34,159 ACCEPTED IN THE PROGRAM AND 1756 01:12:34,159 --> 01:12:35,727 FUNDING ACCOMPLISHMENTS LISTED 1757 01:12:35,727 --> 01:12:35,994 HERE. 1758 01:12:35,994 --> 01:12:37,062 THERE ARE MANY OTHERS BUT THOSE 1759 01:12:37,062 --> 01:12:39,765 ARE JUST A FEW HIGHLIGHTS I 1760 01:12:39,765 --> 01:12:42,301 WANTED TO SHARE. 1761 01:12:42,301 --> 01:12:43,902 WE JUST HAD OUR NIAMS INTRAMURAL 1762 01:12:43,902 --> 01:12:46,038 PROGRAM RETREAT LAST WEEK. 1763 01:12:46,038 --> 01:12:52,611 IT WAS A FANTASTIC OCCASION WITH 1764 01:12:52,611 --> 01:12:54,613 ABOUT A HUNDRED POSTERS OVER TWO 1765 01:12:54,613 --> 01:12:56,381 DAYS WITH DISTINGUISHED 1766 01:12:56,381 --> 01:12:58,851 SPEAKERS, SCIENTISTS AS WELL AS 1767 01:12:58,851 --> 01:13:01,019 MEDICAL WRITER FOR THE 1768 01:13:01,019 --> 01:13:01,920 ASSOCIATED PRESS WHO CAME TO 1769 01:13:01,920 --> 01:13:05,124 INSPIRE AND TEACH US ABOUT THE 1770 01:13:05,124 --> 01:13:09,394 WORK THEY'RE DOING. 1771 01:13:09,394 --> 01:13:11,263 SO THINKING FORWARD ABOUT THE 1772 01:13:11,263 --> 01:13:13,732 NIAMS IRP AS MENTIONED IT'S 1773 01:13:13,732 --> 01:13:15,534 ALREADY A VERY STRONG PROGRAM. 1774 01:13:15,534 --> 01:13:17,169 BUT THERE ARE SOME THINGS THAT 1775 01:13:17,169 --> 01:13:19,371 I'M EXCITED TO IMPLEMENT AND I 1776 01:13:19,371 --> 01:13:20,906 THINK IN FUTURE YEARS I'LL COME 1777 01:13:20,906 --> 01:13:24,376 BACK WITH MORE SPECIFICITY FOR 1778 01:13:24,376 --> 01:13:25,944 YOU ABOUT THOSE. 1779 01:13:25,944 --> 01:13:27,646 FOR NOW, ONE OF THE THINGS WE'VE 1780 01:13:27,646 --> 01:13:32,184 DONE IS ESTABLISHED THIS 1781 01:13:32,184 --> 01:13:33,886 LEADERSHIP CHANGE INCLUDING 1782 01:13:33,886 --> 01:13:36,054 MYSELF AND DR. COLBERT AS THE 1783 01:13:36,054 --> 01:13:36,955 SCIENTIFIC CLINICAL. 1784 01:13:36,955 --> 01:13:39,925 WE HAVE NEW DEPUTY CLINICAL S 1785 01:13:39,925 --> 01:13:50,469 FROM DR. KAPLAN AND DR. KONG AND 1786 01:13:53,539 --> 01:13:58,177 DR. SARTORELLI TO ALLOW THE MOST 1787 01:13:58,177 --> 01:14:01,547 EFFICIENT AND INNOVATIVE USE AND 1788 01:14:01,547 --> 01:14:05,017 DEVELOPMENT OF CORE RESOURCES TO 1789 01:14:05,017 --> 01:14:06,185 SUPPORT NIH. 1790 01:14:06,185 --> 01:14:08,220 ONE THING I WAS INTENTIONAL 1791 01:14:08,220 --> 01:14:10,022 ABOUT IS SECURING REPRESENTATION 1792 01:14:10,022 --> 01:14:11,156 ACROSS THE DIFFERENT TISSUE 1793 01:14:11,156 --> 01:14:13,959 AREAS SO WE CAN REALLY MAKE SURE 1794 01:14:13,959 --> 01:14:17,429 THIS SET OF RESOURCES BENEFITS 1795 01:14:17,429 --> 01:14:20,832 ALL THE DIFFERENT COMMUNITIES 1796 01:14:20,832 --> 01:14:21,867 THAT NIAMS REPRESENTS. 1797 01:14:21,867 --> 01:14:24,670 SO WE ARE RIGHT NOW WORKING ON 1798 01:14:24,670 --> 01:14:26,338 OUR STRATEGIC PLAN AND WE'LL 1799 01:14:26,338 --> 01:14:29,508 COME BACK TO YOU BUT I WILL 1800 01:14:29,508 --> 01:14:31,410 SHARE IN THE SHORT TERM THAT WE 1801 01:14:31,410 --> 01:14:33,145 INTEND TO FOCUS ON THESE 1802 01:14:33,145 --> 01:14:36,315 STRENGTHS AND START THERE. 1803 01:14:36,315 --> 01:14:37,683 REALLY LOOKING FOR OPPORTUNITIES 1804 01:14:37,683 --> 01:14:41,420 TO ADVANCE HUMAN BIOLOGY, HUMAN 1805 01:14:41,420 --> 01:14:42,921 DISCOVERY BIOLOGY USING 1806 01:14:42,921 --> 01:14:46,124 MULTI-MODAL APPROACHES AND DATA 1807 01:14:46,124 --> 01:14:53,332 SCIENCES AS WELL AS THE -- THE 1808 01:14:53,332 --> 01:14:54,933 ACRONYMS KEEP CHANGING THE 1809 01:14:54,933 --> 01:14:58,103 SYSTEMS TO LOOK AT THE HUMAN 1810 01:14:58,103 --> 01:14:59,671 BIOLOGY SYSTEMS AN IN VITRO 1811 01:14:59,671 --> 01:14:59,905 SETTING. 1812 01:14:59,905 --> 01:15:01,540 WE'LL CONTINUE TO ADVANCE 1813 01:15:01,540 --> 01:15:03,609 INTERACTION ACROSS ENGINEERING 1814 01:15:03,609 --> 01:15:06,745 AND LIFE SCIENCES AS WELL AS 1815 01:15:06,745 --> 01:15:08,247 ACROSS INSTITUTES KEEPING A 1816 01:15:08,247 --> 01:15:11,683 FOCUS ON RIGOR AND EFFICIENCY 1817 01:15:11,683 --> 01:15:15,454 AND SUPPORTING THE INVESTMENT IN 1818 01:15:15,454 --> 01:15:15,988 TRAINEES AND WORKFORCE 1819 01:15:15,988 --> 01:15:17,556 DEVELOPMENT AS WE GO. 1820 01:15:17,556 --> 01:15:18,957 FINALLY, I WANTED TO CLOSE NOT 1821 01:15:18,957 --> 01:15:22,461 ONLY WITH REMINDING YOU TO 1822 01:15:22,461 --> 01:15:23,562 ENCOURAGE POST-BACS AND PEOPLE 1823 01:15:23,562 --> 01:15:25,797 INTERESTED IN POSTDOCS TO REACH 1824 01:15:25,797 --> 01:15:29,768 OUT TO US SO WE CAN HELP THEM 1825 01:15:29,768 --> 01:15:31,036 ACCESS THIS TRAINING ENVIRONMENT 1826 01:15:31,036 --> 01:15:32,304 BUT TO LET YOU KNOW WE ARE 1827 01:15:32,304 --> 01:15:34,940 LOOKING FOR A MEDICAL 1828 01:15:34,940 --> 01:15:35,574 DERMATOLOGIST. 1829 01:15:35,574 --> 01:15:38,210 WE HAVE UNFORTUNATELY LOST KEY 1830 01:15:38,210 --> 01:15:40,746 MEMBERS OF OUR TEAM IN BEING 1831 01:15:40,746 --> 01:15:42,481 ABLE TO SUPPORT THE BUSY CONSULT 1832 01:15:42,481 --> 01:15:43,782 SERVICE AND WE WOULD VERY MUCH 1833 01:15:43,782 --> 01:15:46,952 BE INTERESTED IN HEARING FROM 1834 01:15:46,952 --> 01:15:49,087 YOU IF YOU KNOW OF OR ARE 1835 01:15:49,087 --> 01:15:51,490 SOMEONE WHO IS INTERESTED IN 1836 01:15:51,490 --> 01:15:52,157 JOINING US HERE IN THE 1837 01:15:52,157 --> 01:15:52,891 INTRAMURAL PROGRAM. 1838 01:15:52,891 --> 01:15:53,759 SO THANK YOU VERY MUCH. 1839 01:15:53,759 --> 01:15:55,127 I'D BE HAPPY TO ANSWER ANY 1840 01:15:55,127 --> 01:16:05,304 QUESTIONS. 1841 01:16:05,671 --> 01:16:07,239 >> THANK YOU FOR POINTING OUT 1842 01:16:07,239 --> 01:16:15,781 DR. SARTORELLIs WORK AND I LOVE 1843 01:16:15,781 --> 01:16:16,915 TO PLUG THE NIH SUPPORTED 1844 01:16:16,915 --> 01:16:21,386 RESEARCH AND HOW WE GOT THERE 1845 01:16:21,386 --> 01:16:23,955 AND THE NEW STEROID DRUG AND 1846 01:16:23,955 --> 01:16:26,325 ANOTHER INTRODUCED FOR DUCHENNE 1847 01:16:26,325 --> 01:16:28,126 LAST YEAR AND IT'S ALWAYS 1848 01:16:28,126 --> 01:16:29,695 IMPORTANT TO PROMOTE THE NIH 1849 01:16:29,695 --> 01:16:30,796 RESEARCH. 1850 01:16:30,796 --> 01:16:32,164 >> IT'S SATISFYING FOR US TO 1851 01:16:32,164 --> 01:16:33,298 HEAR HOW TO THE RESEARCH 1852 01:16:33,298 --> 01:16:34,333 DISCOVERIES ARE MAKING A 1853 01:16:34,333 --> 01:16:37,469 DIFFERENCE IN YOUR CLINICS AND 1854 01:16:37,469 --> 01:16:38,937 IN THE LIVES OF THE PEOPLE YOU 1855 01:16:38,937 --> 01:16:39,271 ARE TREATING. 1856 01:16:39,271 --> 01:16:43,608 THANK YOU. 1857 01:16:43,608 --> 01:16:46,411 >> SO, THANK YOU FOR THE 1858 01:16:46,411 --> 01:16:48,447 PRESENTATION AND CONGRATULATIONS 1859 01:16:48,447 --> 01:16:50,515 ON MAINTAINING THE MOMENTUM AND 1860 01:16:50,515 --> 01:16:51,249 EXCELLENCE IN THE INTRAMURAL 1861 01:16:51,249 --> 01:16:53,552 PROGRAM. 1862 01:16:53,552 --> 01:17:01,493 IT'S REALLY IMPRESSIVE. 1863 01:17:01,493 --> 01:17:03,428 I HAVE TWO QUESTIONS. 1864 01:17:03,428 --> 01:17:06,565 HAVE YOU SEEN AN IMPACT ON 1865 01:17:06,565 --> 01:17:07,632 APPLICATIONS OR POST-BACS TO 1866 01:17:07,632 --> 01:17:09,334 THIS POINT BECAUSE OF THE 1867 01:17:09,334 --> 01:17:11,570 CHANGES IN THE LANDSCAPE AND I 1868 01:17:11,570 --> 01:17:16,842 ALSO HAD SOME CURIOSITY ABOUT -- 1869 01:17:16,842 --> 01:17:18,944 SELFISHLY BECAUSE I BOTH WORK IN 1870 01:17:18,944 --> 01:17:21,780 THE REGENERATIVE MEDICINE SPACE 1871 01:17:21,780 --> 01:17:23,648 AND ALSO AM A BIOMEDICAL 1872 01:17:23,648 --> 01:17:26,918 ENGINEER THE DEGREE TO WHICH 1873 01:17:26,918 --> 01:17:29,454 ENGINEERING THAT MAY BE APPLIED 1874 01:17:29,454 --> 01:17:30,956 FROM BIO MATERIALS TO BIO CHIPS 1875 01:17:30,956 --> 01:17:34,226 IS REPRESENTED WITHIN THE 1876 01:17:34,226 --> 01:17:36,561 PORTFOLIO OF INVESTIGATOR WITHIN 1877 01:17:36,561 --> 01:17:37,763 THE IRP. 1878 01:17:37,763 --> 01:17:39,364 >> GREAT QUESTIONS. 1879 01:17:39,364 --> 01:17:41,566 ON THE SPECIFIC ABOUT THE 1880 01:17:41,566 --> 01:17:42,267 POST-BAC APPLICATIONS I CAN GET 1881 01:17:42,267 --> 01:17:43,702 THAT INFORMATION FOR YOU. 1882 01:17:43,702 --> 01:17:45,203 I DON'T KNOW IT SPECIFICALLY. 1883 01:17:45,203 --> 01:17:47,105 AS YOU ALL KNOW THERE WERE A 1884 01:17:47,105 --> 01:17:52,110 NUMBER OF PAUSES ON HIRING, 1885 01:17:52,110 --> 01:17:52,778 FIRST OF ALL. 1886 01:17:52,778 --> 01:17:56,248 SECONDARILY THEY'VE BEEN LIFTED 1887 01:17:56,248 --> 01:17:59,484 ONE BY ONE AND THE POST-BAC 1888 01:17:59,484 --> 01:18:00,952 PROGRAM WAS ONE OF THE FIRST 1889 01:18:00,952 --> 01:18:03,121 ONES WHERE THE IRP WAS ABLE TO 1890 01:18:03,121 --> 01:18:05,557 RECRUIT TALENT FROM INDIVIDUALS 1891 01:18:05,557 --> 01:18:10,929 WHO ARE U.S. CITIZENS. 1892 01:18:10,929 --> 01:18:15,367 SO IT'S GREAT THAT CHANNEL HAS 1893 01:18:15,367 --> 01:18:15,767 OPENED. 1894 01:18:15,767 --> 01:18:18,136 I SUSPECT THE UTILIZATION OF 1895 01:18:18,136 --> 01:18:20,338 THAT IS LOWER THAN USUAL BECAUSE 1896 01:18:20,338 --> 01:18:21,940 IT STARTED SO MUCH LATER THAN IT 1897 01:18:21,940 --> 01:18:23,175 USUALLY DOES BUT I'D BE HAPPY TO 1898 01:18:23,175 --> 01:18:24,576 GET MORE INFORMATION FOR YOU. 1899 01:18:24,576 --> 01:18:28,713 IN TERMS OF POSTDOCS,S THAT WAS 1900 01:18:28,713 --> 01:18:30,315 ONE OF THE NEXT THINGS TO OPEN 1901 01:18:30,315 --> 01:18:33,585 UP SO WE CAN AGAIN RECRUIT 1902 01:18:33,585 --> 01:18:36,021 POSTDOCS TO OUR ASSISTANCE AND 1903 01:18:36,021 --> 01:18:40,625 ARE HOPEFUL AS ADDITIONAL HIRING 1904 01:18:40,625 --> 01:18:42,928 PAUSES ARE RELIEVED WELL BE ABLE 1905 01:18:42,928 --> 01:18:45,730 TO RECRUIT INDIVIDUALS NOT 1906 01:18:45,730 --> 01:18:48,099 U.S. CITIZENS TO NIH AS 1907 01:18:48,099 --> 01:18:48,366 POSTDOCS. 1908 01:18:48,366 --> 01:18:50,936 THAT'S DEFINITELY BEEN AFFECTED. 1909 01:18:50,936 --> 01:18:53,271 WE ARE EAGER AND INTENTIONAL 1910 01:18:53,271 --> 01:18:54,973 ABOUT KEEPING THOSE PIPELINES 1911 01:18:54,973 --> 01:18:57,909 OPEN AND READY TO GO AS SOON AS 1912 01:18:57,909 --> 01:19:01,480 THINGS ARE REALLY FREE AGAIN. 1913 01:19:01,480 --> 01:19:04,149 SO PLEASE ENCOURAGE PEOPLE TO 1914 01:19:04,149 --> 01:19:05,016 REACH OUT BECAUSE I THINK ONCE 1915 01:19:05,016 --> 01:19:08,086 THEY GET HERE AS I DID IT'S 1916 01:19:08,086 --> 01:19:09,955 QUITE AN IMPRESSIVE PLACE TO DO 1917 01:19:09,955 --> 01:19:10,322 SCIENCE. 1918 01:19:10,322 --> 01:19:13,692 IN TERMS OF ENGINEERING, I LOVE 1919 01:19:13,692 --> 01:19:14,626 YOUR QUESTION. 1920 01:19:14,626 --> 01:19:16,394 I'M VERY EXCITED ABOUT THE 1921 01:19:16,394 --> 01:19:18,830 OPPORTUNITIES HERE. 1922 01:19:18,830 --> 01:19:20,632 ALREADY WITHIN THE NIAMS IRP WE 1923 01:19:20,632 --> 01:19:21,900 HAVE INVESTIGATORS WHO HAVE BEEN 1924 01:19:21,900 --> 01:19:23,435 USING ESPECIALLY THE RESOURCES 1925 01:19:23,435 --> 01:19:25,704 THAT ARE AVAILABLE TO SUPPORT 1926 01:19:25,704 --> 01:19:28,106 THOSE KINDS OF RESEARCH THROUGH 1927 01:19:28,106 --> 01:19:30,909 NCATS, NIBIB AND OTHERS. 1928 01:19:30,909 --> 01:19:34,946 FOR EXAMPLE, ISAAC BURNEL IS 1929 01:19:34,946 --> 01:19:38,183 DOING A DRUG SCREEN TO TREAT A 1930 01:19:38,183 --> 01:19:40,385 TYPE OF CARCINOMA AND THAT THE 1931 01:19:40,385 --> 01:19:41,887 NOT THE ONLY ONE. 1932 01:19:41,887 --> 01:19:43,121 I THINK THERE'S TREMENDOUS 1933 01:19:43,121 --> 01:19:53,532 OPPORTUNITY TO CONTINUE. 1934 01:19:55,634 --> 01:19:58,937 AND IVE TALKED WITH OTHER 1935 01:19:58,937 --> 01:20:01,072 LEADERS AND NCATS NIS IS THE 1936 01:20:01,072 --> 01:20:04,409 HEART OF WHAT WE DO. 1937 01:20:04,409 --> 01:20:06,878 AS WE WANT TO TAKE ADVANTAGE OF 1938 01:20:06,878 --> 01:20:10,749 PLATFORM TECHNOLOGIES WE NEED TO 1939 01:20:10,749 --> 01:20:12,751 USE THESE WITHIN NIAMS SO I'D 1940 01:20:12,751 --> 01:20:15,220 LOVE TO HEAR MORE ABOUT YOUR 1941 01:20:15,220 --> 01:20:25,330 IDEAS. 1942 01:20:27,198 --> 01:20:29,501 >> I THINK MANY INVESTIGATORS ON 1943 01:20:29,501 --> 01:20:31,770 THE EXTRAMURAL SIDE DON'T HAVE 1944 01:20:31,770 --> 01:20:32,470 THE APPRECIATION OF THE 1945 01:20:32,470 --> 01:20:34,072 INTRAMURAL SIDE AND MY QUESTION 1946 01:20:34,072 --> 01:20:34,940 IS ABOUT THAT. 1947 01:20:34,940 --> 01:20:38,710 I'VE ALWAYS PERCEIVED THERE'S 1948 01:20:38,710 --> 01:20:40,745 TWO ORBITS WITH TWO STRATEGIC 1949 01:20:40,745 --> 01:20:42,714 PLANS AND GREAT SCIENCE BUT I 1950 01:20:42,714 --> 01:20:44,182 WONDERED IF YOU COULD COMMENT ON 1951 01:20:44,182 --> 01:20:47,586 WHETHER THERE'S A FIRE WALL OR 1952 01:20:47,586 --> 01:20:50,722 AN ENCOURAGEMENT OF THE TWO 1953 01:20:50,722 --> 01:20:53,358 PROGRAMS FROM INTERACTING. 1954 01:20:53,358 --> 01:20:54,492 I'M ACTUALLY VERY UNINFORMED 1955 01:20:54,492 --> 01:20:55,293 ABOUT THAT. 1956 01:20:55,293 --> 01:20:56,595 I DON'T KNOW IF OTHERS ARE. 1957 01:20:56,595 --> 01:21:01,866 >> I'M HAPPY TO SPEAK TO THAT 1958 01:21:01,866 --> 01:21:03,702 BASED ON A RELATIVELY LIMITED 1959 01:21:03,702 --> 01:21:06,638 EXPERIENCE HERE SO FAR. 1960 01:21:06,638 --> 01:21:07,272 AS YOU KNOW I HAVE DEEP 1961 01:21:07,272 --> 01:21:10,041 EXTRAMURAL EXPERTISE AND WOULD 1962 01:21:10,041 --> 01:21:11,643 SAY MY VISIBILITY WAS RELATIVELY 1963 01:21:11,643 --> 01:21:12,811 LIMITED UNTIL RECENTLY SO THAT'S 1964 01:21:12,811 --> 01:21:13,878 ONE OF THE REASONS I'M EXCITED 1965 01:21:13,878 --> 01:21:15,280 TO GIVE THE TALK AND SHARE THIS 1966 01:21:15,280 --> 01:21:16,681 PERSPECTIVE ON WHAT IT LOOKS 1967 01:21:16,681 --> 01:21:18,350 LIKE FROM INSIDE. 1968 01:21:18,350 --> 01:21:20,685 SO I SEE THERE IS A GREAT DEAL 1969 01:21:20,685 --> 01:21:23,488 OF OPPORTUNITY TO STRENGTHEN THE 1970 01:21:23,488 --> 01:21:25,857 TIES BETWEEN INTRAMURAL AND 1971 01:21:25,857 --> 01:21:27,225 EXTRAMURAL INVESTIGATORS TO 1972 01:21:27,225 --> 01:21:29,661 ENABLE US TO TAKE ADVANTAGE OF 1973 01:21:29,661 --> 01:21:31,663 WHAT EACH ONE DOES BEST. 1974 01:21:31,663 --> 01:21:34,733 AND YES, THERE'S A FIRE WALL 1975 01:21:34,733 --> 01:21:36,034 FINANCIALLY AND IN THE WAY THE 1976 01:21:36,034 --> 01:21:38,670 RESOURCES ARE SPENT THAT WERE 1977 01:21:38,670 --> 01:21:42,440 VERY VIGILANT TO MAINTAIN 1978 01:21:42,440 --> 01:21:43,108 APPROPRIATE UTILIZATION OF 1979 01:21:43,108 --> 01:21:44,876 RESOURCES BUT IN TERMS OF 1980 01:21:44,876 --> 01:21:47,979 COLLABORATION, THAT'S 1981 01:21:47,979 --> 01:21:50,348 ENCOURAGED, THERE ARE MANY 1982 01:21:50,348 --> 01:21:51,850 INTRAMURAL INVESTIGATORS WHO 1983 01:21:51,850 --> 01:21:53,218 SERVE AS SIGNIFICANT 1984 01:21:53,218 --> 01:21:54,452 CONTRIBUTORS WITHOUT SALARY ON 1985 01:21:54,452 --> 01:21:57,756 EXTRAMURAL GRANTS FOR EXAMPLE. 1986 01:21:57,756 --> 01:21:58,923 AND THERE ARE SPECIFIC FUNDING 1987 01:21:58,923 --> 01:22:00,392 OPPORTUNITIES THAT ENABLE 1988 01:22:00,392 --> 01:22:00,792 COLLABORATION. 1989 01:22:00,792 --> 01:22:03,728 SO I DON'T WANT TO OVER SPEAK 1990 01:22:03,728 --> 01:22:05,630 ALL THOSE DETAILS BUT YES, LET'S 1991 01:22:05,630 --> 01:22:07,132 THINK ABOUT WHAT WE CAN DO 1992 01:22:07,132 --> 01:22:17,308 TOGETHER. 1993 01:22:17,709 --> 01:22:19,277 >> GREAT, I DON'T SEE ANY OTHER 1994 01:22:19,277 --> 01:22:20,945 HANDS UP AND IT'S IMPRESSIVE HOW 1995 01:22:20,945 --> 01:22:22,113 YOU'VE GOTTEN UP TO SPEED AND 1996 01:22:22,113 --> 01:22:23,648 YOUR VISION FOR THE FUTURE. 1997 01:22:23,648 --> 01:22:26,918 WE'RE SO GRATEFUL THAT YOU'RE 1998 01:22:26,918 --> 01:22:29,654 HERE LEADING THAT IMPORTANT 1999 01:22:29,654 --> 01:22:29,854 GROUP. 2000 01:22:29,854 --> 01:22:30,255 THANK YOU SO MUCH. 2001 01:22:30,255 --> 01:22:30,588 >> THANK YOU. 2002 01:22:30,588 --> 01:22:30,922 >> OKAY. 2003 01:22:30,922 --> 01:22:34,492 SO I THINK I'M TURNING THINGS 2004 01:22:34,492 --> 01:22:36,327 BACK OVER TO DR. SLEDJESKI FOR 2005 01:22:36,327 --> 01:22:38,930 THE NEXT PART. 2006 01:22:38,930 --> 01:22:49,407 >> YES, THANK YOU VERY MUCH. 2007 01:22:49,674 --> 01:22:54,913 SO RIGHT NOW WE'RE GOING TO OUR 2008 01:22:54,913 --> 01:22:56,448 OPEN COUNCIL CONCEPT CLEARANCE 2009 01:22:56,448 --> 01:22:59,651 AND WHAT WE MEAN AND WHAT THE 2010 01:22:59,651 --> 01:23:00,452 FUNCTION IS. 2011 01:23:00,452 --> 01:23:05,457 EXTRAMURAL STAFF HERE AT NIAMS 2012 01:23:05,457 --> 01:23:06,391 IDENTIFY CRITICAL RESEARCH 2013 01:23:06,391 --> 01:23:07,058 OPPORTUNITIES AND NEEDS WITHIN 2014 01:23:07,058 --> 01:23:08,760 OUR MISSION AREA. 2015 01:23:08,760 --> 01:23:11,629 THE PROGRAM OFFICERS RECOMMEND 2016 01:23:11,629 --> 01:23:12,464 CONCEPTS WHICH DESCRIBE THE 2017 01:23:12,464 --> 01:23:15,600 BASIC PURPOSE, SCOPE AND 2018 01:23:15,600 --> 01:23:16,568 OBJECTIVE OF AN INITIATIVE WE 2019 01:23:16,568 --> 01:23:21,272 MAY WISH TO PURSUE AND IT'S THE 2020 01:23:21,272 --> 01:23:22,507 PLANNING PROCESS TO RECEIVE 2021 01:23:22,507 --> 01:23:24,876 PUBLIC ADVICE AND INPUT ON THE 2022 01:23:24,876 --> 01:23:26,945 MERITS OF OUR PROPOSED CONCEPTS 2023 01:23:26,945 --> 01:23:28,079 FROM THE COUNCIL. 2024 01:23:28,079 --> 01:23:29,848 EVENTUALLY IF CONCEPTS MOVE 2025 01:23:29,848 --> 01:23:30,882 FORWARD TO BE AN INITIATIVE 2026 01:23:30,882 --> 01:23:32,817 THEY'LL BE PUBLISHED ON OUR 2027 01:23:32,817 --> 01:23:35,220 WEBSITE TO LET THE COMMUNITY 2028 01:23:35,220 --> 01:23:39,057 KNOW OUR INTERESTS AND FUTURE 2029 01:23:39,057 --> 01:23:40,792 FUNDING OPPORTUNITIES. 2030 01:23:40,792 --> 01:23:42,093 SO WITH THAT WE HAVE THREE 2031 01:23:42,093 --> 01:23:44,429 CONCEPTS WE'RE GOING TO DISCUSS 2032 01:23:44,429 --> 01:23:44,963 TODAY. 2033 01:23:44,963 --> 01:23:46,631 AFTER EACH ONE WE'LL HOLD A VOTE 2034 01:23:46,631 --> 01:23:47,665 TO GET CONCURRENCE FROM COUNCIL 2035 01:23:47,665 --> 01:23:49,200 THAT WE'RE ALLOWED TO MOVE 2036 01:23:49,200 --> 01:23:51,436 FORWARD WITH THE CONCEPT IF YOU 2037 01:23:51,436 --> 01:23:53,404 AGREE WITH US. 2038 01:23:53,404 --> 01:23:58,910 I'M GOING TO TURN THIS OVER TO 2039 01:23:58,910 --> 01:24:08,787 DR. CAZARIN AND WE'LL SEEK INPUT 2040 01:24:08,787 --> 01:24:09,754 FROM COUNCIL MEMBERS REGARDING 2041 01:24:09,754 --> 01:24:10,455 THEIR MERIT. 2042 01:24:10,455 --> 01:24:11,656 >> THANK YOU FOR THAT. 2043 01:24:11,656 --> 01:24:13,424 I THINK WE HAVE A FEW MINUTES 2044 01:24:13,424 --> 01:24:15,693 FOR QUESTIONS AFTER EACH OF THE 2045 01:24:15,693 --> 01:24:16,027 PRESENTATIONS. 2046 01:24:16,027 --> 01:24:18,630 SO IT'S MY PLEASURE TO INTRODUCE 2047 01:24:18,630 --> 01:24:19,898 THE FIRST CONCEPT CLEARANCE. 2048 01:24:19,898 --> 01:24:22,333 THIS IS GOING TO BE DONE BY 2049 01:24:22,333 --> 01:24:24,702 DR. HEIYOUNG PARK ABOUT AN 2050 01:24:24,702 --> 01:24:26,538 ANCILLARY STUDY. 2051 01:24:26,538 --> 01:24:29,641 I'M GOING TO INVITE THE PROGRAM 2052 01:24:29,641 --> 01:24:38,516 DIRECTORS TO COME TO THE TABLE. 2053 01:24:38,516 --> 01:24:40,919 >> I'M HEIYOUNG PARK. 2054 01:24:40,919 --> 01:24:45,023 I'M A PROGRAM DIRECTOR WHO 2055 01:24:45,023 --> 01:24:48,459 ACTUALLY MANAGING 2056 01:24:48,459 --> 01:24:49,027 AUTOINFLAMMATORY DISEASES. 2057 01:24:49,027 --> 01:24:52,897 THE PRESENTATION IS SEEKING THE 2058 01:24:52,897 --> 01:24:57,769 APPROVAL OF A CONCEPT FOR 2059 01:24:57,769 --> 01:25:00,939 COUNCIL TO CONTINUE THE PROGRAM 2060 01:25:00,939 --> 01:25:04,008 THE NIAMS ANCILLARY STUDIES TO 2061 01:25:04,008 --> 01:25:05,710 ONGOING PROJECT THAT DOES NOT 2062 01:25:05,710 --> 01:25:08,046 ALLOW CLINICAL TRIALS. 2063 01:25:08,046 --> 01:25:08,947 THE CONCEPT CLEARANCE IS 2064 01:25:08,947 --> 01:25:09,848 EFFECTIVE FOR FIVE YEARS. 2065 01:25:09,848 --> 01:25:11,015 CURRENTLY THE CONCEPT HAS BEEN 2066 01:25:11,015 --> 01:25:16,788 EXPIRED. 2067 01:25:16,788 --> 01:25:20,391 THE PURPOSE OF THE CONCEPT IS TO 2068 01:25:20,391 --> 01:25:23,695 SUPPORT TIME SENSITIVE ANCILLARY 2069 01:25:23,695 --> 01:25:27,131 STUDIES RELATED TO THE NIAMS' 2070 01:25:27,131 --> 01:25:30,535 MISSION IN CONJUNCTION WITH OR 2071 01:25:30,535 --> 01:25:35,707 PUBLICLY FUNDED ONGOING CLINICAL 2072 01:25:35,707 --> 01:25:41,412 PROJECTS. 2073 01:25:41,412 --> 01:25:44,682 TO MAXIMIZE THE RETURN ON 2074 01:25:44,682 --> 01:25:45,850 EXISTING CLINICAL PARENT 2075 01:25:45,850 --> 01:25:46,451 PROJECTS. 2076 01:25:46,451 --> 01:25:49,087 ALSO, WE WOULD LIKE TO SEE THE 2077 01:25:49,087 --> 01:25:51,723 GENERATION OF NEW INFORMATION TO 2078 01:25:51,723 --> 01:25:54,692 ENHANCE CLINICAL AND SCIENTIFIC 2079 01:25:54,692 --> 01:25:56,227 CONTENT OF THE ORIGINAL PROJECT 2080 01:25:56,227 --> 01:25:58,930 TO IMPROVE THE RESEARCH 2081 01:25:58,930 --> 01:26:00,999 COMMUNITY'S UNDERSTANDING OF THE 2082 01:26:00,999 --> 01:26:04,402 DISEASE OR CONDITIONS WITHIN THE 2083 01:26:04,402 --> 01:26:06,905 NIAMS PORTFOLIO AND MAYBE 2084 01:26:06,905 --> 01:26:08,273 IDENTIFIED NOVEL TARGETS FOR 2085 01:26:08,273 --> 01:26:10,742 DIAGNOSIS, TREATMENT AND 2086 01:26:10,742 --> 01:26:11,342 PREVENTION OF DISEASE IN THE 2087 01:26:11,342 --> 01:26:16,180 NIAMS MISSION. 2088 01:26:16,180 --> 01:26:19,851 SO IN TERMS OF HISTORY OF THE 2089 01:26:19,851 --> 01:26:22,020 CONCEPT, NIAMS HAS SUPPORTED 2090 01:26:22,020 --> 01:26:23,321 ANCILLARY STUDIES SINCE 2010. 2091 01:26:23,321 --> 01:26:26,357 IT'S QUITE A LONG PERIOD OF 2092 01:26:26,357 --> 01:26:26,557 TIME. 2093 01:26:26,557 --> 01:26:30,061 SO FAR A TOTAL OF 48 GRANTS WERE 2094 01:26:30,061 --> 01:26:32,563 AWARDED ACROSS THE NIAMS MISSION 2095 01:26:32,563 --> 01:26:32,764 AREA. 2096 01:26:32,764 --> 01:26:35,633 AND FOR THE LAST 10 YEARS, 2097 01:26:35,633 --> 01:26:41,372 SUCCESS RATE IS ABOUT 22%. 2098 01:26:41,372 --> 01:26:43,608 FOR COMPARISON THE NIH SUCCESS 2099 01:26:43,608 --> 01:26:46,911 RATE IS ABOUT 17% FOR THE LAST 2100 01:26:46,911 --> 01:26:54,886 10 YEARS. 2101 01:26:54,886 --> 01:26:57,722 IN TERMS OF THE PERFORMANCE OF 2102 01:26:57,722 --> 01:27:01,426 THE ANCILLARY STUDIES IT SHOWED 2103 01:27:01,426 --> 01:27:04,996 HIGHER RCR COMPARED TO OTHER 2104 01:27:04,996 --> 01:27:07,098 NIAMS FUNDED STUDIES. 2105 01:27:07,098 --> 01:27:12,537 RCR IS A MEASURE OF A 2106 01:27:12,537 --> 01:27:14,939 PUBLICATION. 2107 01:27:14,939 --> 01:27:18,943 IT'S A SPECIFIC PAPER BY 2108 01:27:18,943 --> 01:27:22,046 CITATIONS OF ALL NIH FUNDED 2109 01:27:22,046 --> 01:27:23,247 PUBLICATION IN THE SAME OR 2110 01:27:23,247 --> 01:27:24,082 SIMILAR RESEARCH AREA IN THE 2111 01:27:24,082 --> 01:27:24,882 SAME YEAR. 2112 01:27:24,882 --> 01:27:27,919 SO AS YOU CAN SEE, ANCILLARY 2113 01:27:27,919 --> 01:27:33,958 STUDY R21 PUBLICATION HAS BETTER 2114 01:27:33,958 --> 01:27:34,325 RCR. 2115 01:27:34,325 --> 01:27:40,431 NEXT ONE IS STUDIES SHOWED THE 2116 01:27:40,431 --> 01:27:42,533 HIGHER RCR COMPARED TO OTHER 2117 01:27:42,533 --> 01:27:44,168 NIAMS FUNDED STUDIES. 2118 01:27:44,168 --> 01:27:46,437 THEREFORE THE RETURN OF OUR 2119 01:27:46,437 --> 01:27:50,942 INVESTMENT ON THIS ANCILLARY 2120 01:27:50,942 --> 01:27:51,876 STUDY IS MUCH BETTER. 2121 01:27:51,876 --> 01:27:54,545 ALSO THE PARENT STUDIES CAN BE 2122 01:27:54,545 --> 01:27:58,316 FUNDED BY NIAMS OR OTHER 2123 01:27:58,316 --> 01:28:01,686 ENTITIES SO ABOUT HALF OF 2124 01:28:01,686 --> 01:28:08,793 ANCILLARY STUDIES WEREN'T FUNDED 2125 01:28:08,793 --> 01:28:10,128 OUTSIDE. 2126 01:28:10,128 --> 01:28:11,996 THIS SLIDE THOSE MORE SPECIFIC 2127 01:28:11,996 --> 01:28:14,932 DESCRIPTION OF PARENT AND 2128 01:28:14,932 --> 01:28:16,834 ANCILLARY STUDIES. 2129 01:28:16,834 --> 01:28:18,436 PARENT STUDIES IS ONGOING 2130 01:28:18,436 --> 01:28:20,772 CLINICAL PROJECT. 2131 01:28:20,772 --> 01:28:23,708 IT CAN BE CLINICAL TRIAL OR 2132 01:28:23,708 --> 01:28:25,476 CLINICAL OBSERVATIONAL STUDIES 2133 01:28:25,476 --> 01:28:29,714 AND CAN BE FUNDED BY PUBLICLY OR 2134 01:28:29,714 --> 01:28:33,451 PRIVATELY FUNDED AND CAN BE ON 2135 01:28:33,451 --> 01:28:37,588 ANY TOPIC NOT NECESSARILY NIAMS 2136 01:28:37,588 --> 01:28:37,822 MISSION. 2137 01:28:37,822 --> 01:28:38,723 PARENT STUDIES MUST LAST LONG 2138 01:28:38,723 --> 01:28:40,558 ENOUGH TO ACCOMMODATE THE 2139 01:28:40,558 --> 01:28:42,927 ANCILLARY STUDY. 2140 01:28:42,927 --> 01:28:46,030 IN CONTRAST, ANCILLARY STUDIES 2141 01:28:46,030 --> 01:28:49,133 MUST BE WITHIN THE NIAMS MISSION 2142 01:28:49,133 --> 01:28:52,403 AND WE ENCOURAGE MECHANISTIC 2143 01:28:52,403 --> 01:28:54,772 STUDIES THOUGH WE ALLOW 2144 01:28:54,772 --> 01:28:57,175 NON-MECHANISTIC STUDIES. 2145 01:28:57,175 --> 01:28:59,744 ALSO IMPORTANTLY THE ANCILLARY 2146 01:28:59,744 --> 01:29:03,114 STUDIES MUST HAVE APPROVAL FROM 2147 01:29:03,114 --> 01:29:05,283 PARENT PROJECT COMMITTEE AND 2148 01:29:05,283 --> 01:29:08,986 MUST NOT INTERFERE WITH THE 2149 01:29:08,986 --> 01:29:10,888 PARENT PROJECT OR PARTICIPANTS 2150 01:29:10,888 --> 01:29:11,722 AND MUST JUSTIFY TIME 2151 01:29:11,722 --> 01:29:14,926 SENSITIVITY. 2152 01:29:14,926 --> 01:29:18,529 THIS SLIDE THOSE THE HIGHLIGHT 2153 01:29:18,529 --> 01:29:19,530 OF NIAMS ANCILLARY STUDIES. 2154 01:29:19,530 --> 01:29:22,633 WE WOULD LIKE TO SEE THE 2155 01:29:22,633 --> 01:29:23,768 ENCOURAGEMENT OF COLLABORATION 2156 01:29:23,768 --> 01:29:25,570 BETWEEN BASIC AND CLINICAL 2157 01:29:25,570 --> 01:29:29,240 INVESTIGATORS AND PARTNERSHIP 2158 01:29:29,240 --> 01:29:32,243 WITH PARENT AND PRIVATE ENTITIES 2159 01:29:32,243 --> 01:29:33,945 AND ENCOURAGEMENT OF JUNIOR 2160 01:29:33,945 --> 01:29:36,180 INVESTIGATORS TO TAKE A LEADING 2161 01:29:36,180 --> 01:29:38,216 ROLE IN CLINICAL RESEARCH WITH 2162 01:29:38,216 --> 01:29:41,819 THE SUPPORT AND COLLABORATION OF 2163 01:29:41,819 --> 01:29:42,520 SENIOR INVESTIGATORS. 2164 01:29:42,520 --> 01:29:44,889 SO I'D LOVE TO TAKE ANY 2165 01:29:44,889 --> 01:29:50,261 QUESTIONS ABOUT THIS CONCEPT. 2166 01:29:50,261 --> 01:29:50,895 >> THANK YOU VERY MUCH. 2167 01:29:50,895 --> 01:29:56,734 DO WE HAVE ANY QUESTIONS? 2168 01:29:56,734 --> 01:30:00,905 >> I HAD A QUESTION ABOUT THIS 2169 01:30:00,905 --> 01:30:03,808 HAS BEEN A VERY SUCCESSFUL 2170 01:30:03,808 --> 01:30:05,776 PROGRAM. 2171 01:30:05,776 --> 01:30:09,614 IS IT TAPPED AT A LOWER BUDGET 2172 01:30:09,614 --> 01:30:11,015 THAN THE TRADITIONAL RO1 OUTSIDE 2173 01:30:11,015 --> 01:30:11,816 OF THIS INITIATIVE? 2174 01:30:11,816 --> 01:30:14,485 >> YES, RIGHT. 2175 01:30:14,485 --> 01:30:18,256 SO PARTICULARLY RO1 MECHANISM WE 2176 01:30:18,256 --> 01:30:19,824 ALLOW ONLY FOUR YEARS PROJECT 2177 01:30:19,824 --> 01:30:23,361 COMPARED TO ANY OTHER LIKE FIVE 2178 01:30:23,361 --> 01:30:23,794 YEARS. 2179 01:30:23,794 --> 01:30:26,898 SO BUDGET WISE IS RELATIVELY 2180 01:30:26,898 --> 01:30:28,199 SMALLER COMPARED TO REGULAR 2181 01:30:28,199 --> 01:30:30,935 PARENT RO1. 2182 01:30:30,935 --> 01:30:35,806 THE RETURN ON THE INVESTMENT IS 2183 01:30:35,806 --> 01:30:36,841 FLAT BOTTOM. 2184 01:30:36,841 --> 01:30:38,943 >> THE ANNUAL BUDGET AND 2185 01:30:38,943 --> 01:30:41,279 DURATION OF THE AWARD AT CAPPED 2186 01:30:41,279 --> 01:30:42,914 AT ONE ANNUAL TOTAL COST? 2187 01:30:42,914 --> 01:30:45,550 >> 400. 2188 01:30:45,550 --> 01:30:50,354 >> AND THAT'S WHATTY YOU ARE -- 2189 01:30:50,354 --> 01:30:51,389 WHAT YOU'RE PROPOSING? 2190 01:30:51,389 --> 01:30:51,622 >> YES. 2191 01:30:51,622 --> 01:30:58,095 >> THANK YOU. 2192 01:30:58,095 --> 01:30:58,963 >> WE HAVE ANOTHER QUESTION. 2193 01:30:58,963 --> 01:31:03,868 >> THANK YOU FOR THAT. 2194 01:31:03,868 --> 01:31:05,102 REAL QUICK QUESTION. 2195 01:31:05,102 --> 01:31:09,473 HOW ARE YOU PLANNING TO REVIEW 2196 01:31:09,473 --> 01:31:09,674 THESE? 2197 01:31:09,674 --> 01:31:10,841 ADMINISTRATIVELY OR THROUGH THE 2198 01:31:10,841 --> 01:31:11,409 PEER REVIEW. 2199 01:31:11,409 --> 01:31:17,815 >> THROUGH CENTRALIZED REVIEW. 2200 01:31:17,815 --> 01:31:19,617 >> THANK YOU. 2201 01:31:19,617 --> 01:31:23,254 >> ARE THERE ANYMORE QUESTIONS. 2202 01:31:23,254 --> 01:31:28,559 >> YOU SAID ANY TRAIL, PHARMA OR 2203 01:31:28,559 --> 01:31:30,861 ACADEMIC ARE SUPPORTED BUT IS IT 2204 01:31:30,861 --> 01:31:33,798 COMPLETELY PHARMA SUPPORTED 2205 01:31:33,798 --> 01:31:35,733 TRIAL AND SAMPLES COLLECTED FROM 2206 01:31:35,733 --> 01:31:36,834 THE TRIAL. 2207 01:31:36,834 --> 01:31:41,806 >> YES, IT IS QUALIFYING. 2208 01:31:41,806 --> 01:31:42,907 AS A MATTER OF FACT, THE 2209 01:31:42,907 --> 01:31:46,911 COMMITTEE HAS TO CONSENT TO 2210 01:31:46,911 --> 01:31:53,050 SUPPORT ANCILLARY STUDIES. 2211 01:31:53,050 --> 01:31:54,919 >> THE TIMELINESS FACTOR HAS 2212 01:31:54,919 --> 01:31:58,589 BEEN PART OF THIS EFFORT SO IS 2213 01:31:58,589 --> 01:32:02,026 THE REVIEW MORE TIMELY OR IS THE 2214 01:32:02,026 --> 01:32:05,263 APPROVAL PROCESS ACCELERATED? 2215 01:32:05,263 --> 01:32:06,931 >> RIGHT. 2216 01:32:06,931 --> 01:32:11,802 SO WHEN WE REVIEWED THE 2217 01:32:11,802 --> 01:32:14,939 ANCILLARY STUDIES BY SPECIFIC 2218 01:32:14,939 --> 01:32:17,208 REVIEW WE ARE REALLY FORCING 2219 01:32:17,208 --> 01:32:18,909 REVIEW BUT RIGHT NOW IT'S GOING 2220 01:32:18,909 --> 01:32:23,180 TO BE REVIEWED BY CSR AND AT 2221 01:32:23,180 --> 01:32:27,485 LEAST WE CAN HAVE THE AWARDING 2222 01:32:27,485 --> 01:32:27,718 PROCESS. 2223 01:32:27,718 --> 01:32:28,219 >> ALL RIGHT. 2224 01:32:28,219 --> 01:32:29,854 I DON'T THINK WE HAVE ANYMORE 2225 01:32:29,854 --> 01:32:30,121 QUESTIONS. 2226 01:32:30,121 --> 01:32:35,793 THANK YOU. 2227 01:32:35,793 --> 01:32:38,763 >> I'D LIKE FOR A MOTION TO MOVE 2228 01:32:38,763 --> 01:32:40,364 THE CONCEPT FORWARD. 2229 01:32:40,364 --> 01:32:40,965 >> MOTION. 2230 01:32:40,965 --> 01:32:42,066 >> SECOND. 2231 01:32:42,066 --> 01:32:44,268 ALL OPPOSED TO THIS MOTION 2232 01:32:44,268 --> 01:32:46,937 PLEASE RAISE YOUR HANDS OR SAY 2233 01:32:46,937 --> 01:32:47,705 AYE. 2234 01:32:47,705 --> 01:32:50,775 I SEE NOBODY OPPOSED HERE OR 2235 01:32:50,775 --> 01:32:53,844 ONLINE SO THE MOTION PASSES TO 2236 01:32:53,844 --> 01:32:54,945 MOVE FORWARD WITH THE CONCEPT. 2237 01:32:54,945 --> 01:32:56,814 THANK YOU VERY MUCH. 2238 01:32:56,814 --> 01:32:57,682 >> ALL RIGHT. 2239 01:32:57,682 --> 01:32:58,149 THANK YOU. 2240 01:32:58,149 --> 01:32:59,350 WE'LL MOVING TO OUR SECOND 2241 01:32:59,350 --> 01:32:59,817 CONCEPT CLEARANCE. 2242 01:32:59,817 --> 01:33:05,289 THIS IS GOING TO BE PRESENTED BY 2243 01:33:05,289 --> 01:33:09,260 DR. ARON MARQUITZ AND THE TITLE 2244 01:33:09,260 --> 01:33:11,896 IS RMIP INVESTIGATOR-INITIATED 2245 01:33:11,896 --> 01:33:13,397 STUDIES. 2246 01:33:13,397 --> 01:33:16,267 >> THANKS, EVERYBODY. 2247 01:33:16,267 --> 01:33:22,940 I'M ARON MARQUITZ I MANAGE THE 2248 01:33:22,940 --> 01:33:23,574 MUSCULOSKELETAL REGENERATIVE 2249 01:33:23,574 --> 01:33:24,642 MEDICINE PORTFOLIO AT NIAMS AND 2250 01:33:24,642 --> 01:33:28,145 I'M PRESENTING THE CONCEPT ON 2251 01:33:28,145 --> 01:33:29,580 BEHALF A TRANS NIH GROUP OF 2252 01:33:29,580 --> 01:33:34,251 PROGRAM OFFICERS THAT MANAGE THE 2253 01:33:34,251 --> 01:33:35,252 REGENERATIVE BRING. 2254 01:33:35,252 --> 01:33:40,024 I'LL START BY GIVING YOU 2255 01:33:40,024 --> 01:33:44,328 BACKGROUND ON WHAT MANY RMIP IS. 2256 01:33:44,328 --> 01:33:46,130 IT COMES FROM SPECIFIC 2257 01:33:46,130 --> 01:33:46,764 APPROPRIATIONS FROM CONGRESS IN 2258 01:33:46,764 --> 01:33:52,703 THE 21st CENTURIES CURES ACT AND 2259 01:33:52,703 --> 01:33:55,172 IT'S FOR THE NIH TO ACCELERATE 2260 01:33:55,172 --> 01:33:58,676 PROGRESS IN REGENERATIVE 2261 01:33:58,676 --> 01:34:01,912 MEDICINE WITH STEM CELLS AND THE 2262 01:34:01,912 --> 01:34:06,817 NIH ESTABLISHED THE RMIP FUNDING 2263 01:34:06,817 --> 01:34:09,487 HAS TWO KEY CHARACTERISTICS. 2264 01:34:09,487 --> 01:34:16,394 ONE IS A SET OF $30 MILLION 2265 01:34:16,394 --> 01:34:18,195 AUTHORIZED THAT DOES NOT EXPIRE 2266 01:34:18,195 --> 01:34:19,964 WITH ANY FISCAL YEAR SO WE HAVE 2267 01:34:19,964 --> 01:34:25,636 IT UNTIL WE USE IT UP AND IT 2268 01:34:25,636 --> 01:34:27,505 REQUIRES RECIPIENTS IDENTIFY ONE 2269 01:34:27,505 --> 01:34:29,607 TO ONE MATCHING. 2270 01:34:29,607 --> 01:34:32,643 SO THEY HAVE TO HAVE SUPPORT 2271 01:34:32,643 --> 01:34:35,980 FROM NON FEDERAL FUNDS AND $60 2272 01:34:35,980 --> 01:34:37,882 MILLION WORTH OF PROJECTS. 2273 01:34:37,882 --> 01:34:39,083 THIS SLIDE HERE JUST SHOWS YOU 2274 01:34:39,083 --> 01:34:40,584 SOME OF THE AWARDS THAT HAVE 2275 01:34:40,584 --> 01:34:43,654 BEEN MADE BY THE RMIP THUS FAR. 2276 01:34:43,654 --> 01:34:47,124 I WON'T GO THROUGH THEM ALL. 2277 01:34:47,124 --> 01:34:48,759 THIS STARTED OUT WITH 2278 01:34:48,759 --> 01:34:50,461 SUPPLEMENTED IN 2017 AS WE 2279 01:34:50,461 --> 01:34:51,595 WORKED ON THE FUNDING 2280 01:34:51,595 --> 01:34:53,063 OPPORTUNITIES THEN WE MOVED INTO 2281 01:34:53,063 --> 01:34:55,699 BASICALLY TWO KINDS OF FUNDING 2282 01:34:55,699 --> 01:34:56,267 OPPORTUNITIES. 2283 01:34:56,267 --> 01:34:58,936 ONE FOR CLINICAL TRIALS IN 2284 01:34:58,936 --> 01:35:01,472 REGENERATIVE MEDICINE USING 2285 01:35:01,472 --> 01:35:02,907 ADULT STEM CELLS AND ONE FOR 2286 01:35:02,907 --> 01:35:05,976 PRECLINICAL STUDIES WITH A 2287 01:35:05,976 --> 01:35:06,944 PRECLINICAL STUDIES ARE MEANT TO 2288 01:35:06,944 --> 01:35:10,915 BE LATE STAGE TRANSLATIONAL IND 2289 01:35:10,915 --> 01:35:12,917 ENABLING STUDIES TO PROMOTE MORE 2290 01:35:12,917 --> 01:35:14,885 CLINICAL TRIALS IN THE FUTURE. 2291 01:35:14,885 --> 01:35:17,922 AND THEN I'LL JUST SAY THAT 2292 01:35:17,922 --> 01:35:19,290 NIAMS INVESTIGATORS HAVE BEEN 2293 01:35:19,290 --> 01:35:21,459 SUCCESSFUL IN APPLYING FOR RMIP 2294 01:35:21,459 --> 01:35:22,960 IN THE PAST AND THERE'S TWO 2295 01:35:22,960 --> 01:35:24,428 GROUPS WORKING ON SKIN DISEASES 2296 01:35:24,428 --> 01:35:25,963 THAT HAVE BEEN FUNDED AS WELL 2297 01:35:25,963 --> 01:35:30,000 TWO GROUPS WORKING ON CARTILAGE 2298 01:35:30,000 --> 01:35:34,505 AND NOA. 2299 01:35:34,505 --> 01:35:35,339 ANOTHER ASPECT OF THE PROGRAM 2300 01:35:35,339 --> 01:35:38,943 WE'RE EXCITED ABOUT IS THE IDEA 2301 01:35:38,943 --> 01:35:40,377 OF CHARACTERIZATIONS. 2302 01:35:40,377 --> 01:35:41,812 IT'S RATHER UNIQUE. 2303 01:35:41,812 --> 01:35:43,514 IN ALL THE FUNDING OPPORTUNITIES 2304 01:35:43,514 --> 01:35:47,985 FROM OUR RMIP THUS FAR THE 2305 01:35:47,985 --> 01:35:50,554 INVESTIGATORS NEED TO PROVIDE 2306 01:35:50,554 --> 01:35:53,624 THE CENTRAL HUB WITH 2307 01:35:53,624 --> 01:35:54,992 CHARACTERI 2308 01:35:54,992 --> 01:35:57,862 CHARACTERISTICS STEM CELLS FROM 2309 01:35:57,862 --> 01:35:59,630 THEIR CLINICAL GRADE PRODUCT AND 2310 01:35:59,630 --> 01:36:01,298 THESE GO TO A CENTRAL HUB AND 2311 01:36:01,298 --> 01:36:04,168 ARE DEEPLY CHARACTERIZED. 2312 01:36:04,168 --> 01:36:07,538 WE ESTABLISHED THE HUB AT 2313 01:36:07,538 --> 01:36:10,608 GEORGIA TECH AND THEY DO 2314 01:36:10,608 --> 01:36:11,976 ADVANCED OMICS AND ASSAYS AND 2315 01:36:11,976 --> 01:36:14,945 OTHER THINGS TO TRY TO 2316 01:36:14,945 --> 01:36:17,982 UNDERSTAND THE HETEROGENEITY IN 2317 01:36:17,982 --> 01:36:22,953 THE STEM CELL PRODUCT. 2318 01:36:22,953 --> 01:36:25,022 THE CHARACTERIZATION IS WHERE 2319 01:36:25,022 --> 01:36:28,225 WE'RE PUTTING THE DATA IN THE 2320 01:36:28,225 --> 01:36:29,960 NHLBI BIO DATA CATALYST AND IT 2321 01:36:29,960 --> 01:36:30,895 WILL BE MADE AVAILABLE TO THE 2322 01:36:30,895 --> 01:36:32,463 COMMUNITY AND WE HOPE THIS IS 2323 01:36:32,463 --> 01:36:36,000 GOING TO BE A BENEFIT TO THE 2324 01:36:36,000 --> 01:36:37,668 BROADER GROUP OF RESEARCH GOING 2325 01:36:37,668 --> 01:36:41,772 ON IN REGENERATIVE MEDICINE. 2326 01:36:41,772 --> 01:36:44,141 AND I'LL JUST GIVE YOU ONE 2327 01:36:44,141 --> 01:36:46,911 EXAMPLE OF THE STUDIES. 2328 01:36:46,911 --> 01:36:48,879 I PICKED AN EXAMPLE FROM 2329 01:36:48,879 --> 01:36:52,149 DR. GARZA WHO MANY WILL REMEMBER 2330 01:36:52,149 --> 01:36:55,286 IS A RECENT MEMBER OF THE NIAMS 2331 01:36:55,286 --> 01:36:59,123 COUNCIL HAS AN RMIP PROJECT. 2332 01:36:59,123 --> 01:37:09,667 THE POINT IS TO TAKE MOLAR FAB 2333 01:37:12,202 --> 01:37:15,039 FIBROBLASTS AND INSECT THEM IN 2334 01:37:15,039 --> 01:37:18,909 THE SITE OF AMPUTEES AND ALLOW 2335 01:37:18,909 --> 01:37:20,945 FOR BETTER PROSTHETIC USE. 2336 01:37:20,945 --> 01:37:22,913 HE'S RECENTLY HAD A PAPER COME 2337 01:37:22,913 --> 01:37:24,815 OUT IN SCIENCE WITH SOME OF THE 2338 01:37:24,815 --> 01:37:26,951 PRELIMINARY WORK FROM THE STUDY 2339 01:37:26,951 --> 01:37:30,788 IN WHICH HE TOOK HEALTHY 2340 01:37:30,788 --> 01:37:32,590 CONTROLS FIRST AND TOOK SKIN AND 2341 01:37:32,590 --> 01:37:34,091 FIBROBLASTS FROM HEALTHY 2342 01:37:34,091 --> 01:37:36,493 CONTROLS AND INJECTED INTO A 2343 01:37:36,493 --> 01:37:38,896 SITE OF THESE PARTICIPANTS AND 2344 01:37:38,896 --> 01:37:40,798 LOOKED AT WHAT HAPPENED TO THE 2345 01:37:40,798 --> 01:37:45,069 SKIN AND LOOKING MECHANICALLY 2346 01:37:45,069 --> 01:37:46,937 AND MARKERS IT STARTED TO 2347 01:37:46,937 --> 01:37:47,972 DEVELOP PHENOTYPES. 2348 01:37:47,972 --> 01:37:50,808 IT SUGGESTS THIS MAY BE A 2349 01:37:50,808 --> 01:37:51,775 PROMISING THERAPY AND WE'RE 2350 01:37:51,775 --> 01:37:54,278 EXCITED TO SEE THE PROJECT 2351 01:37:54,278 --> 01:37:55,512 CONTINUE. 2352 01:37:55,512 --> 01:37:56,413 SO THAT'S THE BACKGROUND. 2353 01:37:56,413 --> 01:37:58,282 SO WHAT'S THE CONCEPT? 2354 01:37:58,282 --> 01:38:00,517 THE CONCEPT WE'RE PROPOSING HERE 2355 01:38:00,517 --> 01:38:01,619 IS SHORT TERM FOLLOW-UP STUDIES 2356 01:38:01,619 --> 01:38:03,587 FOR THE PROJECTS THAT ARE 2357 01:38:03,587 --> 01:38:07,925 CURRENTLY FUNDED IN REGENERATIVE 2358 01:38:07,925 --> 01:38:08,325 MEDICINE PROJECT. 2359 01:38:08,325 --> 01:38:12,096 SO AS A SAID, WE HAVE THIS 2360 01:38:12,096 --> 01:38:14,131 APPROPRIATION FROM THE 21st 2361 01:38:14,131 --> 01:38:15,699 CENTURIES CURES ACT. 2362 01:38:15,699 --> 01:38:17,434 WE'RE MERELY DONE WITH THE $30 2363 01:38:17,434 --> 01:38:20,804 MILLION THAT WE'VE BEEN GIVEN BY 2364 01:38:20,804 --> 01:38:21,071 CONGRESS. 2365 01:38:21,071 --> 01:38:22,206 WE HAVE SOME SMALL AMOUNT OF 2366 01:38:22,206 --> 01:38:22,940 MONEY LEFT. 2367 01:38:22,940 --> 01:38:26,910 WHAT WE'D LIKE TO DO IS IDENTIFY 2368 01:38:26,910 --> 01:38:28,646 THE AWARDS IN WHICH MOST 2369 01:38:28,646 --> 01:38:29,980 SUCCESSFUL THROUGH A PEER REVIEW 2370 01:38:29,980 --> 01:38:33,751 PROCESS AND ALLOW THOSE TO 2371 01:38:33,751 --> 01:38:34,918 CONTINUE TOWARDS COMPLETION OF 2372 01:38:34,918 --> 01:38:37,321 DEVELOPING THE TYPES OF 2373 01:38:37,321 --> 01:38:38,656 THERAPIES THAT WERE ORIGINALLY 2374 01:38:38,656 --> 01:38:39,623 INTENDED FOR THE PROJECT. 2375 01:38:39,623 --> 01:38:41,959 SO I'M JUST GOING TO STOP THERE 2376 01:38:41,959 --> 01:38:50,934 AND WILL TAKE ANY QUESTIONS. 2377 01:38:50,934 --> 01:38:57,007 >> ARE THERE ANY QUESTIONS? 2378 01:38:57,007 --> 01:38:57,207 OKAY. 2379 01:38:57,207 --> 01:38:58,642 >> OKAY. 2380 01:38:58,642 --> 01:39:01,011 SEEING NO QUESTIONS, SO I'D LIKE 2381 01:39:01,011 --> 01:39:02,913 A MOTION TO APPROVE MOVING 2382 01:39:02,913 --> 01:39:05,449 FORWARD WITH THIS CONCEPT FOR AN 2383 01:39:05,449 --> 01:39:05,949 INITIATIVE? 2384 01:39:05,949 --> 01:39:08,285 I SEE A SECOND. 2385 01:39:08,285 --> 01:39:10,187 ALL OPPOSED TO THE MOTION PLEASE 2386 01:39:10,187 --> 01:39:12,656 RAISE YOUR HAND OR SAY AYE. 2387 01:39:12,656 --> 01:39:14,858 SEEING NO ONE OPPOSING IT, THE 2388 01:39:14,858 --> 01:39:15,392 MOTION PASSES. 2389 01:39:15,392 --> 01:39:18,929 WE CAN MOVE FORWARD WITH THIS. 2390 01:39:18,929 --> 01:39:20,464 THANK YOU VERY MUCH. 2391 01:39:20,464 --> 01:39:22,399 >> THANK YOU. 2392 01:39:22,399 --> 01:39:22,933 ALL RIGHT. 2393 01:39:22,933 --> 01:39:24,134 SO FAR, SO GOOD. 2394 01:39:24,134 --> 01:39:26,403 WE'LL MOVE TO OUR THIRD CONCEPT 2395 01:39:26,403 --> 01:39:26,670 CLEARANCE. 2396 01:39:26,670 --> 01:39:29,640 THIS IS GOING TO BE PRESENTED BY 2397 01:39:29,640 --> 01:39:30,908 DR. MELISSA GREEN PARKER. 2398 01:39:30,908 --> 01:39:33,811 I JUST WANTED TO SAY THAT 2399 01:39:33,811 --> 01:39:36,246 DR. GREEN PARKER JOINED NIAMS 2400 01:39:36,246 --> 01:39:37,748 DECEMBER 2024 AND TODAY SHE'S 2401 01:39:37,748 --> 01:39:40,517 GOING TO BE PRESENTING THIS 2402 01:39:40,517 --> 01:39:45,689 CONCEPT ON THE CORE CENTERS FOR 2403 01:39:45,689 --> 01:39:46,924 CLINICAL RESEARCH. 2404 01:39:46,924 --> 01:39:48,225 >> GOOD MORNING. 2405 01:39:48,225 --> 01:39:49,927 I'M MELISSA GREEN PARKER AND 2406 01:39:49,927 --> 01:39:53,130 IT'S MY PLEASURE TO COME BEFORE 2407 01:39:53,130 --> 01:39:54,932 YOU THIS MORNING. 2408 01:39:54,932 --> 01:39:56,366 I'M EXCITED TO SHARE THE 2409 01:39:56,366 --> 01:39:57,868 PRESENTATION AS THE GOAL IS TO 2410 01:39:57,868 --> 01:40:00,938 SEEK YOUR APPROVAL FOR THE 2411 01:40:00,938 --> 01:40:04,274 CONCEPT FOR ONE OF NIAMS 2412 01:40:04,274 --> 01:40:05,476 SUCCESSFUL CENTER PROGRAMS 2413 01:40:05,476 --> 01:40:08,212 CALLED THE CORE CENTERS FOR 2414 01:40:08,212 --> 01:40:11,715 CLINICAL RESEARCH OR CCCR. 2415 01:40:11,715 --> 01:40:13,984 THE CORE CENTERS FOR CLINICAL 2416 01:40:13,984 --> 01:40:17,121 RESEARCH HAVE AN OVER ALL GOAL 2417 01:40:17,121 --> 01:40:19,490 TO ADVANCE PREVENTION, DIAGNOSIS 2418 01:40:19,490 --> 01:40:21,825 AND TREATMENT OF NIAMS RELEVANT 2419 01:40:21,825 --> 01:40:24,828 DISEASES AND DISORDERS BY 2420 01:40:24,828 --> 01:40:26,930 FOSTERING THE IMPLEMENTATION OF 2421 01:40:26,930 --> 01:40:28,966 METHODS, METRICS AND MEASURES 2422 01:40:28,966 --> 01:40:32,603 THAT ADDRESS CRITICAL CLINICAL 2423 01:40:32,603 --> 01:40:34,905 RESEARCH NEEDS. 2424 01:40:34,905 --> 01:40:38,008 DOING SO THOUGH WITH PROJECTED 2425 01:40:38,008 --> 01:40:39,910 KNOWLEDGE GAPS AS WELL AS THE 2426 01:40:39,910 --> 01:40:46,383 BROAD STAKEHOLDER VIEWS IN MIND. 2427 01:40:46,383 --> 01:40:50,921 IN FY17, NIAMS ESTABLISHED THE 2428 01:40:50,921 --> 01:40:56,193 CCCR PROGRAM IN ORDER TO ENHANCE 2429 01:40:56,193 --> 01:40:57,327 METHODOLOGICAL SCIENCES THAT 2430 01:40:57,327 --> 01:40:59,296 SUPPORT CLINICAL RESEARCH WITHIN 2431 01:40:59,296 --> 01:41:02,533 AND ACROSS THE NIAMS PORTFOLIO 2432 01:41:02,533 --> 01:41:04,902 OF DISEASES AND TO DATE 10 NEW 2433 01:41:04,902 --> 01:41:08,172 TYPE 1 GRANTS HAVE BEEN AWARDED 2434 01:41:08,172 --> 01:41:10,908 ALONG WITH SEVERAL COMPETITIVE 2435 01:41:10,908 --> 01:41:13,277 RENEWAL GRANTS. 2436 01:41:13,277 --> 01:41:15,846 LOCATED IN ALL THE MAJOR 2437 01:41:15,846 --> 01:41:16,980 QUADRANTS ACROSS THE UNITED 2438 01:41:16,980 --> 01:41:20,984 STATES, THESE CENTERS ADDRESS A 2439 01:41:20,984 --> 01:41:24,054 NUMBER OF RESEARCH AREAS WITHIN 2440 01:41:24,054 --> 01:41:26,723 NIAMS' MISSION INCLUDING JOINT 2441 01:41:26,723 --> 01:41:30,060 REPLACEMENT, LUPUS AND PEDIATRIC 2442 01:41:30,060 --> 01:41:31,929 RHEUMATOLOGY. 2443 01:41:31,929 --> 01:41:35,666 THE GENERAL STRUCTURE OF THE 2444 01:41:35,666 --> 01:41:38,035 CCCR FEATURES A STRONG 2445 01:41:38,035 --> 01:41:38,902 METHODOLOGICAL CORE THAT 2446 01:41:38,902 --> 01:41:41,839 PROVIDED INNOVATIVE APPROACHES 2447 01:41:41,839 --> 01:41:42,906 AS WELL AS THE NECESSARY 2448 01:41:42,906 --> 01:41:45,475 EXPERTISE FOR SUPPORTING LOCAL 2449 01:41:45,475 --> 01:41:48,111 RESEARCH PROJECTS. 2450 01:41:48,111 --> 01:41:51,415 THE CENTERS ALSO INCLUDE AN 2451 01:41:51,415 --> 01:41:53,650 ADMINISTRATIVE CORE LED BY TWO 2452 01:41:53,650 --> 01:41:54,751 DIRECTORS WHO HAVE THE 2453 01:41:54,751 --> 01:41:57,321 FLEXIBILITY TO ORGANIZE CENTER 2454 01:41:57,321 --> 01:41:59,957 ACTIVITIES AROUND A CENTRAL 2455 01:41:59,957 --> 01:42:02,926 SCIENTIFIC THEME OR TO SUPPORT 2456 01:42:02,926 --> 01:42:05,562 STUDIES TO ADDRESS PRESSING 2457 01:42:05,562 --> 01:42:09,032 RESEARCH NEEDS WITH COMMUNITY. 2458 01:42:09,032 --> 01:42:09,933 MOREOVER, PATIENT AND COMMUNITY 2459 01:42:09,933 --> 01:42:12,970 REPRESENTATION IS INCORPORATED 2460 01:42:12,970 --> 01:42:19,409 THROUGHOUT THE PROJECT, 2461 01:42:19,409 --> 01:42:24,381 IMPLEMENTATION AND FORMALIZED 2462 01:42:24,381 --> 01:42:25,582 WITH THE COMMITTEE AND THERE'S 2463 01:42:25,582 --> 01:42:28,485 OPTIONAL COMPONENTS FOR RESEARCH 2464 01:42:28,485 --> 01:42:30,354 CORES AND PILOT AND FEASIBILITY 2465 01:42:30,354 --> 01:42:34,424 PROJECTS. 2466 01:42:34,424 --> 01:42:38,328 SO YOUR CONSENT TO REISSUE THE 2467 01:42:38,328 --> 01:42:41,331 CCCR PROGRAM WILL REPRESENT 2468 01:42:41,331 --> 01:42:44,134 NIAMS' COMMITMENT TO ADVANCING 2469 01:42:44,134 --> 01:42:45,903 METHODOLOGICAL SCIENCE 2470 01:42:45,903 --> 01:42:47,337 CRITICALLY SUPPORT CLINICAL 2471 01:42:47,337 --> 01:42:52,943 RESEARCH WITHIN OUR PORTFOLIO OF 2472 01:42:52,943 --> 01:42:53,210 DISEASES. 2473 01:42:53,210 --> 01:42:54,111 AND CONTINGENT ON OUR 2474 01:42:54,111 --> 01:42:55,579 AVAILABILITY OF FUNDS OUR TEAM 2475 01:42:55,579 --> 01:42:57,514 STANDS READY TO ISSUE NEW AWARDS 2476 01:42:57,514 --> 01:43:00,050 IN FY27 AND FURTHERMORE WE 2477 01:43:00,050 --> 01:43:02,920 WELCOME YOUR FEEDBACK AND OTHER 2478 01:43:02,920 --> 01:43:06,590 COMMENTS VIA THE CENTRAL NIAMS 2479 01:43:06,590 --> 01:43:08,392 COUNCIL ADDRESS SHOWN ON THE 2480 01:43:08,392 --> 01:43:08,792 SCREEN. 2481 01:43:08,792 --> 01:43:13,163 AND HAPPY TO ANSWER ANY 2482 01:43:13,163 --> 01:43:15,799 QUESTIONS. 2483 01:43:15,799 --> 01:43:18,101 >> THANK YOU SO MUCH. 2484 01:43:18,101 --> 01:43:19,770 ANY QUESTIONS? 2485 01:43:19,770 --> 01:43:20,804 >> YES. 2486 01:43:20,804 --> 01:43:24,841 >> I WAS WONDERING WHAT TYPE OF 2487 01:43:24,841 --> 01:43:26,910 EVALUATION OF THE OF THE P30 YOU 2488 01:43:26,910 --> 01:43:30,914 CAN SHARE. 2489 01:43:30,914 --> 01:43:34,284 >> IT'S A MY UNDERSTANDING AN A 2490 01:43:34,284 --> 01:43:37,854 MORE FORMAL EVALUATION HAS NOT 2491 01:43:37,854 --> 01:43:41,391 BEEN CONDUCTED SINCE 2013 2492 01:43:41,391 --> 01:43:43,827 HOWEVER, WE DID HOLD A WORKSHOP 2493 01:43:43,827 --> 01:43:46,930 IN DECEMBER OF LAST YEAR WHERE 2494 01:43:46,930 --> 01:43:48,966 WE RECEIVED FEEDBACK FROM 2495 01:43:48,966 --> 01:43:50,434 GRANTEES AND SO FORTH ABOUT WAYS 2496 01:43:50,434 --> 01:43:54,905 IN WHICH THEY WOULD LIKE TO SEE 2497 01:43:54,905 --> 01:43:56,907 SOME OF OUR CENTERS' PROGRAMS 2498 01:43:56,907 --> 01:43:57,741 EVOLVE. 2499 01:43:57,741 --> 01:44:00,811 >> CAN I ADD TO THAT POINT VERY 2500 01:44:00,811 --> 01:44:02,913 QUICK JUST DO CLARIFY AGAIN 2501 01:44:02,913 --> 01:44:06,049 BECAUSE MELISSA JOINED US AFTER, 2502 01:44:06,049 --> 01:44:08,318 THIS WAS AN INTERNAL WORKSHOP 2503 01:44:08,318 --> 01:44:09,586 WITH OUR DIRECTORS AND NIAMS 2504 01:44:09,586 --> 01:44:10,187 STAFF. 2505 01:44:10,187 --> 01:44:12,289 WE'RE LOOKING INTO WAYS TO 2506 01:44:12,289 --> 01:44:15,692 FORMALIZE AND EVALUATION OF THE 2507 01:44:15,692 --> 01:44:18,462 CENTERS SO YES, THAT'S WHERE WE 2508 01:44:18,462 --> 01:44:22,933 STAND. 2509 01:44:22,933 --> 01:44:24,101 ANYMORE QUESTIONS? 2510 01:44:24,101 --> 01:44:26,036 >> I'LL ALSO JUST ADD THAT THESE 2511 01:44:26,036 --> 01:44:29,506 CONCEPT CLEARANCES ARE AT A VERY 2512 01:44:29,506 --> 01:44:30,407 HIGH LEVEL. 2513 01:44:30,407 --> 01:44:32,009 AS YOU CAN SEE THEY'RE 2514 01:44:32,009 --> 01:44:34,444 PROJECTING IN THE FUTURE WHEN 2515 01:44:34,444 --> 01:44:35,278 CURRENT CONCEPTS WOULD EXPIRE 2516 01:44:35,278 --> 01:44:38,648 AND IT GIVES US PLENTY OF TIME 2517 01:44:38,648 --> 01:44:41,685 AND THE INTENTION IS NOT TO TALK 2518 01:44:41,685 --> 01:44:46,423 ABOUT THE SPECIFICS BUT PLENTY 2519 01:44:46,423 --> 01:44:48,091 OF TIME TO DECIDE HOW THEY'LL 2520 01:44:48,091 --> 01:44:50,427 BEST SUPPORT THE COMMUNITY. 2521 01:44:50,427 --> 01:44:51,395 UNDERSTANDING THE IMPACT THESE 2522 01:44:51,395 --> 01:44:53,663 HAVE HAD IN THE PAST AND EQUALLY 2523 01:44:53,663 --> 01:44:54,865 IMPORTANT, TRYING TO UNDERSTAND 2524 01:44:54,865 --> 01:44:57,401 WHAT'S NEEDED NOW WILL BE PART 2525 01:44:57,401 --> 01:44:58,835 OF THE WORK THAT WE UNDERTAKE 2526 01:44:58,835 --> 01:45:02,939 LEADING UP TO FISCAL YEAR '27 2527 01:45:02,939 --> 01:45:05,642 BUT WE NEED A LOT OF ADVANCED 2528 01:45:05,642 --> 01:45:08,879 NOTICE TO GET APPROVAL SO WE CAN 2529 01:45:08,879 --> 01:45:11,648 BEGIN THE WORK THAT WOULD ENABLE 2530 01:45:11,648 --> 01:45:14,918 US TO RENEW THESE WITHOUT A GAP 2531 01:45:14,918 --> 01:45:15,419 IN FUNDING. 2532 01:45:15,419 --> 01:45:18,221 >> DO WE HAVE ANYMORE QUESTIONS 2533 01:45:18,221 --> 01:45:19,589 HERE? 2534 01:45:19,589 --> 01:45:20,357 >> OKAY. 2535 01:45:20,357 --> 01:45:22,959 LET ME CALL FOR A VOTE THEN. 2536 01:45:22,959 --> 01:45:27,230 SO DO WE HAVE A MOTION I SEE A 2537 01:45:27,230 --> 01:45:28,632 MOTION AND SECOND. 2538 01:45:28,632 --> 01:45:30,200 THANK YOU VERY MUCH. 2539 01:45:30,200 --> 01:45:32,269 ALL OPPOSED TO THE MOTION SAY 2540 01:45:32,269 --> 01:45:33,737 AYE OR RAISE YOUR HAND. 2541 01:45:33,737 --> 01:45:34,671 SEEING NONE THE MOTION PASSES 2542 01:45:34,671 --> 01:45:38,842 AND WE CAN MOVE FORWARD AND I'M 2543 01:45:38,842 --> 01:45:40,944 SURE WE'LL BE HEARING MORE ABOUT 2544 01:45:40,944 --> 01:45:41,211 THIS. 2545 01:45:41,211 --> 01:45:42,212 THANK YOU VERY MUCH. 2546 01:45:42,212 --> 01:45:43,180 MARY, ANY LAST WORDS? 2547 01:45:43,180 --> 01:45:44,347 >> NOPE. 2548 01:45:44,347 --> 01:45:52,289 I JUST WANT TO THANK THE PROGRAM 2549 01:45:52,289 --> 01:45:53,356 DIRECTORS FOR THEIR WORK IN 2550 01:45:53,356 --> 01:45:54,591 CLEARING THE CONCEPT. 2551 01:45:54,591 --> 01:45:57,828 >> WE HAVE SCHEDULED NOW A 2552 01:45:57,828 --> 01:45:58,929 15-MINUTE BREAK. 2553 01:45:58,929 --> 01:46:02,232 I THINK RIGHT AFTER THAT HEAR 2554 01:46:02,232 --> 01:46:03,200 ABOUT THE HEAL STRATEGIC PLAN 2555 01:46:03,200 --> 01:46:04,034 AND THANK YOU VERY MUCH. 2556 01:46:04,034 --> 01:46:07,971 LET'S TAKE A BREAK AND WE'LL SEE 2557 01:46:07,971 --> 01:46:10,740 YOU BACK HERE AT 11:36. 2558 01:46:10,740 --> 01:46:11,650 >> THANK YOU. 2559 01:46:11,650 --> 01:46:15,420 SO I'M NOW GOING TO BE CALLING 2560 01:46:15,420 --> 01:46:22,494 ON DR. ANNA MAZUKO FOR OUR HEAL 2561 01:46:22,494 --> 01:46:23,028 PAIN STRATEGIC PLANNING 2562 01:46:23,028 --> 01:46:23,361 PRESENTATION. 2563 01:46:23,361 --> 01:46:25,997 ANNA. 2564 01:46:25,997 --> 01:46:27,099 >> THANK YOU VERY MUCH. 2565 01:46:27,099 --> 01:46:29,034 I'M VERY CLEAVED TO PRESENT OUR 2566 01:46:29,034 --> 01:46:30,969 NEXT TWO SPEAKERS TODAY. 2567 01:46:30,969 --> 01:46:32,771 SO FIRST JUST A LITTLE BIT OF 2568 01:46:32,771 --> 01:46:36,475 BACKGROUND, ON THE PRESENTATION. 2569 01:46:36,475 --> 01:46:38,176 THE NIH HEAL INITIATIVE WHICH 2570 01:46:38,176 --> 01:46:41,913 WAS LAUNCHED IN 2018 HAS MADE 2571 01:46:41,913 --> 01:46:43,348 SIGNIFICANT PROGRESS IN A SHORT 2572 01:46:43,348 --> 01:46:45,417 PERIOD OF TIME AS DESIGNED IN 2573 01:46:45,417 --> 01:46:46,785 THE HEAL ANNUAL REPORTS BUT IT 2574 01:46:46,785 --> 01:46:48,086 MUST CONTINUE TO EVOLVE TO KEEP 2575 01:46:48,086 --> 01:46:50,756 PACE WITH THE DYNAMIC AND 2576 01:46:50,756 --> 01:46:54,760 CHANGING LANDSCAPE IN OVERDOSE 2577 01:46:54,760 --> 01:46:59,931 AND CHRONIC PAIN. 2578 01:46:59,931 --> 01:47:01,800 THAT END HEAL EMBARKED ON THE 2579 01:47:01,800 --> 01:47:03,068 DEVELOPMENT OF A NEW STRATEGIC 2580 01:47:03,068 --> 01:47:07,472 PLAN IN 2024. 2581 01:47:07,472 --> 01:47:10,742 AS PART OF THAT EFFORT, A 2582 01:47:10,742 --> 01:47:13,845 COMMITTEE WAS CONVENED ON THE 2583 01:47:13,845 --> 01:47:15,547 NATIONAL ADVISORY NEUROLOGICAL 2584 01:47:15,547 --> 01:47:18,550 DISORDERS AND STROKE COUNCIL. 2585 01:47:18,550 --> 01:47:24,389 THIS HEAL PAIN STRATEGIC 2586 01:47:24,389 --> 01:47:26,324 COMMITTEE ENGAGED IN A PROCESS 2587 01:47:26,324 --> 01:47:28,493 TO PROPOSE AND PRIORITIZE 2588 01:47:28,493 --> 01:47:30,061 FORWARD LOOKING STRATEGIC 2589 01:47:30,061 --> 01:47:31,930 RESEARCH PRIORITIES FOR THE NEXT 2590 01:47:31,930 --> 01:47:34,733 PHASE OF PAIN RESEARCH SUPPORTED 2591 01:47:34,733 --> 01:47:35,333 BY THE NIH HEAL INITIATIVE. 2592 01:47:35,333 --> 01:47:38,770 AND I'D LIKE TO ALSO JUST 2593 01:47:38,770 --> 01:47:40,172 BRIEFLY MENTION THAT SEVERAL 2594 01:47:40,172 --> 01:47:41,473 NIAMS PROGRAM DIRECTORS AND 2595 01:47:41,473 --> 01:47:43,008 ANALYSTS ALSO CONTRIBUTED TO 2596 01:47:43,008 --> 01:47:47,879 THAT PROCESS. 2597 01:47:47,879 --> 01:47:49,281 THAT INVOLVED WORKING WITH 2598 01:47:49,281 --> 01:47:50,749 EXPERTS FROM THE RESEARCH 2599 01:47:50,749 --> 01:47:52,551 COMMUNITY AND PEOPLE WITH LIVED 2600 01:47:52,551 --> 01:47:53,752 EXPERIENCE OF PAIN TO INFORM THE 2601 01:47:53,752 --> 01:47:55,654 FINAL RESEARCH PRIORITIES. 2602 01:47:55,654 --> 01:47:56,321 THE EXECUTIVE COMMITTEE 2603 01:47:56,321 --> 01:47:58,590 CONSIDERED AND APPROVED THE 2604 01:47:58,590 --> 01:47:59,224 PROPOSED RESEARCH PRIORITIES 2605 01:47:59,224 --> 01:48:04,029 JUST A FEW WEEKS AGO AT THE MAY 2606 01:48:04,029 --> 01:48:05,697 14, 2025 MEETING OF THE NIAMS 2607 01:48:05,697 --> 01:48:05,931 COUNCIL. 2608 01:48:05,931 --> 01:48:07,732 THE FINAL REPORT FROM THE 2609 01:48:07,732 --> 01:48:09,568 EXECUTIVE COUNTY IDENTIFIES THE 2610 01:48:09,568 --> 01:48:13,071 MOST PROMISING DIRECTIONS FOR 2611 01:48:13,071 --> 01:48:14,739 FUTURE HEAL SUPPORTED PAIN 2612 01:48:14,739 --> 01:48:15,140 RESEARCH. 2613 01:48:15,140 --> 01:48:16,508 THE APPROVED PRIORITIES WILL 2614 01:48:16,508 --> 01:48:18,743 HELP GUIDE THE DEVELOPMENT OF A 2615 01:48:18,743 --> 01:48:21,746 FIVE YEAR STRATEGIC PLAN FOR THE 2616 01:48:21,746 --> 01:48:22,347 NIH HEAL INITIATIVE. 2617 01:48:22,347 --> 01:48:24,983 TO SHARE WITH YOU ALL TODAY MORE 2618 01:48:24,983 --> 01:48:26,618 ABOUT THE RESEARCH PRIORITIES, I 2619 01:48:26,618 --> 01:48:30,088 WOULD LIKE TO INTRODUCE THE 2620 01:48:30,088 --> 01:48:31,489 CO-CHAIRS OF THE HEAL INITIATIVE 2621 01:48:31,489 --> 01:48:32,424 PAIN STRATEGIC PLANNING 2622 01:48:32,424 --> 01:48:33,692 COMMITTEE WHO HAVE GRACIOUSLY 2623 01:48:33,692 --> 01:48:34,993 AGREED TO PRESENT TO US ABOUT 2624 01:48:34,993 --> 01:48:36,862 THESE PRIORITIES TODAY. 2625 01:48:36,862 --> 01:48:40,031 THEY'LL BE PROVIDING AN UPDATE 2626 01:48:40,031 --> 01:48:42,434 ON RECOMMENDATIONS FOR PAIN 2627 01:48:42,434 --> 01:48:45,237 RESEARCH PRIORITIES FOR THE HEAL 2628 01:48:45,237 --> 01:48:49,174 INITIATIVE IN THE FORTHCOMING 2629 01:48:49,174 --> 01:48:50,408 HEAL STRATEGIC PLAN. 2630 01:48:50,408 --> 01:48:55,213 DR. SUKA PROFESSOR OF FISCAL 2631 01:48:55,213 --> 01:48:57,716 THERAPY AND REHAB AND PROFESSOR 2632 01:48:57,716 --> 01:48:58,717 OF NEUROSCIENCE AND PHARMACOLOGY 2633 01:48:58,717 --> 01:49:01,920 AT THE UNIVERSITY OF IOWA IN 2634 01:49:01,920 --> 01:49:04,356 IOWA CITY CARVER COLLEGE OF 2635 01:49:04,356 --> 01:49:05,757 MEDICINE. 2636 01:49:05,757 --> 01:49:07,459 HER LABORATORY STUDIES THE 2637 01:49:07,459 --> 01:49:14,366 PERIPHERAL MECHANISMS OF 2638 01:49:14,366 --> 01:49:18,270 SKELETAL PAIN AND 2639 01:49:18,270 --> 01:49:22,741 NON-PHARMACOLOGIC USE FOR PAIN 2640 01:49:22,741 --> 01:49:26,111 AND PROJECTS IN HUMAN SUBJECTS. 2641 01:49:26,111 --> 01:49:29,114 IN 2024, HAVE SLUKA WAS CHOSEN 2642 01:49:29,114 --> 01:49:33,952 AS ONE OF SIX RECIPIENTS OF THE 2643 01:49:33,952 --> 01:49:37,122 HEAL AWARD FOR MENTORSHIP FOR 2644 01:49:37,122 --> 01:49:38,390 RESEARCHERS WHO DEMONSTRATE 2645 01:49:38,390 --> 01:49:40,091 EXCEPTIONAL COMMITMENT TO THE 2646 01:49:40,091 --> 01:49:41,993 DEVELOPMENT AND MENTORSHIP OF 2647 01:49:41,993 --> 01:49:43,862 EARLY YEAR SCIENTISTS IN THE 2648 01:49:43,862 --> 01:49:45,997 PAIN AND ADDICTION RESEARCH 2649 01:49:45,997 --> 01:49:46,231 FIELDS. 2650 01:49:46,231 --> 01:49:49,367 I'D ALSO LIKE TO INTRODUCE HER 2651 01:49:49,367 --> 01:49:52,070 CO-CHAIR DR. GEREAU, VICE CHAIR 2652 01:49:52,070 --> 01:49:55,440 FOR RESEARCH AND DIRECTOR OF THE 2653 01:49:55,440 --> 01:49:58,376 WASHINGTON UNIVERSITY PAIN 2654 01:49:58,376 --> 01:50:00,679 CENTER AND PROFESSOR THE 2655 01:50:00,679 --> 01:50:06,751 ANESTHESIOLOGY AT THE MEDICINE 2656 01:50:06,751 --> 01:50:14,392 DEPARTMENTANCE THESIOLOGY AND 2657 01:50:14,392 --> 01:50:17,929 ELE TROE PHYSIOLOGY AND 2658 01:50:17,929 --> 01:50:20,165 OPTOGENETICS AND IMAGING AND -- 2659 01:50:20,165 --> 01:50:26,404 I THINK THAT'S DR. KIEL WHO JUST 2660 01:50:26,404 --> 01:50:26,705 JOINED. 2661 01:50:26,705 --> 01:50:28,974 TO UNDERSTAND THE SIGNALLING 2662 01:50:28,974 --> 01:50:34,746 PATHWAYS INVOLVED IN NERVOUS 2663 01:50:34,746 --> 01:50:37,615 SYSTEM PLASTICITY AND PAIN 2664 01:50:37,615 --> 01:50:39,784 SENSITIZATION TO IDENTIFY NOVEL 2665 01:50:39,784 --> 01:50:41,286 APPROACHES TO REVERSE THIS 2666 01:50:41,286 --> 01:50:42,754 MALADAPTIVE PLASTICITY TO 2667 01:50:42,754 --> 01:50:44,289 PROVIDE NEW THERAPEUTIC STRATEGY 2668 01:50:44,289 --> 01:50:45,590 TO REDUCE PAIN AND ITS IMPACT ON 2669 01:50:45,590 --> 01:50:48,259 PATIENT QUALITY OF LIFE. 2670 01:50:48,259 --> 01:50:50,261 WORK IN THE LAB ALSO INCLUDES 2671 01:50:50,261 --> 01:50:52,464 CLINICAL SCIENCE AIMED AT 2672 01:50:52,464 --> 01:50:53,331 TRANSLATING FINDINGS FROM THE 2673 01:50:53,331 --> 01:50:55,500 LAB INTO NEW OR IMPROVED 2674 01:50:55,500 --> 01:50:57,235 THERAPIES FOR PATIENTS WITH 2675 01:50:57,235 --> 01:50:57,569 PAIN. 2676 01:50:57,569 --> 01:50:59,170 THANK YOU, KATHLEEN AND ROB FOR 2677 01:50:59,170 --> 01:51:01,439 JOINING US TODAY AND WE LOOK 2678 01:51:01,439 --> 01:51:03,541 FORWARD TO HEARING MORE ABOUT 2679 01:51:03,541 --> 01:51:05,810 THE PAIN STRATEGIC PLANNING 2680 01:51:05,810 --> 01:51:06,044 PROCESS. 2681 01:51:06,044 --> 01:51:08,246 SO WITH THAT WE'LL HAND IT OVER 2682 01:51:08,246 --> 01:51:09,047 TO KATHLEEN AND ROB. 2683 01:51:09,047 --> 01:51:18,289 THANK YOU SO MUCH. 2684 01:51:18,289 --> 01:51:19,691 >> THANK YOU FOR THE OPPORTUNITY 2685 01:51:19,691 --> 01:51:20,458 TO BE HERE. 2686 01:51:20,458 --> 01:51:21,526 I'LL GIVE MORE DETAIL ON THE 2687 01:51:21,526 --> 01:51:23,862 BACKGROUND BUT THAT WAS A GREAT 2688 01:51:23,862 --> 01:51:25,163 INTRODUCTION AND THEN WE'LL DIVE 2689 01:51:25,163 --> 01:51:26,297 IN AND DISCUSS THE RESEARCH 2690 01:51:26,297 --> 01:51:28,099 PRIORITIES THAT CAME OUT NEF 2691 01:51:28,099 --> 01:51:28,333 PROCESS. 2692 01:51:28,333 --> 01:51:29,634 I'LL GIVE YOU BACKGROUND AND 2693 01:51:29,634 --> 01:51:32,404 FRAMEWORK FOR HOW WE WENT 2694 01:51:32,404 --> 01:51:34,739 THROUGH THIS PROCESS. 2695 01:51:34,739 --> 01:51:42,047 WITH THAT AND THE HEAL 2696 01:51:42,047 --> 01:51:44,449 INITIATIVE LAUNCHED AND CONGRESS 2697 01:51:44,449 --> 01:51:46,684 ADDED AN ADDITIONAL $5 MILLION 2698 01:51:46,684 --> 01:51:48,353 TO THE BASIC APPROPRIATION OF 2699 01:51:48,353 --> 01:51:51,256 NIH TO HAVE A NEW INITIATIVE FOR 2700 01:51:51,256 --> 01:51:54,159 THE DEVELOPMENT OF OPIOID 2701 01:51:54,159 --> 01:51:55,693 ALTERNATIVES AND PAIN MANAGE. 2702 01:51:55,693 --> 01:51:58,396 AND DIRECTIVE TREATMENT. 2703 01:51:58,396 --> 01:51:59,964 THAT WAS A FAST ROLL OUT AT THE 2704 01:51:59,964 --> 01:52:00,832 BEGINNING OF HEAL FROM THE 2705 01:52:00,832 --> 01:52:04,702 INCEPTION TO THE FUNDING TO 2706 01:52:04,702 --> 01:52:06,771 HAVING TO LAUNCH AND SO THE 2707 01:52:06,771 --> 01:52:08,440 INITIAL INVESTMENTS IN HEAL 2708 01:52:08,440 --> 01:52:10,742 AROUND PAIN WERE GUIDED BY A 2709 01:52:10,742 --> 01:52:13,578 COUPLE OF THINGS THAT HAD 2710 01:52:13,578 --> 01:52:16,047 FORTUNATELY JUST BEEN COMPLETED 2711 01:52:16,047 --> 01:52:18,750 WHICH WAS THE FEDERAL PAIN 2712 01:52:18,750 --> 01:52:21,820 RESEARCH STRATEGY OF 2017 AND 2713 01:52:21,820 --> 01:52:24,722 ALSO BASED ON A SERIES OF WHAT 2714 01:52:24,722 --> 01:52:26,558 WERE CALLED SCIENCE MEETINGS TO 2715 01:52:26,558 --> 01:52:28,593 END THE OPIOID CRISIS AND THOSE 2716 01:52:28,593 --> 01:52:29,994 DISCUSSIONS TOGETHER WITH THE 2717 01:52:29,994 --> 01:52:32,197 FEDERAL PAIN RESEARCH STRATEGY 2718 01:52:32,197 --> 01:52:33,665 HELPED TO FORM THE BASIS OF 2719 01:52:33,665 --> 01:52:36,768 PROJECTS THAT WERE GOING TO BE 2720 01:52:36,768 --> 01:52:38,503 TAKEN ON FOR PAIN RESEARCH UNDER 2721 01:52:38,503 --> 01:52:41,473 HEAL WHICH HAS A SPECIFIC 2722 01:52:41,473 --> 01:52:44,442 MANDATE DIFFERENT FROM WHAT IS 2723 01:52:44,442 --> 01:52:49,180 FUNDED FROM THE INSTITUTES AND 2724 01:52:49,180 --> 01:52:50,448 CENTERS NORMALLY. 2725 01:52:50,448 --> 01:52:51,883 THOSE DISCUSSIONS INFORMED THE 2726 01:52:51,883 --> 01:52:53,218 STUDY IN JAMA. 2727 01:52:53,218 --> 01:52:57,355 FROM 2018 TO 2023 IT WAS MANAGED 2728 01:52:57,355 --> 01:52:59,090 THROUGH THE OFFICE OF THE 2729 01:52:59,090 --> 01:53:02,427 DIRECTOR AND THEREAFTER WAS 2730 01:53:02,427 --> 01:53:10,735 MANAGED IN NIDA AND NINDS FROM 2731 01:53:10,735 --> 01:53:16,207 DR. KOROSHETZ AND ONE OTHER. 2732 01:53:16,207 --> 01:53:19,244 THERE'S BEEN GREATER THAN 2200 2733 01:53:19,244 --> 01:53:21,546 RESEARCH PROJECT IN ALL 50 2734 01:53:21,546 --> 01:53:24,582 STATES TOTALLING OVER $3.9 2735 01:53:24,582 --> 01:53:26,751 BILLION IN INVESTMENT. 2736 01:53:26,751 --> 01:53:28,019 IMPORTANTLY INVOLVES 2737 01:53:28,019 --> 01:53:28,920 COLLABORATION ACROSS NIH 2738 01:53:28,920 --> 01:53:30,421 INSTITUTES, CENTERS AND OFFICES. 2739 01:53:30,421 --> 01:53:32,991 IN TERMS OF METRICS OF OUTCOMES 2740 01:53:32,991 --> 01:53:34,726 THERE'S OVER 40 FDA APPROVALS 2741 01:53:34,726 --> 01:53:37,095 FOR INVESTIGATIONAL NEW DRUGS OR 2742 01:53:37,095 --> 01:53:38,897 DEVICES AND OVER 300 CLINICAL 2743 01:53:38,897 --> 01:53:42,734 TRIALS UNDERWAY OR HAVING JUST 2744 01:53:42,734 --> 01:53:43,001 COMPLETED. 2745 01:53:43,001 --> 01:53:44,903 SO WITH THAT RAPID LAUNCH, MANY 2746 01:53:44,903 --> 01:53:47,505 OF THOSE INITIAL PROJECTS 2747 01:53:47,505 --> 01:53:48,439 ESPECIALLY THE CLINICAL TRIALS 2748 01:53:48,439 --> 01:53:50,441 WHICH TAKE A FEW YEARS TO RUN, 2749 01:53:50,441 --> 01:53:52,510 THOSE ARE KIND OF WRAPPING UP OR 2750 01:53:52,510 --> 01:53:55,046 AT A TRANSITION POINT TO THE 2751 01:53:55,046 --> 01:53:56,481 NEXT PHASE. 2752 01:53:56,481 --> 01:54:01,252 AND BASED ON THAT THE HEAL 2753 01:54:01,252 --> 01:54:02,754 MULTI-DISCIPLINARY WORKING GROUP 2754 01:54:02,754 --> 01:54:05,056 DEVELOPED A NEW STRATEGIC PLAN 2755 01:54:05,056 --> 01:54:08,393 AS AN INCLUSIVE WAY PROVIDE 2756 01:54:08,393 --> 01:54:09,260 INPUT TO GUIDE FUTURE HEAL 2757 01:54:09,260 --> 01:54:09,761 INVESTMENTS AROUND PAIN 2758 01:54:09,761 --> 01:54:19,938 RESEARCH. 2759 01:54:22,440 --> 01:54:24,542 THERE'S ANALYSIS ON HOW PAIN 2760 01:54:24,542 --> 01:54:26,211 RESEARCH HAD BEEN GOING BECAUSE 2761 01:54:26,211 --> 01:54:28,513 THERE WERE QUESTIONS WHETHER 2762 01:54:28,513 --> 01:54:30,181 HEAL INITIATIVE FUNDING SHIFT 2763 01:54:30,181 --> 01:54:31,716 THE LOCUS OF WHERE THE FUNDING 2764 01:54:31,716 --> 01:54:35,853 COMES FROM BUT AS THIS SLIDE IS 2765 01:54:35,853 --> 01:54:37,255 INDICATING, YOU'RE SEEING THE 2766 01:54:37,255 --> 01:54:40,892 TREND LINE FOR THE OVER ALL NIH 2767 01:54:40,892 --> 01:54:43,895 BUDGET IN THE BLUE LINE AND 2768 01:54:43,895 --> 01:54:46,731 SALMONY COLORED LOWER BARS IS 2769 01:54:46,731 --> 01:54:48,366 THE FUNDING FOR PAIN THAT COMES 2770 01:54:48,366 --> 01:54:51,803 FROM THE NIH INSTITUTES AND 2771 01:54:51,803 --> 01:54:54,372 CENTERS AND THE TEAL BAR ON TO 2772 01:54:54,372 --> 01:54:55,740 THE TOP REPRESENT THE ADDITIVE 2773 01:54:55,740 --> 01:54:57,275 FUNDING TO HEAL. 2774 01:54:57,275 --> 01:55:00,278 YOU CAN SEE PAIN RESEARCH 2775 01:55:00,278 --> 01:55:02,213 FUNDING TRENDED CONSISTENT WITH 2776 01:55:02,213 --> 01:55:03,748 OVER ALL NIH FUNDING AND IT WAS 2777 01:55:03,748 --> 01:55:05,450 ADDITIVE TO ABOUT WHAT WAS 2778 01:55:05,450 --> 01:55:07,619 ALREADY GOING ON WHICH IS 2779 01:55:07,619 --> 01:55:09,020 APPROPRIATE BECAUSE HEAL HAS A 2780 01:55:09,020 --> 01:55:09,754 DIFFERENT GOAL AND THE MISSION 2781 01:55:09,754 --> 01:55:11,289 STATEMENT IS IN THE BOX. 2782 01:55:11,289 --> 01:55:12,223 YOU CAN SEE HEAL PAIN RESEARCH 2783 01:55:12,223 --> 01:55:14,425 AIMS TO REDUCE PAIN AND THE RISK 2784 01:55:14,425 --> 01:55:16,227 OF OPIOID USE DISORDER BY 2785 01:55:16,227 --> 01:55:18,263 DEVELOPING SAFE AND EFFECTIVE 2786 01:55:18,263 --> 01:55:19,664 PAIN TREATMENTS AND PREVENTION 2787 01:55:19,664 --> 01:55:20,865 STRATEGY TO IMPROVE QUALITY OF 2788 01:55:20,865 --> 01:55:24,135 LIFE FOR ALL PEOPLE. 2789 01:55:24,135 --> 01:55:25,270 IT'S VERY MUCH FOCUSSED ON 2790 01:55:25,270 --> 01:55:26,971 DEVELOPMENT MUCH NEW AND 2791 01:55:26,971 --> 01:55:29,040 REFINEMENT AND VALIDATION OF 2792 01:55:29,040 --> 01:55:30,008 EXISTING THERAPIES TO PICK THE 2793 01:55:30,008 --> 01:55:31,109 BEST TREATMENT AND GET NEW 2794 01:55:31,109 --> 01:55:32,076 TREATMENTS TO PEOPLE AS QUICKLY 2795 01:55:32,076 --> 01:55:32,844 AS POSSIBLE. 2796 01:55:32,844 --> 01:55:34,078 THE GOAL IS TO SPEED THERAPY 2797 01:55:34,078 --> 01:55:44,455 IMPROVEMENT FOR PAIN. 2798 01:55:48,960 --> 01:55:52,997 SO WHAT ARE EXAMPLES OF THE HEAL 2799 01:55:52,997 --> 01:55:53,264 PORTFOLIO? 2800 01:55:53,264 --> 01:56:00,238 THERE'S FARPHARMACOLOGIC APPROAS 2801 01:56:00,238 --> 01:56:02,740 VALIDATED FOR PAIN ANEW 2802 01:56:02,740 --> 01:56:07,412 ACETAMINOPHEN ANALOG AND THE 2803 01:56:07,412 --> 01:56:09,347 INHIBIT ERS IN CLINICAL TRIAL 2804 01:56:09,347 --> 01:56:12,517 AND LIGANDS DEVELOPED IN TERMS 2805 01:56:12,517 --> 01:56:14,619 OF PHARMACOLOGIC APPROACHES 2806 01:56:14,619 --> 01:56:15,987 NON-OPIOID TARGETS. 2807 01:56:15,987 --> 01:56:19,624 THERE'S BEEN A BIG INVESTMENT IN 2808 01:56:19,624 --> 01:56:22,060 WE HEARD ABOUT THIS EARLIER 2809 01:56:22,060 --> 01:56:25,630 FOCUSSED ON HUMAN BIOLOGY BUT 2810 01:56:25,630 --> 01:56:32,437 THE HEAL INITIATIVE WENT INTO 2811 01:56:32,437 --> 01:56:36,974 THIS IN GENERATING DATA IN 2812 01:56:36,974 --> 01:56:38,743 PROTEINS AND DEVELOPED A SENSORY 2813 01:56:38,743 --> 01:56:40,645 NEURONS ACROSS SPECIES INCLUDING 2814 01:56:40,645 --> 01:56:44,549 HUMANS WHERE WE DEVELOPED A REAL 2815 01:56:44,549 --> 01:56:47,151 TIME CHRONIC PAIN SIGNATURE 2816 01:56:47,151 --> 01:56:49,887 COVID BY STROKE OR AMPUTATION 2817 01:56:49,887 --> 01:56:52,590 AND BIOMARKERS TO ALLOW THE 2818 01:56:52,590 --> 01:56:56,561 DISTINGUISHED AGING AND 2819 01:56:56,561 --> 01:56:58,730 DEGENERATIVE CHANGES ASSOCIATED 2820 01:56:58,730 --> 01:57:00,665 WITH CHRONIC LOW BACK PAIN AND 2821 01:57:00,665 --> 01:57:05,169 THERE'S OPTIMIZATION FOR 2822 01:57:05,169 --> 01:57:05,803 HOME-BASED TRANSCUTANEOUS 2823 01:57:05,803 --> 01:57:08,373 STIMULATION FOR ABDOMINAL PAIN 2824 01:57:08,373 --> 01:57:11,008 AND FDA CLEARANCE OF A DEVICE TO 2825 01:57:11,008 --> 01:57:11,509 TREAT CHRONIC PAIN. 2826 01:57:11,509 --> 01:57:12,543 OVER 40 CLINICAL TRIALS. 2827 01:57:12,543 --> 01:57:16,047 MANY OF WHICH ARE WRAPPING UP 2828 01:57:16,047 --> 01:57:16,714 THIS YEAR. 2829 01:57:16,714 --> 01:57:18,549 WON'T GO INTO DETAIL THERE BUT 2830 01:57:18,549 --> 01:57:20,585 ALSO A BIG INVESTMENT IN THE 2831 01:57:20,585 --> 01:57:22,053 PAIN WORKFORCE WHICH IS 2832 01:57:22,053 --> 01:57:23,755 SOMETHING THAT WAS NEEDED AND 2833 01:57:23,755 --> 01:57:28,326 THAT'S REALLY HELPED MOVE THE 2834 01:57:28,326 --> 01:57:34,399 NE 2835 01:57:34,399 --> 01:57:34,932 NEEDLE THERE. 2836 01:57:34,932 --> 01:57:37,568 WITH THAT NOTION WAS TAKING A 2837 01:57:37,568 --> 01:57:39,137 MOMENT TO LOOK AT WHAT HEAL HAS 2838 01:57:39,137 --> 01:57:40,638 DONE WELL AND WHAT THE GAPS ARE 2839 01:57:40,638 --> 01:57:44,509 AND WHAT HAS BEEN MISSED AND TO 2840 01:57:44,509 --> 01:57:47,845 REALLY PROVIDE BROAD STAKEHOLDER 2841 01:57:47,845 --> 01:57:48,479 ENGAGEMENT IN THE PROCESS. 2842 01:57:48,479 --> 01:57:53,050 THE WORKING GROUP THE HEAL PAIN 2843 01:57:53,050 --> 01:57:55,853 STRATEGIC WORKING GROUP WAS 2844 01:57:55,853 --> 01:57:58,289 MENTIONED AS A WORKING GROUP OF 2845 01:57:58,289 --> 01:57:59,957 THE ADVISORY COUNCIL AND ONE OF 2846 01:57:59,957 --> 01:58:01,426 THE FIRST THINGS WE DID WAS GET 2847 01:58:01,426 --> 01:58:02,293 A REQUEST FOR INFORMATION OUT 2848 01:58:02,293 --> 01:58:06,798 THERE TO GET INPUT FROM 2849 01:58:06,798 --> 01:58:08,065 STAKEHOLDERS AND THAT WAS OPEN 2850 01:58:08,065 --> 01:58:11,669 FOR A PERIOD OF TIME AND WE 2851 01:58:11,669 --> 01:58:13,304 COLLECTED THAT INFORMATION AND 2852 01:58:13,304 --> 01:58:17,074 THAT WORKING GROUP THEN CONVENED 2853 01:58:17,074 --> 01:58:19,710 AROUND SCIENTIFIC AREAS TO 2854 01:58:19,710 --> 01:58:23,281 INFORM SEVEN SUBCOMMITTEES BASED 2855 01:58:23,281 --> 01:58:26,651 ON INFORMATION FROM INSIDE NIH 2856 01:58:26,651 --> 01:58:37,195 AND THE REQUEST FOR INFORMATION. 2857 01:58:39,464 --> 01:58:42,733 WE HAVE A FOCUS AREA INCLUDING 2858 01:58:42,733 --> 01:58:44,635 ADDITIONAL PUBLIC INPUT ON THE 2859 01:58:44,635 --> 01:58:46,737 SPECIFIC SUBCOMMITTEES. 2860 01:58:46,737 --> 01:58:50,775 SO SO, THE WORKING GROUP THEN 2861 01:58:50,775 --> 01:58:54,278 TOOK THE INFORMATION AND 2862 01:58:54,278 --> 01:58:54,879 SUBCOMMITTEES DETERMINE THE 2863 01:58:54,879 --> 01:58:56,647 FINAL LIST OF RECOMMENDATIONS 2864 01:58:56,647 --> 01:59:00,117 AND JUST PRESENTED THIS TO NINDS 2865 01:59:00,117 --> 01:59:01,786 COUNCIL AS AN OFFICIAL LIST OF 2866 01:59:01,786 --> 01:59:02,553 RECOMMENDATIONS WE'LL GO OVER 2867 01:59:02,553 --> 01:59:03,454 WITH YOU TODAY. 2868 01:59:03,454 --> 01:59:08,326 ALL OF THIS WILL BE USED TO 2869 01:59:08,326 --> 01:59:09,460 GENERATE NOTICES OF FUNDING 2870 01:59:09,460 --> 01:59:10,895 OPPORTUNITIES IS THE PLAN FOR 2871 01:59:10,895 --> 01:59:12,330 FISCAL YEAR '27 AND BEYOND. 2872 01:59:12,330 --> 01:59:22,640 SO THAT WAS THE SCOPE. 2873 01:59:22,640 --> 01:59:25,309 THESE ARE THE MEMBERS OF THE 2874 01:59:25,309 --> 01:59:26,010 SUBCOMMITTEES AND MEMBERS OF 2875 01:59:26,010 --> 01:59:29,046 VARIOUS SUBCOMMITTEES. 2876 01:59:29,046 --> 01:59:32,650 THEY'RE AS FOLLOWS. 2877 01:59:32,650 --> 01:59:36,020 HEATH EQUITY AND PAIN ACROSS THE 2878 01:59:36,020 --> 01:59:37,655 LIFE COURSE AND NON-ADDICTIVE 2879 01:59:37,655 --> 01:59:39,991 THERAPEUTICS AND BIOMARKERS AND 2880 01:59:39,991 --> 01:59:41,158 PREDICTORS, ANOTHER ON 2881 01:59:41,158 --> 01:59:42,727 OPTIMIZATION OF INTERVENTION TO 2882 01:59:42,727 --> 01:59:43,427 IMPROVE PAIN. 2883 01:59:43,427 --> 01:59:45,329 ONE ON IMPLEMENTATION AND HEALTH 2884 01:59:45,329 --> 01:59:46,764 SERVICES, ONE ON THE 2885 01:59:46,764 --> 01:59:48,966 INTERSECTION OF PAIN AND 2886 01:59:48,966 --> 01:59:50,234 SUBSTITUTE USE DISORDER ARE A 2887 01:59:50,234 --> 01:59:52,003 CRITICAL GOAL FOR THE HEAL 2888 01:59:52,003 --> 01:59:54,505 INITIATIVE AND ANOTHER AREA 2889 01:59:54,505 --> 01:59:55,072 FOCUSSED ON PAIN RESEARCH 2890 01:59:55,072 --> 02:00:01,946 WORKFORCE AND TRAINING. 2891 02:00:01,946 --> 02:00:06,250 YOU CAN SEE THE CO-CHAIRS AND 2892 02:00:06,250 --> 02:00:10,588 DR. SLUKA AND THE COMMITTEE AND 2893 02:00:10,588 --> 02:00:14,659 THE LIVED EXPERIENCES ADVISER 2894 02:00:14,659 --> 02:00:21,832 FOR THE PROCESS. 2895 02:00:21,832 --> 02:00:26,337 THEY EACH HAD A SEVERAL HOURS 2896 02:00:26,337 --> 02:00:27,772 LONG WORKSHOP THAT HAD MEMBERS 2897 02:00:27,772 --> 02:00:29,974 OF THE PUBLIC AVAILABLE THERE. 2898 02:00:29,974 --> 02:00:31,442 EACH TOOK INFORMATION AND WE 2899 02:00:31,442 --> 02:00:32,410 SOUGHT ADDITIONAL INFORMATION TO 2900 02:00:32,410 --> 02:00:38,015 EACH OF THE SUBCOMMITTEES TO 2901 02:00:38,015 --> 02:00:42,753 DEVELOP A SET OF PRIORITIES 2902 02:00:42,753 --> 02:00:48,092 WITHIN THE GROUPS. 2903 02:00:48,092 --> 02:00:49,827 WE TOOK THE RECOMMENDATIONS AND 2904 02:00:49,827 --> 02:00:51,796 THERE WAS OVERLAP NOT 2905 02:00:51,796 --> 02:00:54,899 SURPRISINGLY AND WENT THROUGH A 2906 02:00:54,899 --> 02:00:59,870 PROCESS TO PRIORITIZE THOSE 2907 02:00:59,870 --> 02:01:00,705 RECOMMENDATIONS BASED ON THEIR 2908 02:01:00,705 --> 02:01:05,576 ABILITY TO ADVANCE THE HEAL PAIN 2909 02:01:05,576 --> 02:01:05,810 MISSION. 2910 02:01:05,810 --> 02:01:07,678 THE EXECUTIVE COMMITTEE DID THE 2911 02:01:07,678 --> 02:01:09,380 WORK AND CAME UP WITH PRIORITIES 2912 02:01:09,380 --> 02:01:10,381 GOING FORWARD BASED ON THAT 2913 02:01:10,381 --> 02:01:14,652 PROCESS ALONG WITH A SET OF CORE 2914 02:01:14,652 --> 02:01:18,923 PRINCIPLES THAT HELP ADVANCE THE 2915 02:01:18,923 --> 02:01:22,026 HEAL PAIN MISSION. 2916 02:01:22,026 --> 02:01:24,362 THE CORE PRINCIPLES ARE CROSS 2917 02:01:24,362 --> 02:01:25,630 CUTTING AND CAME UP TIME AND 2918 02:01:25,630 --> 02:01:26,063 AGAIN. 2919 02:01:26,063 --> 02:01:26,998 THESE ARE THINGS THAT ARE TO BE 2920 02:01:26,998 --> 02:01:30,134 CONSIDERED IN THE CONTEXT OF ALL 2921 02:01:30,134 --> 02:01:31,135 THE RESEARCH GOING ON. 2922 02:01:31,135 --> 02:01:33,337 FIRST BEING THE INVOLVEMENT OF 2923 02:01:33,337 --> 02:01:36,774 PEOPLE WITH LIVED EXPERIENCE AND 2924 02:01:36,774 --> 02:01:37,775 NIH HEAL RESEARCH INCLUDING 2925 02:01:37,775 --> 02:01:39,276 TRAINING OF INVESTIGATOR ON HOW 2926 02:01:39,276 --> 02:01:42,713 TO WORK WITH PEOPLE WITH LIVED 2927 02:01:42,713 --> 02:01:48,786 EXPERIENCE THE INCLUSION OF 2928 02:01:48,786 --> 02:01:49,453 LIVED EXPERIENCE THROUGH DATA 2929 02:01:49,453 --> 02:01:55,926 ANALYSIS AND THE WHOLE PROCESS. 2930 02:01:55,926 --> 02:01:58,729 THERE'S A LOT OF ENERGY AROUND 2931 02:01:58,729 --> 02:02:02,199 PUBLIC EDUCATION FOR PUBLIC AND 2932 02:02:02,199 --> 02:02:02,700 PROVIDERS. 2933 02:02:02,700 --> 02:02:04,368 THERE ARE A NUMBER OF 2934 02:02:04,368 --> 02:02:07,004 METHODOLOGICAL PRINCIPLES FOR 2935 02:02:07,004 --> 02:02:08,806 PRE CLINICAL AND CLINICAL TRIAL 2936 02:02:08,806 --> 02:02:09,674 RESEARCH MENTIONED. 2937 02:02:09,674 --> 02:02:13,210 YOU CAN SEE THE REPORTING OF 2938 02:02:13,210 --> 02:02:16,313 SEX, LONGER TERM OUTCOMES FOCUS 2939 02:02:16,313 --> 02:02:19,050 ON PAIN ACROSS THE LIFE SPAN AND 2940 02:02:19,050 --> 02:02:22,753 NEEDS TO BE MIMICKED IN PRE 2941 02:02:22,753 --> 02:02:24,388 CLINICAL WORK AND CO-OCCURRING 2942 02:02:24,388 --> 02:02:25,690 CONDITIONS IN THE MODELS. 2943 02:02:25,690 --> 02:02:26,857 THE INFLUENCE OF SOCIAL FACTORS 2944 02:02:26,857 --> 02:02:30,728 AND THAT WILL COME UP LATER 2945 02:02:30,728 --> 02:02:35,900 AROUND ANTIGRATING PRINCIPLES 2946 02:02:35,900 --> 02:02:37,702 INTO ALL CLINICAL TRIALS AND USE 2947 02:02:37,702 --> 02:02:40,337 OF TEAMS TO CATALYZE ON UNIQUE 2948 02:02:40,337 --> 02:02:44,341 SKILLS AND METHODOLOGIES AND 2949 02:02:44,341 --> 02:02:48,112 EMPHASIS ON ALLOWING AND 2950 02:02:48,112 --> 02:02:48,979 ENCOURAGING SECONDARY ANALYSIS 2951 02:02:48,979 --> 02:02:52,116 OF DATA SETS AND SAMPLES MANY OF 2952 02:02:52,116 --> 02:02:54,185 WHICH ARE ALREADY STORED IN THE 2953 02:02:54,185 --> 02:02:55,352 HEAL DATA ECO SYSTEM AND THOSE 2954 02:02:55,352 --> 02:02:56,721 ARE CAREER PRINCIPLES. 2955 02:02:56,721 --> 02:03:03,494 WITH THOSE IN MIND, WE'LL DIVE 2956 02:03:03,494 --> 02:03:04,729 INTO THE RESEARCH PRIORITIES. 2957 02:03:04,729 --> 02:03:09,834 THESE WERE PRESENTED TO YOU HERE 2958 02:03:09,834 --> 02:03:11,569 IN NO PARTICULAR ORDER JUST THE 2959 02:03:11,569 --> 02:03:15,039 TEN THAT CAME TO THE TOP OF THE 2960 02:03:15,039 --> 02:03:19,710 PILE. 2961 02:03:19,710 --> 02:03:22,046 I'LL GIVE THE FIRST FEW AND 2962 02:03:22,046 --> 02:03:25,249 WE'LL FINISH UP. 2963 02:03:25,249 --> 02:03:32,623 THE FIRST WAS TO SUPPORT CAREER 2964 02:03:32,623 --> 02:03:34,125 AWARDS INCLUDING 2965 02:03:34,125 --> 02:03:35,793 NON-U.S. CITIZENS TO GROW THE 2966 02:03:35,793 --> 02:03:37,294 PAIN WORKFORCE. 2967 02:03:37,294 --> 02:03:38,529 WE WANTED TO FOSTER THE 2968 02:03:38,529 --> 02:03:39,730 CONTINUED GROWTH OF ESTABLISHED 2969 02:03:39,730 --> 02:03:41,966 PAIN RESEARCHERS AND PROVIDE 2970 02:03:41,966 --> 02:03:43,768 TARGETED OPPORTUNITIES FOR 2971 02:03:43,768 --> 02:03:45,536 INDIVIDUALS WITH NO PRIOR PAIN 2972 02:03:45,536 --> 02:03:46,737 RESEARCH EXPERIENCE BUT STRONG 2973 02:03:46,737 --> 02:03:50,040 POTENTIAL TO DEVELOP IMPACTFUL 2974 02:03:50,040 --> 02:03:54,111 CAREERS IN PAIN SCIENCE WE'VE 2975 02:03:54,111 --> 02:03:54,912 SEEN POSITIVE RESULTS FROM 2976 02:03:54,912 --> 02:03:56,747 PEOPLE FROM OTHER FIELDS AND 2977 02:03:56,747 --> 02:03:58,215 BRINGING NEW EXPERTS AND THAT 2978 02:03:58,215 --> 02:04:08,425 WAS EVOLVED TO FOCUS ON THAT. 2979 02:04:08,425 --> 02:04:10,895 PEOPLE THAT WAS A GOOD OUTCOME 2980 02:04:10,895 --> 02:04:13,130 FOCUSSED ON PAIN WORKFORCE 2981 02:04:13,130 --> 02:04:14,298 GROWTH IN THE FIRST PHASE OF 2982 02:04:14,298 --> 02:04:14,965 HEAL AND WAND TO EXPAND THAT IN 2983 02:04:14,965 --> 02:04:22,640 THESE DAYS. 2984 02:04:22,640 --> 02:04:26,577 THE NEXT IS TO SUPPORT 2985 02:04:26,577 --> 02:04:27,478 MECHANISTI 2986 02:04:27,478 --> 02:04:30,681 MECHANISTICALLY PHARMACEUTICAL 2987 02:04:30,681 --> 02:04:31,081 MODALITIES. 2988 02:04:31,081 --> 02:04:32,216 DEVELOPING NEW THERAPIES FOR 2989 02:04:32,216 --> 02:04:34,919 PAIN BUT EXPANDING THE MODAL 2990 02:04:34,919 --> 02:04:38,722 MODALITIES BEYOND SMALL 2991 02:04:38,722 --> 02:04:40,291 MOLECULES. 2992 02:04:40,291 --> 02:04:42,359 INCORPORATING ANTIBODY BASED 2993 02:04:42,359 --> 02:04:45,429 THERAPIES, mRNA THERAPIES AND 2994 02:04:45,429 --> 02:04:48,499 PROTEIN DEGRADATION WERE 2995 02:04:48,499 --> 02:04:53,671 DISCUSSED IN THE GROUP AND THE 2996 02:04:53,671 --> 02:04:54,738 HEAL INITIATIVE DEVELOPED A 2997 02:04:54,738 --> 02:04:59,310 WHOLE ECO SYSTEM FOR TAKING 2998 02:04:59,310 --> 02:05:03,380 TARGETS IDEAS FROM TARGET 2999 02:05:03,380 --> 02:05:05,249 MOLECULES AND VALIDATING THEM 3000 02:05:05,249 --> 02:05:08,452 AND THERE'S BIG SUPPORT FROM 3001 02:05:08,452 --> 02:05:09,720 ENABLING PROCESS TO ALLOW 3002 02:05:09,720 --> 02:05:11,288 THERAPEUTIC DEVELOPMENT IN 3003 02:05:11,288 --> 02:05:15,459 ACADEMIA AND IN SMALL START UPS 3004 02:05:15,459 --> 02:05:19,129 BECAUSE IT BROUGHT NEW 3005 02:05:19,129 --> 02:05:20,698 MODALITIES AND TARGETS FORWARD 3006 02:05:20,698 --> 02:05:23,634 BUT WANT TO EXPAND THAT TO WHERE 3007 02:05:23,634 --> 02:05:24,735 THESE OTHER NEW THERAPEUTIC 3008 02:05:24,735 --> 02:05:26,770 MODALITY INCLUDED BECAUSE 3009 02:05:26,770 --> 02:05:27,371 THERE'S A LOT OF OPPORTUNITY 3010 02:05:27,371 --> 02:05:34,378 THERE. 3011 02:05:34,378 --> 02:05:35,646 I MENTIONED EARLIER THE BIOLOGY 3012 02:05:35,646 --> 02:05:37,514 WAS A BIG PART OF WHAT WAS 3013 02:05:37,514 --> 02:05:40,417 HAPPENING IN THE FIRST PART OF 3014 02:05:40,417 --> 02:05:45,489 HEAL AND THEY WANT TO CONTINUE 3015 02:05:45,489 --> 02:05:46,857 THE INVESTMENT FOCUSSED ON HUMAN 3016 02:05:46,857 --> 02:05:51,328 BIOLOGY TO SUPPORT THE 3017 02:05:51,328 --> 02:05:52,396 DEVELOPMENT OF NOVEL 3018 02:05:52,396 --> 02:05:53,797 THERAPEUTICS FIRST BY 3019 02:05:53,797 --> 02:05:54,665 IDENTIFYING HIGH QUALITY TARGETS 3020 02:05:54,665 --> 02:05:56,300 FOR THE DEVELOPMENT OF NEW 3021 02:05:56,300 --> 02:05:58,736 EFFECTIVE PAIN THERAPEUTICS AND 3022 02:05:58,736 --> 02:06:01,705 TO ALLOW REVERSE TRANSLATION IN 3023 02:06:01,705 --> 02:06:03,207 THAT UNDERSTANDING THE HUMAN 3024 02:06:03,207 --> 02:06:04,041 BIOLOGY AROUND PAIN CONDITIONS 3025 02:06:04,041 --> 02:06:06,777 WILL ALLOW THE DEVELOPMENT OF A 3026 02:06:06,777 --> 02:06:08,679 NEW GENERATION OF MUCH MORE 3027 02:06:08,679 --> 02:06:10,514 PREDICTIVE DISEASE SPECIFIC 3028 02:06:10,514 --> 02:06:12,116 ANIMAL AND CELLULAR MODELS THAT 3029 02:06:12,116 --> 02:06:21,859 WILL HELP TO ADVANCE THE FIELD. 3030 02:06:21,859 --> 02:06:25,829 I'LL PASSIVE OFF TO HAVE SLUKA 3031 02:06:25,829 --> 02:06:26,730 DO MOVE AHEAD. 3032 02:06:26,730 --> 02:06:34,672 BEING -- TO MOVE AHEAD. 3033 02:06:34,672 --> 02:06:38,742 >> I'LL MOVE ON WITH OUR NEXT 3034 02:06:38,742 --> 02:06:40,010 PRIORITIES. 3035 02:06:40,010 --> 02:06:42,746 THESE TEND TO SPAN SOME MORE 3036 02:06:42,746 --> 02:06:44,348 CLINICALLY BASED PRIORITIES. 3037 02:06:44,348 --> 02:06:48,719 THE FIRST ONE IS TO DEVELOP WAYS 3038 02:06:48,719 --> 02:06:50,721 TO PREVENT THE DEVELOPMENT OF 3039 02:06:50,721 --> 02:06:56,827 CHRONIC PAIN. 3040 02:06:56,827 --> 02:06:58,729 THROUGHOUT THE LIFE SPAN IN REAL 3041 02:06:58,729 --> 02:06:59,964 KEY TRANSITION PHASES ACROSS THE 3042 02:06:59,964 --> 02:07:01,632 LIFE COURSE AND THIS IS A BIG 3043 02:07:01,632 --> 02:07:02,566 THING. 3044 02:07:02,566 --> 02:07:04,935 WE WOULD HAVE TO DEVELOP AND 3045 02:07:04,935 --> 02:07:09,273 TEST SCREENING TOOLS AND 3046 02:07:09,273 --> 02:07:10,975 BIOMARKERS AND DEVELOP 3047 02:07:10,975 --> 02:07:12,309 STRATEGIES THAT COULD PREVENT 3048 02:07:12,309 --> 02:07:13,777 THE DEVELOPMENT OF PAIN ONCE WE 3049 02:07:13,777 --> 02:07:15,679 KNOW WHAT THOSE RISKS AND 3050 02:07:15,679 --> 02:07:18,749 BIOMARKERS ARE CAN WE TARGET 3051 02:07:18,749 --> 02:07:20,784 THEM AND THEN CHANGE AND REDUCE 3052 02:07:20,784 --> 02:07:22,720 THE TRANSITION RATES BECAUSE 3053 02:07:22,720 --> 02:07:24,088 RIGHT NOW TRANSITION RATES ARE 3054 02:07:24,088 --> 02:07:27,791 20% TO 40% DEPENDING ON HOW YOU 3055 02:07:27,791 --> 02:07:33,864 CALCULATE IT AND THE CONDITION 3056 02:07:33,864 --> 02:07:36,967 THEN WE WOULD NEED TO TEST OTHER 3057 02:07:36,967 --> 02:07:38,702 STRATEGIES GEARED TOWARDS 3058 02:07:38,702 --> 02:07:39,570 PREVENTING IT TOGETHER WITH 3059 02:07:39,570 --> 02:07:44,508 LIFESTYLE CHANGES SIM IS -- 3060 02:07:44,508 --> 02:07:45,776 SIMILAR TO CARDIOVASCULAR 3061 02:07:45,776 --> 02:07:48,212 DISEASE AND PREVENTING IT BEFORE 3062 02:07:48,212 --> 02:07:53,517 OR AFTER AN ACUTE INJURY OR 3063 02:07:53,517 --> 02:07:55,419 SURGERY AND COULD TREAT THEM 3064 02:07:55,419 --> 02:07:56,520 FIRST BEFORE THE SURGICAL EVENT 3065 02:07:56,520 --> 02:07:58,422 OR AT THE TIME OF THE INITIAL 3066 02:07:58,422 --> 02:08:00,958 TRAUMA AND THIS LEADS ITSELF TO 3067 02:08:00,958 --> 02:08:04,461 PRE CLINICAL STUDIES TOO THAT 3068 02:08:04,461 --> 02:08:07,498 COULD BEGIN TO EXAM MECHANISMS 3069 02:08:07,498 --> 02:08:08,932 AND BIOMARKERS IN THAT 3070 02:08:08,932 --> 02:08:09,500 TRANSITION PHASE TO CHRONIC 3071 02:08:09,500 --> 02:08:18,742 PAIN. 3072 02:08:18,742 --> 02:08:20,511 THE NEXT WILL BE ABOUT 3073 02:08:20,511 --> 02:08:20,944 BIOMARKERS. 3074 02:08:20,944 --> 02:08:23,447 YOU CAN SEE OVERLAP BETWEEN THEM 3075 02:08:23,447 --> 02:08:25,282 BUT THEN THERE'S SOME NOVELTIES 3076 02:08:25,282 --> 02:08:26,450 WITH EACH OF THEM. 3077 02:08:26,450 --> 02:08:27,551 AND THIS WILL BE ABOUT 3078 02:08:27,551 --> 02:08:29,753 DEVELOPING PREDICTORS FOR 3079 02:08:29,753 --> 02:08:31,922 TREATMENT RESPONSE SO WE ALL 3080 02:08:31,922 --> 02:08:35,559 KNOW NOT EVERYBODY RESPONDS TO 3081 02:08:35,559 --> 02:08:38,195 ALL TREATMENTS ONLY ABOUT 40% TO 3082 02:08:38,195 --> 02:08:39,263 50% RESPOND TO ANY ONE TREATMENT 3083 02:08:39,263 --> 02:08:41,965 SO IF WE CAN PICK THOSE WHO DO 3084 02:08:41,965 --> 02:08:44,935 RESPOND WE CAN IDENTIFY PEOPLE 3085 02:08:44,935 --> 02:08:50,774 WHO WILL RESPOND IN AND BETTER 3086 02:08:50,774 --> 02:08:51,241 SELECT THE TREATMENTS. 3087 02:08:51,241 --> 02:08:53,377 SO WE'RE LOOKING FOR TREATMENT 3088 02:08:53,377 --> 02:08:54,745 RESPONSE PREDICTORS, SAFETY OR 3089 02:08:54,745 --> 02:08:57,181 TARGET ENGAGEMENT AND COULD 3090 02:08:57,181 --> 02:08:58,949 SERVE AS SURROGATE END POINTS IN 3091 02:08:58,949 --> 02:08:59,550 CLINICAL TRIALS. 3092 02:08:59,550 --> 02:09:01,585 THESE COULD BE INCORPORATED INTO 3093 02:09:01,585 --> 02:09:05,456 ALL OF OUR CLINICAL TRIALS. 3094 02:09:05,456 --> 02:09:06,757 IT WILL REQUIRE RIGOROUS 3095 02:09:06,757 --> 02:09:07,357 VALIDATION. 3096 02:09:07,357 --> 02:09:08,725 WE KNOW THERE'S A BIOMARKER 3097 02:09:08,725 --> 02:09:10,327 PROGRAM THAT SUPPORTS THIS THAT 3098 02:09:10,327 --> 02:09:13,397 HAS ALREADY STARTED IN THE FIRST 3099 02:09:13,397 --> 02:09:14,731 PHASE OF HEAL A NUMBER OF 3100 02:09:14,731 --> 02:09:16,867 BIOMARKER STUDIES THAT COULD BE 3101 02:09:16,867 --> 02:09:18,735 CONTINUED AND TAKE THIS TOTS 3102 02:09:18,735 --> 02:09:28,912 NEXT STAGE. 3103 02:09:28,912 --> 02:09:31,849 WE AT A TAILORED MECHANISM BASED 3104 02:09:31,849 --> 02:09:33,517 APPROACH SHOULD IMPROVE 3105 02:09:33,517 --> 02:09:34,718 OUTCOMES. 3106 02:09:34,718 --> 02:09:36,386 IN MEDICINE PRACTICES THIS WAY 3107 02:09:36,386 --> 02:09:38,355 THEY PICK TARGETS BASED ON THE 3108 02:09:38,355 --> 02:09:39,223 MECHANISM OF THE DISEASE BUT A 3109 02:09:39,223 --> 02:09:41,058 LOT OF NON-DRUG THERAPIES ARE 3110 02:09:41,058 --> 02:09:44,528 JUST KIND OF THROWN AT THAT AS 3111 02:09:44,528 --> 02:09:45,429 WELL WITHOUT KNOWING NECESSARILY 3112 02:09:45,429 --> 02:09:46,430 HOW THEY ALL WORK. 3113 02:09:46,430 --> 02:09:49,166 SO THIS PRIORITY IS REALLY TO 3114 02:09:49,166 --> 02:09:51,468 EVALUATE WHETHER INDIVIDUALIZED 3115 02:09:51,468 --> 02:09:52,402 TAILORED MECHANISM BASED 3116 02:09:52,402 --> 02:09:53,137 APPROACH ARE BETTER THAN JUST 3117 02:09:53,137 --> 02:09:54,905 THE STANDARD APPROACH THAT WE 3118 02:09:54,905 --> 02:09:57,908 USE TODAY. 3119 02:09:57,908 --> 02:10:01,145 IN ORDER TO DO THIS WE HAVE TO 3120 02:10:01,145 --> 02:10:12,122 DEVELOP DEVELOPTHE COMPLEXITY A 3121 02:10:17,528 --> 02:10:21,298 CAPTURE THE NATURE OF PAIN AND 3122 02:10:21,298 --> 02:10:23,167 THE INDIVIDUALITY OF PAIN AND 3123 02:10:23,167 --> 02:10:26,937 LOOK AT MECHANISMS UNDERLYING 3124 02:10:26,937 --> 02:10:28,572 NON-PHARMACOLOGIC INTERVENTIONS 3125 02:10:28,572 --> 02:10:30,741 TO BE TARGETED TO THE PHENOTYPES 3126 02:10:30,741 --> 02:10:37,247 AND SIGNATURES. 3127 02:10:37,247 --> 02:10:42,252 THEN LOOK AT THE SIGNATURE WITH 3128 02:10:42,252 --> 02:10:44,855 TREATMENTS AIMED AT THE 3129 02:10:44,855 --> 02:10:46,723 MECHANISMS AND EXPECT A MULTI 3130 02:10:46,723 --> 02:10:49,860 DISCIPLINARY APPROACH LOOKING AT 3131 02:10:49,860 --> 02:10:52,129 MECHANISMS OF THE DRUG DEVICES 3132 02:10:52,129 --> 02:10:54,998 AS WELL AS THE PHARMACEUTICAL 3133 02:10:54,998 --> 02:11:02,739 TREATMENTS TOGETHER. 3134 02:11:02,739 --> 02:11:05,209 THE OTHER THING WE KNOW IS 3135 02:11:05,209 --> 02:11:06,276 MULTI-MODAL APPROACHES WE THINK 3136 02:11:06,276 --> 02:11:08,445 ARE USEFUL AND BETTER THAN JUST 3137 02:11:08,445 --> 02:11:09,379 THE SINGLE TREATMENT APPROACH 3138 02:11:09,379 --> 02:11:11,215 YET WE DON'T REALLY KNOW WHAT 3139 02:11:11,215 --> 02:11:17,621 TREATMENT SHOULD BE GIVEN WHEN 3140 02:11:17,621 --> 02:11:19,323 AND UNDER WHAT CONDITIONS AND 3141 02:11:19,323 --> 02:11:22,359 THIS IS VALIDATING AND TESTING 3142 02:11:22,359 --> 02:11:25,195 EVIDENCE-BASED GUIDELINES ON THE 3143 02:11:25,195 --> 02:11:26,964 APPROPRIATE INITIAL THERAPY AND 3144 02:11:26,964 --> 02:11:28,532 ORDER AND TIMING OF THE 3145 02:11:28,532 --> 02:11:31,401 MULTI-MODAL APPROACHES AND ALSO 3146 02:11:31,401 --> 02:11:32,970 THE NON SPECIFIC EFFECTS AND HOW 3147 02:11:32,970 --> 02:11:36,807 TO MAXIMIZE THEM TO ACHIEVE A 3148 02:11:36,807 --> 02:11:38,742 MAXIMAL BENEFIT FOR THE 3149 02:11:38,742 --> 02:11:45,249 INDIVIDUAL WITHOUT UNDUE RISK. 3150 02:11:45,249 --> 02:11:47,251 WE WOULD HAVE TO LOOK AT 3151 02:11:47,251 --> 02:11:47,985 TREATMENT RESPONSE AND ALREADY 3152 02:11:47,985 --> 02:11:55,259 TALKED ABOUT THAT IN A PRIORITY 3153 02:11:55,259 --> 02:11:57,060 AND NOT SINGLE INDIVIDUALIZED 3154 02:11:57,060 --> 02:11:59,263 APPROACHES AND EVALUATE ALL 3155 02:11:59,263 --> 02:12:02,266 THERAPIES PARTICULARLY NON DRUG 3156 02:12:02,266 --> 02:12:02,966 APPROACHES AND UNDERSTAND THE 3157 02:12:02,966 --> 02:12:07,037 NON SPECIFIC EFFECTS AND THEIR 3158 02:12:07,037 --> 02:12:09,039 INFLUENCE. 3159 02:12:09,039 --> 02:12:12,276 THERE WAS ALREADY A CLINICAL 3160 02:12:12,276 --> 02:12:13,744 EFFECTIVENESS NETWORK THAT HAS 3161 02:12:13,744 --> 02:12:15,579 DONE A COUPLE OF STUDIES ON THIS 3162 02:12:15,579 --> 02:12:20,951 IN PROGRESS OR WRAPPING UP NOW 3163 02:12:20,951 --> 02:12:31,428 AND THERE'S A PRISM NETWORK 3164 02:12:32,162 --> 02:12:33,063 APPROACH TO SUPPORT THESE 3165 02:12:33,063 --> 02:12:43,307 STUDIES WELL. 3166 02:12:43,907 --> 02:12:45,442 THIS IS ON IMPROVING CLINICAL 3167 02:12:45,442 --> 02:12:49,379 OUTCOME AND TAKING THE 3168 02:12:49,379 --> 02:12:50,280 EVIDENCE-BASED TREATMENTS AND 3169 02:12:50,280 --> 02:12:53,950 FIGURE OUT IF THEY WORK WHEN YOU 3170 02:12:53,950 --> 02:12:57,721 PUT THEM IN THE REAL WORLD AND 3171 02:12:57,721 --> 02:12:58,722 LOOKING AT HYBRID IMPLEMENTATION 3172 02:12:58,722 --> 02:13:01,358 AND EFFECTIVENESS STUDIES OF 3173 02:13:01,358 --> 02:13:02,726 PRAGMATIC TRIALS THAT WOULD 3174 02:13:02,726 --> 02:13:06,563 IMPACT SCALABILITY AND 3175 02:13:06,563 --> 02:13:06,930 SUSTAINABILITY. 3176 02:13:06,930 --> 02:13:12,936 SO THE GOAL IS TO NOT ONLY KNOW 3177 02:13:12,936 --> 02:13:15,005 WHAT WORKS BUT GET THEM IN THE 3178 02:13:15,005 --> 02:13:19,309 CLINIC AND ALIGN WITH METRICS TO 3179 02:13:19,309 --> 02:13:22,713 MEANING 3180 02:13:22,713 --> 02:13:26,249 MEANINGFUL EFFECT AND PAYERS AND 3181 02:13:26,249 --> 02:13:27,084 HEALTH CARE SYSTEMS AND PEOPLE 3182 02:13:27,084 --> 02:13:28,685 ONE LIVED EXPERIENCE AND A 3183 02:13:28,685 --> 02:13:30,854 PARTNERSHIP TO GET THESE 3184 02:13:30,854 --> 02:13:37,594 INTEGRATED. 3185 02:13:37,594 --> 02:13:40,430 WE WOULD ASSESS SHARED DECISION 3186 02:13:40,430 --> 02:13:42,132 MAKING TOOLS CLINICIANS TALK 3187 02:13:42,132 --> 02:13:45,068 ABOUT AS BEING VALUABLE AND IN 3188 02:13:45,068 --> 02:13:48,171 IMPROVING OUTCOMES BUT HAS NOT 3189 02:13:48,171 --> 02:13:50,173 TESTED WELL AND EVALUATE THE 3190 02:13:50,173 --> 02:13:51,074 INTEGRATIVE CARE MODELS IN THE 3191 02:13:51,074 --> 02:13:52,109 COMMUNITY SETTINGS TO SEE 3192 02:13:52,109 --> 02:13:55,712 WHETHER OR NOT THEY ACTUALLY 3193 02:13:55,712 --> 02:13:58,415 WORK BETTER THAN WHAT THEY'RE 3194 02:13:58,415 --> 02:13:59,583 DOING NOW AND A KEY FACTOR THAT 3195 02:13:59,583 --> 02:14:03,086 CAME OUT OF THIS WAS NOT ONLY 3196 02:14:03,086 --> 02:14:05,489 WOULD WE IMPLEMENT THE HIGH 3197 02:14:05,489 --> 02:14:07,758 VALUE INTERVENTIONS BASED ON 3198 02:14:07,758 --> 02:14:10,093 CLINICAL EVIDENCE WOULD BE 3199 02:14:10,093 --> 02:14:12,229 COUPLED WITH DE-IMPLEMENTATION 3200 02:14:12,229 --> 02:14:14,831 OF LOW VALUE, HIGHER RISK PAIN 3201 02:14:14,831 --> 02:14:19,069 INTERVENTIONS. 3202 02:14:19,069 --> 02:14:24,508 IT WAS THOUGHT YOU CAN'T JUST 3203 02:14:24,508 --> 02:14:25,275 TAKE OUT SOMETHING WITHOUT 3204 02:14:25,275 --> 02:14:27,077 SOMETHING TO REPLACE IT. 3205 02:14:27,077 --> 02:14:30,747 IT WAS AN IMPORTANT PART OF 3206 02:14:30,747 --> 02:14:32,616 THESE PRAGMATIC TRIALS AND THE 3207 02:14:32,616 --> 02:14:33,850 CLINICAL EFFECTIVE NETWORK ARE 3208 02:14:33,850 --> 02:14:37,821 ALREADY IN PLACE TO HELP SUPPORT 3209 02:14:37,821 --> 02:14:48,265 THESE NEXT STAGE STUDIES. 3210 02:14:50,167 --> 02:14:51,468 THIS IS AN INTERSECTION BETWEEN 3211 02:14:51,468 --> 02:14:53,537 SUBSTITUTE USE DISORDER AND 3212 02:14:53,537 --> 02:14:53,737 PAIN. 3213 02:14:53,737 --> 02:14:56,473 MANY PEOPLE WITH SUBSTANCE USE 3214 02:14:56,473 --> 02:14:58,742 DISORDER HAVE PAIN AND SOME TAKE 3215 02:14:58,742 --> 02:15:02,746 PAIN THERAPEUTICS AND PAIN 3216 02:15:02,746 --> 02:15:04,014 ITSELF AND SUBSTANCE USE 3217 02:15:04,014 --> 02:15:06,917 DISORDER CAN IMPACT PAIN. 3218 02:15:06,917 --> 02:15:07,984 THERE'S AN INTERACTION BETWEEN 3219 02:15:07,984 --> 02:15:08,718 THE TWO. 3220 02:15:08,718 --> 02:15:12,756 THE PRIORITY IS ABOUT 3221 02:15:12,756 --> 02:15:16,493 IDENTIFYING POPULATIONS THAT ARE 3222 02:15:16,493 --> 02:15:17,594 DISPROPORTIONATELY IMPACTED BY 3223 02:15:17,594 --> 02:15:19,629 PAIN AND SUBSTANCE USE. 3224 02:15:19,629 --> 02:15:21,064 UNDERSTANDING THE MECHANISM 3225 02:15:21,064 --> 02:15:23,366 DIFFERENTLY IMPACT THE 3226 02:15:23,366 --> 02:15:24,334 POPULATIONS AND DEVELOP AND 3227 02:15:24,334 --> 02:15:26,736 INTERVENTIONS TO ADDRESS THIS 3228 02:15:26,736 --> 02:15:32,309 IMPACT. 3229 02:15:32,309 --> 02:15:35,345 THIS WOULD ENTAIL PRIORITIZING 3230 02:15:35,345 --> 02:15:38,181 THE HIGHLY IMPACTED POPULATION 3231 02:15:38,181 --> 02:15:40,350 AND THE RESEARCH INTERSECTION 3232 02:15:40,350 --> 02:15:42,986 BETWEEN SUBSTANCE USE AND 3233 02:15:42,986 --> 02:15:45,088 INTERVENTION FOR HIGH POTENTIAL 3234 02:15:45,088 --> 02:15:48,758 FOR IMPACT AND DEPRESCRIBING 3235 02:15:48,758 --> 02:15:51,828 OPIOIDS AND REPLACING IT -- YOU 3236 02:15:51,828 --> 02:15:54,231 CAN'T JUST DE PRESCRIBE IT 3237 02:15:54,231 --> 02:15:54,931 WITHOUT REPLACING IT WITH 3238 02:15:54,931 --> 02:15:56,366 SOMETHING LIKE MULTI-MODAL CARE 3239 02:15:56,366 --> 02:15:58,735 AND PRE CLINICAL STUDIES 3240 02:15:58,735 --> 02:15:59,669 DEVELOPING NOVEL INTERVENTIONS 3241 02:15:59,669 --> 02:16:03,073 AND ADDRESS THE MECHANISMS OF 3242 02:16:03,073 --> 02:16:09,079 THAT RELATIONSHIP. 3243 02:16:09,079 --> 02:16:11,915 INVESTIGATE EVIDENCE-BASED, 3244 02:16:11,915 --> 02:16:12,582 INFORMED APPROACHES AND APPLYING 3245 02:16:12,582 --> 02:16:16,386 THEM EQUALLY TO ALL INDIVIDUALS 3246 02:16:16,386 --> 02:16:17,020 THAT ADDRESS THE OPIOID 3247 02:16:17,020 --> 02:16:19,823 COMPLEXITY AND ENGAGING HEALTH 3248 02:16:19,823 --> 02:16:21,391 EQUITY EXPERTISE AND COMMUNITY 3249 02:16:21,391 --> 02:16:21,691 ENGAGEMENT. 3250 02:16:21,691 --> 02:16:23,026 COMMUNITY ENGAGEMENT IS 3251 02:16:23,026 --> 02:16:26,730 PARTICULARLY BENEFICIAL FOR THIS 3252 02:16:26,730 --> 02:16:33,069 POPULATION. 3253 02:16:33,069 --> 02:16:34,738 AND I THINK THIS IS THE LAST 3254 02:16:34,738 --> 02:16:37,641 PRIORITY AND THIS IS REEL THIS 3255 02:16:37,641 --> 02:16:39,109 CALLS OUT SUPPORTING NON-DRUG 3256 02:16:39,109 --> 02:16:40,577 APPROACH TO THE TREATMENT AND 3257 02:16:40,577 --> 02:16:41,745 PREVENTION OF CHRONIC PAIN. 3258 02:16:41,745 --> 02:16:45,081 WE TALK ABOUT NON-DRUG 3259 02:16:45,081 --> 02:16:46,449 APPROACHES BEING VALUABLE AND 3260 02:16:46,449 --> 02:16:49,719 NECESSARY AND KEY TO THIS BUT 3261 02:16:49,719 --> 02:16:51,688 THEY'RE EMBEDDED IN OTHER THINGS 3262 02:16:51,688 --> 02:16:55,492 AND SOMETIMES GET LOST IN THE 3263 02:16:55,492 --> 02:16:55,692 MIX. 3264 02:16:55,692 --> 02:16:58,228 THE SUPPORT FOR THIS ONE IS TO 3265 02:16:58,228 --> 02:17:01,364 REALLY LOOK AT NON-DRUG 3266 02:17:01,364 --> 02:17:02,732 APPROACHMENT TO TREATMENT 3267 02:17:02,732 --> 02:17:04,734 INTERVENTION WHICH WOULD INCLUDE 3268 02:17:04,734 --> 02:17:05,502 THOSE WITH CO-OCCURRING 3269 02:17:05,502 --> 02:17:06,036 SUBSTANCE USE DISORDER. 3270 02:17:06,036 --> 02:17:09,072 WE WOULD HAVE TO IDENTIFY 3271 02:17:09,072 --> 02:17:10,440 EXISTING EVIDENCE-BASED 3272 02:17:10,440 --> 02:17:13,343 APPROACHES AND TAILOR THESE 3273 02:17:13,343 --> 02:17:14,110 USING HYBRID IMPLEMENTATION 3274 02:17:14,110 --> 02:17:15,412 TRIALS AND WOULD HAVE TO 3275 02:17:15,412 --> 02:17:16,846 EVALUATE THE UNDERLYING 3276 02:17:16,846 --> 02:17:18,481 MECHANISMS OF THESE IN PRE 3277 02:17:18,481 --> 02:17:24,354 CLINICAL AND CLINICAL STUDIES. 3278 02:17:24,354 --> 02:17:25,889 WE HAVE LOOKED AT RESPONDER 3279 02:17:25,889 --> 02:17:27,357 ANALYSIS AND WHO RESPONDS AND 3280 02:17:27,357 --> 02:17:29,459 DOESN'T RESPOND WITH PREDICTORS 3281 02:17:29,459 --> 02:17:32,329 IN BIOMARKERS WHICH COULD 3282 02:17:32,329 --> 02:17:33,096 IMPROVE THEIR USE AND 3283 02:17:33,096 --> 02:17:35,365 IMPLEMENTATION IN A MORE 3284 02:17:35,365 --> 02:17:35,899 INDIVIDUALIZED APPROACH. 3285 02:17:35,899 --> 02:17:39,803 AND THEN AGAIN WE'RE LOOKING AT 3286 02:17:39,803 --> 02:17:43,773 OPTIMAL TIMING OF INITIATING THE 3287 02:17:43,773 --> 02:17:45,075 INTERVENTION AND ROLE OF SHARED 3288 02:17:45,075 --> 02:17:47,010 DECISION MAKING IN 3289 02:17:47,010 --> 02:17:47,477 PERSON-CENTERED CARE. 3290 02:17:47,477 --> 02:17:49,512 AS YOU CAN SEE ALL THE 3291 02:17:49,512 --> 02:17:51,414 PRIORITIES HAVE A BIT OF AN 3292 02:17:51,414 --> 02:17:54,751 OVERLAP AND SOME INDIVIDUALIZED 3293 02:17:54,751 --> 02:17:57,754 APPROACHES BETWEEN THEM. 3294 02:17:57,754 --> 02:18:00,924 NEXT, SO THIS SUMMARIZES OUR 10 3295 02:18:00,924 --> 02:18:01,224 PRIORITIES. 3296 02:18:01,224 --> 02:18:04,461 I KIND OF THOUGHT ABOUT THIS. 3297 02:18:04,461 --> 02:18:06,763 WE HAVE PRIORITY BASED ON 3298 02:18:06,763 --> 02:18:09,065 TRAINING THAT'S NEEDED IN THE 3299 02:18:09,065 --> 02:18:11,434 PAIN FIELD TO MOVE THIS FIELD 3300 02:18:11,434 --> 02:18:13,236 FORWARD AND HAVE PRIORITIES ON 3301 02:18:13,236 --> 02:18:14,504 DRUG DEVELOPMENT AND HAVE 3302 02:18:14,504 --> 02:18:18,208 PRIORITIES ON BIOMARKERS AND 3303 02:18:18,208 --> 02:18:19,676 PREDICTORS OF CHRONIC PAIN AND 3304 02:18:19,676 --> 02:18:20,410 TREATMENT RESPONSE. 3305 02:18:20,410 --> 02:18:22,746 AND THEN WE HAVE THINGS TO 3306 02:18:22,746 --> 02:18:24,547 IMPROVE THE TREATMENT OF THOSE 3307 02:18:24,547 --> 02:18:26,716 WITH EXISTING PAIN OR PREVENT 3308 02:18:26,716 --> 02:18:29,819 THE DEVELOPMENT OF CHRONIC PAIN 3309 02:18:29,819 --> 02:18:30,553 ALTOGETHER. 3310 02:18:30,553 --> 02:18:33,156 AND THEY ALL INVOLVE A 3311 02:18:33,156 --> 02:18:35,525 MULTI-MODAL APPROACH AND INVOLVE 3312 02:18:35,525 --> 02:18:37,494 KIND OF AN INDIVIDUALIZED KIND 3313 02:18:37,494 --> 02:18:39,729 OF PATIENT CENTERED APPROACH 3314 02:18:39,729 --> 02:18:41,231 WITH THE ULTIMATE GOAL OF THAT'S 3315 02:18:41,231 --> 02:18:42,732 WHERE I THINK WE'LL END UP IF WE 3316 02:18:42,732 --> 02:18:45,468 CAN GET THE DATA TO SUPPORT 3317 02:18:45,468 --> 02:18:53,009 THAT. 3318 02:18:53,009 --> 02:18:55,912 THERE WAS A BIG GROUP THAT 3319 02:18:55,912 --> 02:18:57,147 WORKED HARD. 3320 02:18:57,147 --> 02:18:58,148 EVERYBODY CONTRIBUTED AN AMAZING 3321 02:18:58,148 --> 02:19:01,618 AMOUNT OF WORK TO MAKE THIS 3322 02:19:01,618 --> 02:19:01,985 HAPPEN. 3323 02:19:01,985 --> 02:19:12,529 THERE WAS A HUGE NIH STAFF ACT 3324 02:19:14,531 --> 02:19:15,965 WANT TO THANK THOSE WHO HELPED 3325 02:19:15,965 --> 02:19:17,934 TO GET THE DOCUMENT TOGETHER 3326 02:19:17,934 --> 02:19:21,171 PARTICULARLY JACKIE WARD WHO WAS 3327 02:19:21,171 --> 02:19:26,743 OUR GO-TO AT NINDS PRIOR TO HER 3328 02:19:26,743 --> 02:19:26,976 LEAVING. 3329 02:19:26,976 --> 02:19:28,445 WITH THAT I THINK THAT IS MY 3330 02:19:28,445 --> 02:19:28,945 LAST SLIDE. 3331 02:19:28,945 --> 02:19:29,946 WE THANK YOU. 3332 02:19:29,946 --> 02:19:32,782 THIS IS OUR EXECUTIVE COMMITTEE 3333 02:19:32,782 --> 02:19:34,150 MEETING WHERE WE MET IN THE 3334 02:19:34,150 --> 02:19:35,185 MIDDLE OF THE WINTER. 3335 02:19:35,185 --> 02:19:38,655 THERE WAS SNOW ALL OVER THE 3336 02:19:38,655 --> 02:19:41,291 GROUND SO WE'RE ALL WEARING OUR 3337 02:19:41,291 --> 02:19:42,425 CASUAL CLOTHES AND BIG BOOTS TO 3338 02:19:42,425 --> 02:19:44,094 GET HERE BUT IT WAS A WONDERFUL 3339 02:19:44,094 --> 02:19:44,961 MEETING AND WE WANT TO THANK 3340 02:19:44,961 --> 02:19:48,865 EVERYBODY FOR DOING IT. 3341 02:19:48,865 --> 02:19:52,869 WE'RE HAPPY TO ANSWER QUESTIONS, 3342 02:19:52,869 --> 02:20:03,113 TAKE THOUGHTS. 3343 02:20:06,316 --> 02:20:06,883 I SEE CLAPPING. 3344 02:20:06,883 --> 02:20:10,720 >> I HAVE A QUESTION. 3345 02:20:10,720 --> 02:20:12,088 IT'S REGARDING PRIORITY NUMBER 9 3346 02:20:12,088 --> 02:20:13,823 WHERE YOU TALK ABOUT POPULATIONS 3347 02:20:13,823 --> 02:20:14,958 THAT ARE DISPROPORTIONATELY 3348 02:20:14,958 --> 02:20:16,526 AFFECTED BY PAIN. 3349 02:20:16,526 --> 02:20:17,827 I'M WONDERING BASED ON THE DATA 3350 02:20:17,827 --> 02:20:21,197 THAT I'M AWARE OF THAT THERE'S A 3351 02:20:21,197 --> 02:20:23,967 BIT OF BIAS REGARDING PAIN 3352 02:20:23,967 --> 02:20:26,503 MANAGEMENT AMONG ETHNIC 3353 02:20:26,503 --> 02:20:29,239 COMMUNITIES PARTICULARLY AFRICAN 3354 02:20:29,239 --> 02:20:30,740 AMERICANS WHO MAY NOT RECEIVE 3355 02:20:30,740 --> 02:20:34,511 PAIN AS REQUESTED IN HOSPITALS 3356 02:20:34,511 --> 02:20:38,715 UPON THE THOUGHT IT MAY BE MORE 3357 02:20:38,715 --> 02:20:42,952 OF SUBSTANCE ABUSE RATHER THAN 3358 02:20:42,952 --> 02:20:43,887 AFRICAN AMERICANS HAVING A 3359 02:20:43,887 --> 02:20:45,722 HIGHER TOLERANCE OF PAIN THAN 3360 02:20:45,722 --> 02:20:46,389 OTHER GROUPS. 3361 02:20:46,389 --> 02:20:48,024 ARE YOU LOOKING AT ALL 3362 02:20:48,024 --> 02:20:51,995 POPULATIONS AND THEN MAKING A 3363 02:20:51,995 --> 02:20:54,330 MEASURE OF WHERE WHERE THERE MAY 3364 02:20:54,330 --> 02:20:56,065 BE AN ISSUE AROUND SUBSTANCE 3365 02:20:56,065 --> 02:20:57,734 ABUSE AND PAIN MANAGEMENT AND 3366 02:20:57,734 --> 02:20:58,368 TOLERANCE FOR PAIN? 3367 02:20:58,368 --> 02:21:02,572 >> YES, THAT'S VERY BROAD. 3368 02:21:02,572 --> 02:21:06,476 INDEED WE TALKED A LOT ABOUT S 3369 02:21:06,476 --> 02:21:07,110 AND THE DISPARITIES IN HEALTH 3370 02:21:07,110 --> 02:21:09,045 CARE AMONG DIFFERENT RACES, 3371 02:21:09,045 --> 02:21:11,648 ETHNICITIES, WOMEN, MEN AND IT'S 3372 02:21:11,648 --> 02:21:14,717 MEANT FOR REALLY TO LOOK AT ALL 3373 02:21:14,717 --> 02:21:19,455 OF THAT WHETHER OR NOT THERE ARE 3374 02:21:19,455 --> 02:21:21,191 DIFFERENCES IN HOW AFRICAN 3375 02:21:21,191 --> 02:21:23,426 AMERICANS PER SE ARE TREATED, 3376 02:21:23,426 --> 02:21:26,162 HOW THEY'RE APPROACHED. 3377 02:21:26,162 --> 02:21:29,599 DO WE NEED A DIFFERENT STRATEGY. 3378 02:21:29,599 --> 02:21:33,603 DO WE NEED TO CHANGE AND LOOK AT 3379 02:21:33,603 --> 02:21:36,206 IMPLEMENTATION DIFFERENTLY TO 3380 02:21:36,206 --> 02:21:39,609 GET THAT BACK INTO PRACTICE? 3381 02:21:39,609 --> 02:21:50,119 SO FOR SUBSTANCE USE AND PAIN 3382 02:21:51,221 --> 02:21:53,590 TREATMENT BECAUSE WE RECOGNIZE 3383 02:21:53,590 --> 02:21:55,692 THE DISPARITIES ACROSS MULTIPLE 3384 02:21:55,692 --> 02:21:57,560 DIFFERENT POPULATIONS INCLUDING 3385 02:21:57,560 --> 02:22:01,030 AFRICAN AMERICANS, HISPANICS, 3386 02:22:01,030 --> 02:22:04,701 OLDER FOLKS WHO ALSO GET A 3387 02:22:04,701 --> 02:22:06,936 LITTLE BIT LOST IN THE MIX 3388 02:22:06,936 --> 02:22:16,112 SOMETIMES TOO. 3389 02:22:16,112 --> 02:22:18,715 >> ANY OTHER QUESTIONS FROM THE 3390 02:22:18,715 --> 02:22:28,825 GROUP? 3391 02:22:30,793 --> 02:22:32,662 THERE WAS A MOVE TO DIVERSIFY 3392 02:22:32,662 --> 02:22:35,164 AWAY FROM SMALL MOLECULES AND 3393 02:22:35,164 --> 02:22:36,566 WONDERING IF AV MEDIA AND GENE 3394 02:22:36,566 --> 02:22:39,202 THERAPY WOULD BE ONE OF THEM? 3395 02:22:39,202 --> 02:22:43,172 >> YEAH, THAT'S CERTAINLY IN 3396 02:22:43,172 --> 02:22:49,078 PLAY. 3397 02:22:49,078 --> 02:22:53,316 THERE'S CAPABILITY AND 3398 02:22:53,316 --> 02:22:53,683 PRIORITIZATION. 3399 02:22:53,683 --> 02:22:56,119 I THINK THERAPIES ARE HAVING A 3400 02:22:56,119 --> 02:22:58,121 MOMENT BUT THERE'S DIFFERENT 3401 02:22:58,121 --> 02:22:59,923 MODALITIES AND ENCOURAGING 3402 02:22:59,923 --> 02:23:02,292 INNOVATION IN THAT SPACE BECAUSE 3403 02:23:02,292 --> 02:23:04,060 I THINK DIFFERENT APPROACHES ARE 3404 02:23:04,060 --> 02:23:05,828 NEEDED FOR SOME OF ESPECIALLY 3405 02:23:05,828 --> 02:23:07,330 SOME OF THE PAIN TARGETS AND 3406 02:23:07,330 --> 02:23:08,731 GENE THERAPIES. 3407 02:23:08,731 --> 02:23:09,399 SOMETHING IN PLAY THERE. 3408 02:23:09,399 --> 02:23:19,509 YEAH. 3409 02:23:35,892 --> 02:23:38,494 >> I'D LIKE TO THANK ROBERT AND 3410 02:23:38,494 --> 02:23:39,295 KATHLEEN FOR THE TREMENDOUS 3411 02:23:39,295 --> 02:23:40,663 AMOUNT OF WORK THEY UNDERTOOK TO 3412 02:23:40,663 --> 02:23:41,664 DO THIS. 3413 02:23:41,664 --> 02:23:42,732 CAN YOU IMAGINE? 3414 02:23:42,732 --> 02:23:46,569 THIS WAS A HUGE EFFORT AND WE'RE 3415 02:23:46,569 --> 02:23:48,604 SO GRATEFUL BECAUSE OF THE 3416 02:23:48,604 --> 02:23:50,807 OPPORTUNITIES THIS WILL PROVIDE 3417 02:23:50,807 --> 02:23:53,977 FOR ALL OF NIH AND WE AT NIAMS 3418 02:23:53,977 --> 02:23:55,712 FEEL PAIN IS SO CENTRAL AND SO 3419 02:23:55,712 --> 02:23:56,779 IMPORTANT TO MANY OF OUR 3420 02:23:56,779 --> 02:23:59,148 DISEASES AND CONDITIONS SO WE 3421 02:23:59,148 --> 02:24:00,817 WANTED TO TAKE THIS OPPORTUNITY 3422 02:24:00,817 --> 02:24:04,454 TO MAKE YOU ALL AWARE AND HOPE 3423 02:24:04,454 --> 02:24:06,756 WE CAN TAKE ADVANTAGE OF THE 3424 02:24:06,756 --> 02:24:09,292 INVESTMENT AND TIME AND EFFORT 3425 02:24:09,292 --> 02:24:13,529 TO CHART A PATH FORWARD ALSO FOR 3426 02:24:13,529 --> 02:24:14,964 THOSE NEW TO COUNCIL OR AREN'T 3427 02:24:14,964 --> 02:24:17,600 FAMILIAR WITH THE HEAL PROGRAM 3428 02:24:17,600 --> 02:24:18,701 WERE GOING TO CALL OUT PREVIOUS 3429 02:24:18,701 --> 02:24:21,471 AND ONGOING INVESTMENTS WE'VE 3430 02:24:21,471 --> 02:24:24,741 BEEN ABLE TO LEAD AND CREATE BY 3431 02:24:24,741 --> 02:24:26,342 VIRTUE OF HEAL RESOURCES. 3432 02:24:26,342 --> 02:24:27,510 THERE'S THE BACPAC RESEARCH 3433 02:24:27,510 --> 02:24:32,215 PROGRAM FOR LOW BACK PAIN AND 3434 02:24:32,215 --> 02:24:34,117 SUCCESSFUL EFFORT HUGE TEAM 3435 02:24:34,117 --> 02:24:34,684 FUNDED. 3436 02:24:34,684 --> 02:24:36,085 THERE'S ANOTHER EFFORT CALLED 3437 02:24:36,085 --> 02:24:38,054 REJOIN THAT NIAMS IS DEEPLY 3438 02:24:38,054 --> 02:24:40,857 INVOLVED IN TRYING TO UNDERSTAND 3439 02:24:40,857 --> 02:24:45,028 MORE ABOUT THE INNERVATION 3440 02:24:45,028 --> 02:24:46,095 WITHIN TISSUES AND SPECIFIC 3441 02:24:46,095 --> 02:24:46,729 JOINTS. 3442 02:24:46,729 --> 02:24:48,064 MOVING FORWARD THERE'S AN EFFORT 3443 02:24:48,064 --> 02:24:50,600 ON CHRONIC PAIN IN CHILDREN THAT 3444 02:24:50,600 --> 02:24:51,334 WE'RE EXCITED ABOUT AND WE'RE 3445 02:24:51,334 --> 02:24:53,436 ALSO INCREASINGLY TRYING TO 3446 02:24:53,436 --> 02:24:55,104 THINK IN A MORE INTEGRATED 3447 02:24:55,104 --> 02:24:58,274 FASHION AS WE MOVE FORWARD WITH 3448 02:24:58,274 --> 02:24:59,475 SOME OF THESE VARIOUS HEALS 3449 02:24:59,475 --> 02:25:02,745 EFFORT AND MORE OF AN 3450 02:25:02,745 --> 02:25:04,247 INTEGRATIVE MUSCULOSKELETAL PAIN 3451 02:25:04,247 --> 02:25:05,982 EFFORT WE'RE HELPING MOVE 3452 02:25:05,982 --> 02:25:06,215 FORWARD. 3453 02:25:06,215 --> 02:25:10,720 WE'VE ALREADY BENEFITTED SO MUCH 3454 02:25:10,720 --> 02:25:11,754 FROM THESE RESOURCES AND LOOK 3455 02:25:11,754 --> 02:25:12,422 FORWARD TO TAKING ADVANTAGE OF 3456 02:25:12,422 --> 02:25:14,157 THE TIME AND EFFORT THESE 3457 02:25:14,157 --> 02:25:15,291 WORKING GROUPS HAVE DEVOTED TO 3458 02:25:15,291 --> 02:25:16,192 CHART A PATH FORWARD FOR US. 3459 02:25:16,192 --> 02:25:21,030 SO THANK YOU SO MUCH. 3460 02:25:21,030 --> 02:25:28,071 >> THANK YOU FOR HAVING US. 3461 02:25:28,071 --> 02:25:29,939 >> WITH THAT I'LL TURN IT BACK 3462 02:25:29,939 --> 02:25:30,640 TO LINDSEY. 3463 02:25:30,640 --> 02:25:32,675 I THINK WE HAVE TIME FOR MORE 3464 02:25:32,675 --> 02:25:33,576 QUESTIONS BEFORE THE END OF THE 3465 02:25:33,576 --> 02:25:34,343 OPEN SESSION. 3466 02:25:34,343 --> 02:25:40,883 >> YES, OUR CURRENT PLANS 3467 02:25:40,883 --> 02:25:48,224 INVOLVE BREAKING FOR LUNCH AT 3468 02:25:48,224 --> 02:25:49,859 12:45 AND LEAVES ALMOST HALF AN 3469 02:25:49,859 --> 02:25:51,294 HOUR, IF WE'D LIKE TO HAVE IT TO 3470 02:25:51,294 --> 02:25:54,931 RAISE QUESTIONS ABOUT TOPICS 3471 02:25:54,931 --> 02:25:56,499 MENTIONED, DISCUSSED TODAY, NEW 3472 02:25:56,499 --> 02:25:57,800 TOPICS, THINGS YOU WANT US TO BE 3473 02:25:57,800 --> 02:25:59,435 THINKING ABOUT, CONCERNS YOU 3474 02:25:59,435 --> 02:26:03,306 HAVE WE HAVEN'T TOUCHED UPON, 3475 02:26:03,306 --> 02:26:06,742 IDEAS FOR TOPICS FOR FUTURE 3476 02:26:06,742 --> 02:26:17,086 MEETINGS, ETCETERA. 3477 02:26:24,627 --> 02:26:27,630 SO WOULD ANYBODY LIKE TO SPEAK 3478 02:26:27,630 --> 02:26:37,707 UP? 3479 02:26:39,509 --> 02:26:40,376 >> THANK YOU FOR THE OPPORTUNITY 3480 02:26:40,376 --> 02:26:41,811 TO BE HERE. 3481 02:26:41,811 --> 02:26:45,314 IT'S AGAIN AMAZING TO GET A LOOK 3482 02:26:45,314 --> 02:26:46,716 BEHIND THE CURTAIN AND HEAR 3483 02:26:46,716 --> 02:26:47,683 ABOUT THE WORK AND RESEARCH 3484 02:26:47,683 --> 02:26:50,086 BEING DONE AT NIAMS. 3485 02:26:50,086 --> 02:26:52,955 MY QUESTION IS ABOUT DATA 3486 02:26:52,955 --> 02:26:53,189 SCIENCE. 3487 02:26:53,189 --> 02:26:59,762 SO I ASK THIS A BIT SELFISHLY AS 3488 02:26:59,762 --> 02:27:02,532 SOMEONE WHO DOES ADMINISTRATIVE 3489 02:27:02,532 --> 02:27:05,201 RESEARCH AND I THINK IT'S CALLED 3490 02:27:05,201 --> 02:27:07,303 OUT IN PRIORITY 3 TO ENHANCE THE 3491 02:27:07,303 --> 02:27:08,070 EXPERTISE IN DATA SCIENCE AND 3492 02:27:08,070 --> 02:27:11,174 HOW WE USE IT SO I WAS CURIOUS 3493 02:27:11,174 --> 02:27:12,408 TO HEAR MORE ABOUT THE 3494 02:27:12,408 --> 02:27:14,744 INITIATIVES THAT ARE MAYBE IN 3495 02:27:14,744 --> 02:27:17,513 PLACE HERE AT NIAMS TO ENHANCE 3496 02:27:17,513 --> 02:27:21,083 IT AND ADVANCE THE SCIENCE 3497 02:27:21,083 --> 02:27:23,719 ESPECIALLY IN MUSCULOSKELETAL 3498 02:27:23,719 --> 02:27:24,287 CONDITIONS. 3499 02:27:24,287 --> 02:27:25,721 >> I'M MAKE A COUPLE COMMENTS 3500 02:27:25,721 --> 02:27:27,290 AND THEN MAYBE ANNA OR OTHERS 3501 02:27:27,290 --> 02:27:29,125 WANT TO CHIME IN. 3502 02:27:29,125 --> 02:27:30,726 I MENTIONED FAIRLY BRIEFLY 3503 02:27:30,726 --> 02:27:34,730 DURING MY REPORT THE SYS BIO 3504 02:27:34,730 --> 02:27:37,433 EFFORT FOCUSSING ON DATA 3505 02:27:37,433 --> 02:27:39,368 INTEROPERABILITY WHICH IS A 3506 02:27:39,368 --> 02:27:41,470 CRUCIAL ISSUE AND ROAD BLOCK NOW 3507 02:27:41,470 --> 02:27:44,073 AND THAT IS RESONATING WELL 3508 02:27:44,073 --> 02:27:47,410 ACROSS THE NIH AND WITH 3509 02:27:47,410 --> 02:27:49,045 LEADERSHIP AND OFFICE OF 3510 02:27:49,045 --> 02:27:50,713 DIRECTOR OF STRATEGY AND NEW 3511 02:27:50,713 --> 02:27:53,549 PRINCIPLE DIRECTOR HAD AN 3512 02:27:53,549 --> 02:27:55,351 OPPORTUNITY TO HEAR A 3513 02:27:55,351 --> 02:27:57,787 PRESENTATION ABOUT SYS BIO AND 3514 02:27:57,787 --> 02:28:00,256 EXPRESSED INTEREST IN THE 3515 02:28:00,256 --> 02:28:00,489 PROGRAM. 3516 02:28:00,489 --> 02:28:02,792 THOSE FOLLOWING WHAT'S BEEN 3517 02:28:02,792 --> 02:28:03,426 SHARED, WHAT LITTLE HAS BEEN 3518 02:28:03,426 --> 02:28:05,661 SHARED SO FAR, WE'RE ONLY A FEW 3519 02:28:05,661 --> 02:28:08,264 MONTHS INTO THE TENURE OF THE 3520 02:28:08,264 --> 02:28:10,600 CURRENT NIH DIRECTOR, HE IS VERY 3521 02:28:10,600 --> 02:28:12,501 INTERESTED IN REAL WORLD DATA 3522 02:28:12,501 --> 02:28:15,338 AND TALKING ABOUT A REAL WORLD 3523 02:28:15,338 --> 02:28:20,042 DATA PLATFORM THAT WOULD SUPPORT 3524 02:28:20,042 --> 02:28:21,410 UTILIZATION OF DATA AND 3525 02:28:21,410 --> 02:28:23,879 TECHNICAL CHALLENGES. 3526 02:28:23,879 --> 02:28:31,087 WE HEARD MENTION OF FOCUS ON 3527 02:28:31,087 --> 02:28:32,688 AUTISM AND A FOCUS OF THE REAL 3528 02:28:32,688 --> 02:28:33,522 WORLD DATA INITIATIVE AND 3529 02:28:33,522 --> 02:28:34,156 THERE'S A LOT OF DISCUSSION 3530 02:28:34,156 --> 02:28:36,792 ABOUT THE NEED, THE 3531 02:28:36,792 --> 02:28:37,660 OPPORTUNITIES AND WE'RE 3532 02:28:37,660 --> 02:28:39,895 FOLLOWING THAT VERY CLOSELY BUT 3533 02:28:39,895 --> 02:28:41,264 LET ME LET ANN AND OTHERS WHO 3534 02:28:41,264 --> 02:28:43,566 WANT TO CHIME IN ABOUT OTHER 3535 02:28:43,566 --> 02:28:45,201 THINGS AND BY THE WAY WE HAD A 3536 02:28:45,201 --> 02:28:48,738 WORKING GROUP OF COUNCIL FOLKS 3537 02:28:48,738 --> 02:28:50,273 IN DATA SCIENCE PRIOR TO 3538 02:28:50,273 --> 02:28:52,842 COMPLETION OF OUR STRATEGIC 3539 02:28:52,842 --> 02:28:53,643 PLANNING PROCESS THAT WAS USEFUL 3540 02:28:53,643 --> 02:28:54,310 AS WELL. 3541 02:28:54,310 --> 02:28:55,544 >> THANK YOU SO MUCH FOR THAT 3542 02:28:55,544 --> 02:28:58,014 QUESTION AND I CAN ELABORATE A 3543 02:28:58,014 --> 02:29:00,650 LITTLE FURTHER ON DR. CRISWELL'S 3544 02:29:00,650 --> 02:29:01,484 COMMENTS. 3545 02:29:01,484 --> 02:29:04,220 DR. CRISWELL ACTUALLY PRESENTED 3546 02:29:04,220 --> 02:29:06,756 JUST ABOUT A MONTH AGO TO 3547 02:29:06,756 --> 02:29:09,425 DR. BHATTACHARYA, OUR NEW NIH 3548 02:29:09,425 --> 02:29:14,730 DIRECTOR AND THE OTHER NIH 3549 02:29:14,730 --> 02:29:18,734 INSTITUTE DIRECTORS AND 3550 02:29:18,734 --> 02:29:28,277 HIGHLIGHTED THE SYS B BIO PROGRM 3551 02:29:28,277 --> 02:29:29,612 IN ADDRESSING USERABILITY ACROSS 3552 02:29:29,612 --> 02:29:31,580 NIH AND THAT'S ONE FACET OF DATA 3553 02:29:31,580 --> 02:29:33,716 SCIENCE ACTIVITIES AT NIH BUT I 3554 02:29:33,716 --> 02:29:35,718 THINK WE'RE REALLY EXCITED TO 3555 02:29:35,718 --> 02:29:38,287 CONTINUE TO PARTICIPATE IN THAT 3556 02:29:38,287 --> 02:29:41,390 AND AS DR. CRISWELL SAID IT 3557 02:29:41,390 --> 02:29:45,428 CERTAINLY IS A PRIORITY FOR OUR 3558 02:29:45,428 --> 02:29:46,162 NEW LEADERSHIP AND SOMETHING 3559 02:29:46,162 --> 02:29:49,031 WHERE WE'RE REALLY ENGAGED 3560 02:29:49,031 --> 02:29:51,434 WORKING WITH OUR COLLEAGUES NOT 3561 02:29:51,434 --> 02:29:53,736 ONLY AT OTHER NIH INSTITUTED BUT 3562 02:29:53,736 --> 02:29:55,638 IN THE OFFICE OF THE DIRECTOR 3563 02:29:55,638 --> 02:29:57,840 THERE'S AN NIH OFFICE OF DATA 3564 02:29:57,840 --> 02:30:00,343 SCIENCE STRATEGY SO ACTUALLY 3565 02:30:00,343 --> 02:30:04,580 DR. CRISWELL CO-CHAIRS THE SYS 3566 02:30:04,580 --> 02:30:06,749 BIO EFFORT AND THEY'RE WORKING 3567 02:30:06,749 --> 02:30:09,585 ON A RANGE OF DATA SCIENCE 3568 02:30:09,585 --> 02:30:19,729 ISSUES. 3569 02:30:20,196 --> 02:30:21,430 AND THERE'S HEAL INITIATIVES AND 3570 02:30:21,430 --> 02:30:22,732 NIAMS PROGRAMS WE'VE BEEN ABLE 3571 02:30:22,732 --> 02:30:24,533 TO PARTICIPATE IN OVER THE YEARS 3572 02:30:24,533 --> 02:30:26,202 AND WANTING TO HAVE MORE 3573 02:30:26,202 --> 02:30:28,437 INTEGRATIVE RESOURCES FOR 3574 02:30:28,437 --> 02:30:29,872 MUSCULOSKELETAL PAIN IS ANOTHER 3575 02:30:29,872 --> 02:30:31,807 EXAMPLE WHERE WE TRIED TO REALLY 3576 02:30:31,807 --> 02:30:33,442 TAKE ADVANTAGE OF THE RESOURCES 3577 02:30:33,442 --> 02:30:36,545 THROUGH THE HEAL DATA ECHO 3578 02:30:36,545 --> 02:30:38,614 SYSTEM AND MAKE SURE -- ECO 3579 02:30:38,614 --> 02:30:40,282 SYSTEM AND MAKE SURE OUR 3580 02:30:40,282 --> 02:30:42,451 PROGRAMS AND REJOIN AND BACPAC 3581 02:30:42,451 --> 02:30:43,786 ARE FULLY LEVERAGING AND 3582 02:30:43,786 --> 02:30:46,055 INTEGRATED INTO THAT EFFORT AND 3583 02:30:46,055 --> 02:30:49,992 THAT WE CAN FOCUS ON WAYS TO 3584 02:30:49,992 --> 02:30:53,295 CONTINUE TO TAKE ADVANTAGE OF 3585 02:30:53,295 --> 02:30:54,764 THOSE RESOURCES AND MAKE THEM 3586 02:30:54,764 --> 02:30:57,133 MORE ACCESSIBLE TO THE NIAMS 3587 02:30:57,133 --> 02:30:57,433 COMMUNITIES. 3588 02:30:57,433 --> 02:30:59,602 THAT'S JUST A FEW EXAMPLES BUT 3589 02:30:59,602 --> 02:31:00,169 CERTAINLY SOMETHING WE'RE 3590 02:31:00,169 --> 02:31:00,770 WANTING TO CONTINUE FOCUSSING 3591 02:31:00,770 --> 02:31:10,846 ON. 3592 02:31:16,952 --> 02:31:18,788 >> A KNOWLEDGE PORTAL IN TERMS 3593 02:31:18,788 --> 02:31:21,490 OF INTEROPERABILITY AND MAKE 3594 02:31:21,490 --> 02:31:23,559 MORE ACCESSIBLE THE RICH DATA 3595 02:31:23,559 --> 02:31:25,728 FROM THE VARIOUS AMP PROGRAMS 3596 02:31:25,728 --> 02:31:29,532 AND THE PORTAL STANDS FOR 3597 02:31:29,532 --> 02:31:31,734 ARTHRITIS AND AUTOIMMUNE RELATED 3598 02:31:31,734 --> 02:31:33,769 KNOWLEDGE PORTAL ARK, AND WE'RE 3599 02:31:33,769 --> 02:31:35,638 CONTINUING TO PUSH REALLY HARD 3600 02:31:35,638 --> 02:31:36,972 TO SUPPORT ITS FURTHER 3601 02:31:36,972 --> 02:31:37,740 DEVELOPMENT FOR THE RESEARCH 3602 02:31:37,740 --> 02:31:38,007 COMMUNITY. 3603 02:31:38,007 --> 02:31:42,244 THANKS FOR ASKING ABOUT THAT. 3604 02:31:42,244 --> 02:31:46,248 >> SO I WAS INTRIGUED BY THE 3605 02:31:46,248 --> 02:31:47,550 HEAL INITIATIVE'S RECOMMENDATION 3606 02:31:47,550 --> 02:31:48,717 TO EXPAND TRAINING PROGRAM WHICH 3607 02:31:48,717 --> 02:31:50,786 IS GREATLY NEEDED AND TO 3608 02:31:50,786 --> 02:31:53,622 INCORPORATE NON-U.S. CITIZENS IN 3609 02:31:53,622 --> 02:31:55,024 THE TRAINING PROGRAM WHICH I 3610 02:31:55,024 --> 02:31:56,525 THINK IS CRITICAL GIVEN WE'RE 3611 02:31:56,525 --> 02:31:58,127 FACING A SHORTAGE OF RESEARCHERS 3612 02:31:58,127 --> 02:32:02,765 IN THE COUNTRY AND CURIOUS OF 3613 02:32:02,765 --> 02:32:04,700 THOSE NIRINITIATIVES MAY EXTENDT 3614 02:32:04,700 --> 02:32:06,469 TO OTHER INITIATIVES AND HOW IT 3615 02:32:06,469 --> 02:32:07,803 MAY BE INCORPORATED. 3616 02:32:07,803 --> 02:32:09,071 IT'S A GREAT OPPORTUNITY TO 3617 02:32:09,071 --> 02:32:10,139 EXPAND THE TALENT POOL. 3618 02:32:10,139 --> 02:32:11,273 >> YEAH, THANK YOU FOR PICKING 3619 02:32:11,273 --> 02:32:13,075 UP ON THAT. 3620 02:32:13,075 --> 02:32:15,911 AND I AGREE THAT'S A VERY 3621 02:32:15,911 --> 02:32:17,079 IMPORTANT CONSIDERATION TO US 3622 02:32:17,079 --> 02:32:18,714 CONSIDERING THIS CHANGING 3623 02:32:18,714 --> 02:32:19,248 LANDSCAPE, ETCETERA. 3624 02:32:19,248 --> 02:32:21,250 BUT AS YOU'RE PROBABLY ALSO 3625 02:32:21,250 --> 02:32:25,054 AWARE, WE'RE WORKING THROUGH A 3626 02:32:25,054 --> 02:32:26,055 LOT OF CHALLENGING ISSUES 3627 02:32:26,055 --> 02:32:30,759 RELATED TO INTERACTIONS, 3628 02:32:30,759 --> 02:32:31,494 COLLABORATIONS WITH FOREIGN 3629 02:32:31,494 --> 02:32:32,928 ENTITIES THROUGH SUBAWARDS AND 3630 02:32:32,928 --> 02:32:35,431 THE CONCERN IS WITH CAN'T TRACK 3631 02:32:35,431 --> 02:32:36,198 THE FUNDS. 3632 02:32:36,198 --> 02:32:36,866 WHAT HAPPENS TO THE FUNDS AFTER 3633 02:32:36,866 --> 02:32:39,235 THEY GO OUT TO A SUB AWARD. 3634 02:32:39,235 --> 02:32:42,738 THERE'S BEEN SOME DISCUSSIONS AS 3635 02:32:42,738 --> 02:32:45,174 DR. ALLISTON IS AWARE IN TERMS 3636 02:32:45,174 --> 02:32:49,945 OF OUR TRAINEES AND SITUATIONS 3637 02:32:49,945 --> 02:32:51,480 WHERE WE'RE HOST TRAINEE BEING 3638 02:32:51,480 --> 02:32:53,582 PAID BY ANOTHER COUNTRY, SOME 3639 02:32:53,582 --> 02:32:55,618 CONFLICTS OF INTEREST THERE. 3640 02:32:55,618 --> 02:32:57,253 SO THERE'S A LOT OF TRICKY 3641 02:32:57,253 --> 02:32:58,287 SECURITY AND OTHER ISSUES WE'RE 3642 02:32:58,287 --> 02:33:00,022 WORKING THROUGH BUT I HOPE WHEN 3643 02:33:00,022 --> 02:33:01,323 WE GET TO THE OTHER SIDE OF SOME 3644 02:33:01,323 --> 02:33:04,793 OF THOSE DISCUSSIONS WE CAN 3645 02:33:04,793 --> 02:33:12,167 CIRCLE BACK AND TALK ABOUT THE 3646 02:33:12,167 --> 02:33:13,769 COMMUNITIES PRESENTED TO US BY 3647 02:33:13,769 --> 02:33:14,937 REACHING OUT TO THE BROADER 3648 02:33:14,937 --> 02:33:15,204 COMMUNITY. 3649 02:33:15,204 --> 02:33:17,606 I'M SURE YOU'LL HEAR MORE ABOUT 3650 02:33:17,606 --> 02:33:19,608 THE TOPIC AND I'M NOT SURE WHEN 3651 02:33:19,608 --> 02:33:22,878 ROB AND KATHLEEN ARE STILL ON 3652 02:33:22,878 --> 02:33:33,389 BUT IS THERE WAS AN UPDATE IN 3653 02:33:39,295 --> 02:33:39,728 THE ADMINISTRATION AND 3654 02:33:39,728 --> 02:33:50,205 PRIORITIES AND FOCUS AREAS. 3655 02:33:51,640 --> 02:33:53,576 THERE'S AN OPPORTUNITY TO BRING 3656 02:33:53,576 --> 02:33:55,044 NEW TALENT AND STRENGTHEN THE 3657 02:33:55,044 --> 02:33:55,344 WORKFORCE. 3658 02:33:55,344 --> 02:33:57,580 THAT'S A RECOMMENDATION AND I 3659 02:33:57,580 --> 02:34:00,883 THINK IT'S GOING TO HAVE TO BE 3660 02:34:00,883 --> 02:34:04,954 HOW IT'S INACTED IN THE CONTEXT 3661 02:34:04,954 --> 02:34:06,622 OF THE PROGRAMS WILL HAVE TO BE 3662 02:34:06,622 --> 02:34:08,157 IN LINE WITH THE GUIDANCE AND I 3663 02:34:08,157 --> 02:34:10,359 THINK THE MECHANISM THE GOAL IS 3664 02:34:10,359 --> 02:34:11,727 THE SAME. 3665 02:34:11,727 --> 02:34:12,928 THE MECHANISM OF HOW WE GET TO 3666 02:34:12,928 --> 02:34:23,372 THAT HAS TO BE WORKED OUT. 3667 02:34:24,073 --> 02:34:25,975 OUR SENSE IS THIS IS WHAT WE'RE 3668 02:34:25,975 --> 02:34:27,309 SUPPOSED TO BE DOING AND YOU 3669 02:34:27,309 --> 02:34:37,820 MAKE IT HAPPEN AS BEST WE CAN. 3670 02:34:38,921 --> 02:34:40,489 >> OTHER QUESTIONS FOLKS HAVE? 3671 02:34:40,489 --> 02:34:41,690 OKAY. 3672 02:34:41,690 --> 02:34:45,194 I'M NOT SEEING ANY OTHER HANDS. 3673 02:34:45,194 --> 02:34:47,763 LET ME CONFER WITH DARREN. 3674 02:34:47,763 --> 02:34:50,032 WE'RE 15 MINUTES AHEAD OF 3675 02:34:50,032 --> 02:34:50,733 SCHEDULE. 3676 02:34:50,733 --> 02:34:52,167 SHOULD WE CLOSE OUT AND BREAK 3677 02:34:52,167 --> 02:34:54,370 EARLIER FOR LUNCH AND KEEP WITH 3678 02:34:54,370 --> 02:34:57,606 THE 45 MINUTE LUNCH PLAN? 3679 02:34:57,606 --> 02:34:59,108 >> THAT'S FINE WITH ME. 3680 02:34:59,108 --> 02:35:01,944 DO YOU WANT 45 MINUTES OR AN 3681 02:35:01,944 --> 02:35:02,311 HOUR FOR LUNCH? 3682 02:35:02,311 --> 02:35:03,812 >> KEEP IN MIND YOU HAVE TO GO 3683 02:35:03,812 --> 02:35:05,848 DOWN TO THE CAFETERIA IN THIS 3684 02:35:05,848 --> 02:35:08,684 BUILDING AND GET YOUR LUNCH AND 3685 02:35:08,684 --> 02:35:09,885 BRING IT BACK UP. 3686 02:35:09,885 --> 02:35:12,021 >> SO WE'LL COME BACK AT 1:30 3687 02:35:12,021 --> 02:35:13,522 WHICH WAS OUR SCHEDULED TIME TO 3688 02:35:13,522 --> 02:35:13,989 START CLOSED SESSION. 3689 02:35:13,989 --> 02:35:17,059 >> OKAY. 3690 02:35:17,059 --> 02:35:19,461 >> I WANTED TO HIGHLIGHT OUR 3691 02:35:19,461 --> 02:35:21,330 GRANTS MANAGEMENT STAFF. 3692 02:35:21,330 --> 02:35:23,599 THEY DON'T OFTEN GET HIGHLIGHTED 3693 02:35:23,599 --> 02:35:24,700 OR HEARD ABOUT MUCH BUT HAVE 3694 02:35:24,700 --> 02:35:26,368 BEEN DOING AN AMAZING JOB TRYING 3695 02:35:26,368 --> 02:35:27,536 TO IMPLEMENT A LOT OF THE 3696 02:35:27,536 --> 02:35:30,305 CHANGES THAT ARE HAPPENING 3697 02:35:30,305 --> 02:35:32,841 ESPECIALLY ERIC AND SAHAR OUR 3698 02:35:32,841 --> 02:35:33,409 CHIEF AND DEPUTY. 3699 02:35:33,409 --> 02:35:36,412 SO IS JUST THINK ABOUT THEM TOO 3700 02:35:36,412 --> 02:35:37,846 THE GRANTS MANAGEMENT STAFF ARE 3701 02:35:37,846 --> 02:35:39,548 WORKING MARD TO GET STUFF DONE 3702 02:35:39,548 --> 02:35:42,151 AND IT'S ONLY GOING TO GET 3703 02:35:42,151 --> 02:35:43,185 HARDER BECAUSE WE'RE AT THE END 3704 02:35:43,185 --> 02:35:44,953 OF THE FISCAL YEAR WHICH IS 3705 02:35:44,953 --> 02:35:45,688 ALWAYS TOUGHER FOR GRANTS 3706 02:35:45,688 --> 02:35:47,222 MANAGEMENT STAFF. 3707 02:35:47,222 --> 02:35:50,759 IF YOU SEE A GRANTS MANAGEMENT 3708 02:35:50,759 --> 02:35:52,928 SPECIALIST OR TALK TO ONE JUST 3709 02:35:52,928 --> 02:35:53,395 SAY THANK YOU. 3710 02:35:53,395 --> 02:35:57,933 >> I COULD NOT AGREE MORE ABOUT 3711 02:35:57,933 --> 02:35:58,767 THAT COMMENT. 3712 02:35:58,767 --> 02:36:01,837 YOU MIGHT WANT TO THINK OF 3713 02:36:01,837 --> 02:36:05,240 PUTTING YOURSELVES IN THEIR 3714 02:36:05,240 --> 02:36:07,242 SHOES THEY'VE BEEN DOING A 3715 02:36:07,242 --> 02:36:08,510 FABULOUS JOB SUPPORTING YOU ALL 3716 02:36:08,510 --> 02:36:09,578 AND US. 3717 02:36:09,578 --> 02:36:13,282 THEY'RE AMAZING. 3718 02:36:13,282 --> 02:36:14,283 THANK YOU. 3719 02:36:14,283 --> 02:36:14,750 OKAY. 3720 02:36:14,750 --> 02:36:16,518 I THINK WE CAN OFFICIALLY CLOSE 3721 02:36:16,518 --> 02:36:18,754 OUT OPEN SESSION WITH THE GAVEL. 3722 02:36:18,754 --> 02:36:21,657 MAKES IT OFFICIAL AND THANK YOU 3723 02:36:21,657 --> 02:36:24,626 ALL FOR JOINING US AND I HOPE 3724 02:36:24,626 --> 02:36:25,761 YOU ENJOY YOUR LUNCH BREAK AND 3725 02:36:25,761 --> 02:36:27,996 CHAT AND COME BACK WITH OTHER 3726 02:36:27,996 --> 02:36:29,498 IDEAS YOU MAY WANT TO DISCUSS. 3727 02:36:29,498 --> 02:36:30,666 THANK YOU ALL FOR JOINING US ON 3728 02:36:30,666 --> 02:36:40,666 THE VIDEOCAST.